,ID,Event Name,Award ID,Project Title,PI Institution,Other Institution,Prevention and diagnostic tools,Novel approaches and new therapeutic platforms,Immunotherapies and personalized vaccines,Addressing cancer disparities,Pediatric cancers,Specific Aims,Aim 1,Aim 2,Aim 3,Aim 4,Aim 5,Aim 6,Public Health Significance,Award Amount,Grant Start Date:,Grant End Date:,Complete,SR - None,SR - Biobehaviorial MCC,SR - Biorepository & Tissue Tech. MCC,SR - Biostatistics MCC,SR - Clinical Trials Office MCC,SR - Flow Cytometry MCC,SR - Genomics & Computational Bio. MCC,SR - In Vivo Imaging MCC,SR - Microscopy MCC,SR - Radiation Medicine MCC,SR - Transgenic Mouse MCC,SR - Gene Transfer/Targeting/Therap Salk,SR - Transgenic Salk,SR - Mass Spect - Proteom/Metabol Salk,SR - Chemical Library Screening SBPMDI,SR - Functional Genomics SBPMDI,Cancer Metabolism SBPMDI,"Pedal Importance (recruitment, retention, advancement)","If yes, please specify","If no, please specify",Clinical Trials Resulted,First Clinical Trial,First Clinical Trial Patient Count,Second Clinical Trial,Second Clinical Trial Patient Count,Companies Founded,Patents Filed,Patent Details,Peer-Reviewed Publications Count
0,52.0,Initial,52.1,Discovery of non-coding oncogenic mutations in pediatric acute lymphoblastic leukemia using ATAC-seq and Hi-C,Salk Institute,,False,False,False,False,True,Two Specific Aims,Discover non-coding regulatory mutations in ALL tumors using ATAC-seq.,Discover large-scale structural mutations and disrupted TAD boundaries using Hi-C.,,,,,"Acute Lymphoblastic Leukemia (ALL) is the most common form of cancer in children. Studies of ALL tumors have led to improved therapies, and increased long-term survival rates in children from ~58% in the 1970s to over 90% today. Yet 10-20% of ALL patients relapse following their initial treatment, and these patients have a  grim prognosis with survival rates between 21% and 53%. Therefore, there is a need for improved therapies stemming from a better understanding of the molecular events that promote ALL progression and relapse. We hypothesize that some genetic mutations that are important for ALL onset and relapse have remained  undiscovered because they are located in parts of the genome that are difficult to study. Specifically, most studies have focused on mutations that directly affect protein-coding genes, rather than ""non-coding regulatory"" mutations that affect which genes are expressed. We propose to develop new approaches to  identify non-coding mutations in ALL tumors. The basis for our approach is computational analysis of data from new methods (known as ATAC-seq and Hi-C) that provide information about the location and 3D organization of non-coding regulatory sequences in the genome. We will perform ATAC-seq and Hi-C experiments on 20 ALL tumor samples from patients at Rady Children's Hospital-San Diego and use the resulting data to identify non-coding regulatory mutations. Any non-coding regulatory mutations that we discover will help illuminate the  molecular causes of ALL onset and relapse, and could eventually lead to improvements in targeted therapy. ",75000.0,2017-06-01,2018-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,The funding for this project and the data generated by this project have allowed research to be conducted by an undergraduate (Arya Massarat) and a postdoctoral scholar (Arko Sen) in my laboratory.,,0.0,,,,,None,No,,Two
1,131.0,Initial,52.2,Discovery of non-coding oncogenic mutations in pediatric acute lymphoblastic leukemia using ATAC-seq and Hi-C,Salk Institute,,False,False,False,False,True,Two Specific Aims,Discover non-coding regulatory mutations in ALL tumors using ATAC-seq.,Discover large-scale structural mutations and disrupted TAD boundaries using Hi-C.,,,,,"Acute Lymphoblastic Leukemia (ALL) is the most common form of cancer in children. Studies of ALL tumors have led to improved therapies, and increased long-term survival rates in children from ~58% in the 1970s to over 90% today. Yet 10-20% of ALL patients relapse following their initial treatment, and these patients have a grim prognosis with survival rates between 21% and 53%. Therefore, there is a need for improved therapies stemming from a better understanding of the molecular events that promote ALL progression and relapse. We hypothesize that some genetic mutations that are important for ALL onset and relapse have remained undiscovered because they are located in parts of the genome that are difficult to study. Specifically, most studies have focused on mutations that directly affect protein-coding genes, rather than ""non-coding regulatory"" mutations that affect which genes are expressed. We propose to develop new approaches to identify non-coding mutations in ALL tumors. The basis for our approach is computational analysis of data from new methods (known as ATAC-seq and Hi-C) that provide information about the location and 3D organization of non-coding regulatory sequences in the genome. We will perform ATAC-seq and Hi-C experiments on 20 ALL tumor samples from patients at Rady Children's Hospital-San Diego and use the resulting data to identify non-coding regulatory mutations. Any non-coding regulatory mutations that we discover will help illuminate the molecular causes of ALL onset and relapse, and could eventually lead to improvements in targeted therapy.",75000.0,2017-06-01,2018-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,Obtaining funding is important for career advancement.,,0.0,,,,,None,No,,One
2,132.0,Initial,52.3,Discovery of non-coding oncogenic mutations in pediatric acute lymphoblastic leukemia using ATAC-seq and Hi-C,Rady Children's,,False,False,False,False,True,Two Specific Aims,Discover non-coding regulatory mutations in ALL tumors using ATAC-seq.,Discover large-scale structural mutations and disrupted TAD boundaries using Hi-C.,,,,,"Acute Lymphoblastic Leukemia (ALL) is the most common form of cancer in children. Studies of ALL tumors have led to improved therapies, and increased long-term survival rates in children from ~58% in the 1970s to over 90% today. Yet 10-20% of ALL patients relapse following their initial treatment, and these patients have a grim prognosis with survival rates between 21% and 53%. Therefore, there is a need for improved therapies stemming from a better understanding of the molecular events that promote ALL progression and relapse. We hypothesize that some genetic mutations that are important for ALL onset and relapse have remained undiscovered because they are located in parts of the genome that are difficult to study. Specifically, most studies have focused on mutations that directly affect protein-coding genes, rather than ""non-coding regulatory"" mutations that affect which genes are expressed. We propose to develop new approaches to identify non-coding mutations in ALL tumors. The basis for our approach is computational analysis of data from new methods (known as ATAC-seq and Hi-C) that provide information about the location and 3D organization of non-coding regulatory sequences in the genome. We will perform ATAC-seq and Hi-C experiments on 20 ALL tumor samples from patients at Rady Children's Hospital-San Diego and use the resulting data to identify non-coding regulatory mutations. Any non-coding regulatory mutations that we discover will help illuminate the molecular causes of ALL onset and relapse, and could eventually lead to improvements in targeted therapy.",75000.0,2017-06-01,2018-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,"Funding for this project enhanced innovative collaborative work between me and our co-investigators at the Salk Institute, Graham McVicker and Jesse Dixon.",,0.0,,,,,None,No,,Two
3,200.0,Initial,200.1,Discovery of non-coding oncogenic mutations in pediatric acute lymphoblastic leukemia using ATAC-seq and Hi-C,Salk Institute,,False,False,False,False,True,Two Specific Aims,Discover non-coding regulatory mutations in ALL tumors using ATAC-seq.,Discover large-scale structural mutations and disrupted TAD boundaries using Hi-C.,,,,,"Acute Lymphoblastic Leukemia (ALL) is the most common form of cancer in children. Studies of ALL tumors have led to improved therapies, and increased long-term survival rates in children from ~58% in the 1970s to over 90% today. Yet 10-20% of ALL patients relapse following their initial treatment, and these patients have a  grim prognosis with survival rates between 21% and 53%. Therefore, there is a need for improved therapies stemming from a better understanding of the molecular events that promote ALL progression and relapse. We hypothesize that some genetic mutations that are important for ALL onset and relapse have remained undiscovered because they are located in parts of the genome that are difficult to study. Specifically, most studies have focused on mutations that directly affect protein-coding genes, rather than ""non-coding regulatory"" mutations that affect which genes are expressed. We propose to develop new approaches to  identify non-coding mutations in ALL tumors. The basis for our approach is computational analysis of data from new methods (known as ATAC-seq and Hi-C) that provide information about the location and 3D organization  of non-coding regulatory sequences in the genome. We will perform ATAC-seq and Hi-C experiments on 20 ALL tumor samples from patients at Rady Children's Hospital-San Diego and use the resulting data to identify  non-coding regulatory mutations. Any non-coding regulatory mutations that we discover will help illuminate the molecular causes of ALL onset and relapse, and could eventually lead to improvements in targeted therapy. ",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
4,201.0,Initial,200.2,Discovery of non-coding oncogenic mutations in pediatric acute lymphoblastic leukemia using ATAC-seq and Hi-C,Salk Institute,,False,False,False,False,True,Two Specific Aims,Discover non-coding regulatory mutations in ALL tumors using ATAC-seq.,Discover large-scale structural mutations and disrupted TAD boundaries using Hi-C.,,,,,"Acute Lymphoblastic Leukemia (ALL) is the most common form of cancer in children. Studies of ALL tumors have led to improved therapies, and increased long-term survival rates in children from ~58% in the 1970s to over 90% today. Yet 10-20% of ALL patients relapse following their initial treatment, and these patients have a  grim prognosis with survival rates between 21% and 53%. Therefore, there is a need for improved therapies stemming from a better understanding of the molecular events that promote ALL progression and relapse. We hypothesize that some genetic mutations that are important for ALL onset and relapse have remained  undiscovered because they are located in parts of the genome that are difficult to study. Specifically, most studies have focused on mutations that directly affect protein-coding genes, rather than ""non-coding  regulatory"" mutations that affect which genes are expressed. We propose to develop new approaches to identify non-coding mutations in ALL tumors. The basis for our approach is computational analysis of data from  new methods (known as ATAC-seq and Hi-C) that provide information about the location and 3D organization of non-coding regulatory sequences in the genome. We will perform ATAC-seq and Hi-C experiments on 20 ALL tumor samples from patients at Rady Children's Hospital-San Diego and use the resulting data to identify  non-coding regulatory mutations. Any non-coding regulatory mutations that we discover will help illuminate the molecular causes of ALL onset and relapse, and could eventually lead to improvements in targeted therapy. ",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
5,202.0,Initial,200.3,Discovery of non-coding oncogenic mutations in pediatric acute lymphoblastic leukemia using ATAC-seq and Hi-C,Rady Children's,,False,False,False,False,True,Two Specific Aims,Discover non-coding regulatory mutations in ALL tumors using ATAC-seq.,Discover large-scale structural mutations and disrupted TAD boundaries using Hi-C.,,,,,"Acute Lymphoblastic Leukemia (ALL) is the most common form of cancer in children. Studies of ALL tumors have led to improved therapies, and increased long-term survival rates in children from ~58% in the 1970s to over 90% today. Yet 10-20% of ALL patients relapse following their initial treatment, and these patients have a  grim prognosis with survival rates between 21% and 53%. Therefore, there is a need for improved therapies stemming from a better understanding of the molecular events that promote ALL progression and relapse. We hypothesize that some genetic mutations that are important for ALL onset and relapse have remained  undiscovered because they are located in parts of the genome that are difficult to study. Specifically, most studies have focused on mutations that directly affect protein-coding genes, rather than ""non-coding  regulatory"" mutations that affect which genes are expressed. We propose to develop new approaches to identify non-coding mutations in ALL tumors. The basis for our approach is computational analysis of data from  new methods (known as ATAC-seq and Hi-C) that provide information about the location and 3D organization of non-coding regulatory sequences in the genome. We will perform ATAC-seq and Hi-C experiments on 20 ALL tumor samples from patients at Rady Children's Hospital-San Diego and use the resulting data to identify  non-coding regulatory mutations. Any non-coding regulatory mutations that we discover will help illuminate the molecular causes of ALL onset and relapse, and could eventually lead to improvements in targeted therapy. ",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
6,44.0,Initial,44.1,Irreversible electroporation as an In Situ vaccine for pancreatic cancer,Moores Cancer Center,,False,False,True,False,False,Three Specific Aims,To determine whether IRE induces neoantigen-specific T cell responses.,To examine the effects of IRE on the tumor microenvironment (TME). ,To augment IRE-induced tumor-specific T-cell responses through overcoming inhibitory pathways. ,,,,"Approximately 40,000 people are diagnosed with pancreatic cancer each year in this country.  Unfortunately, most patients-even those with tumors that appear localized on imaging-will  eventually develop distant metastatic disease. The goal of immunotherapy is to utilize the patient's immune system to reject the invading ""foreign"" tumor like an infection. ""In situ vaccination"" refers to approaches in which the tumor is made to appear more foreign to generate immune responses against it. Electroporation is a common laboratory technique in which electrical voltage is applied to cells to make holes for intracellular delivery of DNA and RNA. Irreversible electroporation (IRE) is a technique now being used clinically for localized tumors that cannot be removed surgically (locally advanced tumors). Our hypothesis is that IRE stimulates immunes responses to tumor cells and that we can augment immune responses to IRE with immunotherapy. We will use mouse models of pancreatic cancer to evaluate the effects of IRE on the immune system. We will evaluate the combination of IRE with immunotherapy drugs that are already available as well as novel agents in development. We envision that this approach will increase the proportion of patients with localized disease who are cured. Since we have already started a clinical IRE program at UCSD, a clinical trial in which an immunotherapy drug is given during or after IRE as adjuvant therapy would likely be feasible within 2-3 years. ",75000.0,2017-06-01,2018-05-31,Complete,False,False,True,True,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,"These pilot projects were critical for generating the preliminary data that led to my first R01 funding.  In part due to this milestone, I was elected president of the Society of University Surgeons.  It has led to my inclusion as PI on one of the main projects for a SPORE submission and new collaborations that will likely lead to other funding and publications. ",,0.0,,,,,None,No,,Two
7,121.0,Initial,44.2,Irreversible electroporation as an In Situ vaccine for pancreatic cancer,LJI,,False,False,True,False,False,Three Specific Aims,To determine whether IRE induces neoantigen-specific T cell responses.,To examine the effects of IRE on the tumor microenvironment (TME).,To augment IRE-induced tumor-specific T-cell responses through overcoming inhibitory pathways.,,,,"Approximately 40,000 people are diagnosed with pancreatic cancer each year in this country. Unfortunately, most patients-even those with tumors that appear localized on imaging-will eventually develop distant metastatic disease. The goal of immunotherapy is to utilize the patient's immune system to reject the invading ""foreign"" tumor like an infection. ""In situ vaccination"" refers to approaches in which the tumor is made to appear more foreign to generate immune responses against it. Electroporation is a common laboratory technique in which electrical voltage is applied to cells to make holes for intracellular delivery of DNA and RNA. Irreversible electroporation (IRE) is a technique now being used clinically for localized tumors that cannot be removed surgically (locally advanced tumors). Our hypothesis is that IRE stimulates immunes responses to tumor cells and that we can augment immune responses to IRE with immunotherapy. We will use mouse models of pancreatic cancer to evaluate the effects of IRE on the immune system. We will evaluate the combination of IRE with immunotherapy drugs that are already available as well as novel agents in development. We envision that this approach will increase the proportion of patients with localized disease who are cured. Since we have already started a clinical IRE program at UCSD, a clinical trial in which an immunotherapy drug is given during or after IRE as adjuvant therapy would likely be feasible within 2-3 years.",75000.0,2017-06-01,2018-05-31,Complete,False,False,True,False,False,True,True,False,False,False,False,False,False,False,False,False,False,Yes,"Pedal the Cause funding enabled me to participate in an area of experimental therapeutic intervention that I otherwise would not have, and allowed me to bring my lab's expertise to UCSD faculty scientist who could benefit from our clear synergies.",,0.0,,,,,No,No,,Two
8,122.0,Initial,44.3,Irreversible electroporation as an In Situ vaccine for pancreatic cancer,Moores Cancer Center,,False,False,True,False,False,Three Specific Aims,To determine whether IRE induces neoantigen-specific T cell responses.,To examine the effects of IRE on the tumor microenvironment (TME).,To augment IRE-induced tumor-specific T-cell responses through overcoming inhibitory pathways.,,,,"Approximately 40,000 people are diagnosed with pancreatic cancer each year in this country. Unfortunately, most patients-even those with tumors that appear localized on imaging-will eventually develop distant metastatic disease. The goal of immunotherapy is to utilize the patient's immune system to reject the invading ""foreign"" tumor like an infection. ""In situ vaccination"" refers to approaches in which the tumor is made to appear more foreign to generate immune responses against it. Electroporation is a common laboratory technique in which electrical voltage is applied to cells to make holes for intracellular delivery of DNA and RNA. Irreversible electroporation (IRE) is a technique now being used clinically for localized tumors that cannot be removed surgically (locally advanced tumors). Our hypothesis is that IRE stimulates immunes responses to tumor cells and that we can augment immune responses to IRE with immunotherapy. We will use mouse models of pancreatic cancer to evaluate the effects of IRE on the immune system. We will evaluate the combination of IRE with immunotherapy drugs that are already available as well as novel agents in development. We envision that this approach will increase the proportion of patients with localized disease who are cured. Since we have already started a clinical IRE program at UCSD, a clinical trial in which an immunotherapy drug is given during or after IRE as adjuvant therapy would likely be feasible within 2-3 years.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
9,182.0,Initial,182.1,Irreversible electroporation as an In Situ vaccine for pancreatic cancer,UCSD - not a member of Moores Cancer Center,,False,False,True,False,False,Three Specific Aims,To determine whether IRE induces neoantigen-specific T cell responses.,To examine the effects of IRE on the tumor microenvironment (TME).,To augment IRE-induced tumor-specific T-cell responses through overcoming inhibitory pathways.,,,,"Approximately 40,000 people are diagnosed with pancreatic cancer each year in this country.  Unfortunately, most patients-even those with tumors that appear localized on imaging-will  eventually develop distant metastatic disease. The goal of immunotherapy is to utilize the patient's  immune system to reject the invading ""foreign"" tumor like an infection. ""In situ vaccination"" refers to approaches in which the tumor is made to appear more foreign to generate immune responses against it. Electroporation is a common laboratory technique in which electrical voltage is applied to cells to make holes for intracellular delivery of DNA and RNA. Irreversible electroporation (IRE) is a  technique now being used clinically for localized tumors that cannot be removed surgically (locally  advanced tumors). Our hypothesis is that IRE stimulates immunes responses to tumor cells and that we can augment immune responses to IRE with immunotherapy. We will use mouse models of pancreatic cancer to evaluate the effects of IRE on the immune system. We will evaluate the combination of IRE with immunotherapy drugs that are already available as well as novel agents in development. We envision that this approach will increase the proportion of patients with localized disease who are cured. Since we have already started a clinical IRE program at UCSD, a clinical trial in which an immunotherapy drug is given during or after IRE as adjuvant therapy would likely be feasible within 2-3 years.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
10,183.0,Initial,182.2,Irreversible electroporation as an In Situ vaccine for pancreatic cancer,LJI,,False,False,True,False,False,Three Specific Aims,To determine whether IRE induces neoantigen-specific T cell responses.,To examine the effects of IRE on the tumor microenvironment (TME).,To augment IRE-induced tumor-specific T-cell responses through overcoming inhibitory pathways.,,,,"Approximately 40,000 people are diagnosed with pancreatic cancer each year in this country.  Unfortunately, most patients-even those with tumors that appear localized on imaging-will  eventually develop distant metastatic disease. The goal of immunotherapy is to utilize the patient's  immune system to reject the invading ""foreign"" tumor like an infection. ""In situ vaccination"" refers to approaches in which the tumor is made to appear more foreign to generate immune responses against it. Electroporation is a common laboratory technique in which electrical voltage is applied to cells to make holes for intracellular delivery of DNA and RNA. Irreversible electroporation (IRE) is a  technique now being used clinically for localized tumors that cannot be removed surgically (locally  advanced tumors). Our hypothesis is that IRE stimulates immunes responses to tumor cells and that we can augment immune responses to IRE with immunotherapy. We will use mouse models of pancreatic cancer to evaluate the effects of IRE on the immune system. We will evaluate the combination of IRE with immunotherapy drugs that are already available as well as novel agents in development. We envision that this approach will increase the proportion of patients with localized disease who are cured. Since we have already started a clinical IRE program at UCSD, a clinical trial in which an immunotherapy drug is given during or after IRE as adjuvant therapy would likely be feasible within 2-3 years.  ",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
11,184.0,Initial,182.3,Irreversible electroporation as an In Situ vaccine for pancreatic cancer,UCSD - not a member of Moores Cancer Center,,False,False,True,False,False,Three Specific Aims,To determine whether IRE induces neoantigen-specific T cell responses.,To examine the effects of IRE on the tumor microenvironment (TME).,To augment IRE-induced tumor-specific T-cell responses through overcoming inhibitory pathways.,,,,"Approximately 40,000 people are diagnosed with pancreatic cancer each year in this country.  Unfortunately, most patients-even those with tumors that appear localized on imaging-will  eventually develop distant metastatic disease. The goal of immunotherapy is to utilize the patient's  immune system to reject the invading ""foreign"" tumor like an infection. ""In situ vaccination"" refers to approaches in which the tumor is made to appear more foreign to generate immune responses against it. Electroporation is a common laboratory technique in which electrical voltage is applied to cells to make holes for intracellular delivery of DNA and RNA. Irreversible electroporation (IRE) is a  technique now being used clinically for localized tumors that cannot be removed surgically (locally  advanced tumors). Our hypothesis is that IRE stimulates immunes responses to tumor cells and that we can augment immune responses to IRE with immunotherapy. We will use mouse models of pancreatic cancer to evaluate the effects of IRE on the immune system. We will evaluate the combination of IRE with immunotherapy drugs that are already available as well as novel agents in development. We envision that this approach will increase the proportion of patients with localized disease who are cured. Since we have already started a clinical IRE program at UCSD, a clinical trial in which an immunotherapy drug is given during or after IRE as adjuvant therapy would likely be feasible within 2-3 years.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
12,49.0,Initial,49.1,Decoding Colon Cancers Using Boolean Principles,Moores Cancer Center,,True,False,False,False,False,Three Specific Aims,Build a virtual colon crypt,Visualize the altered organization of crypts in colon cancers,Assess the risk of neoplasia in pre-neoplastic lesions of the colon,,,,"Colorectal cancer is the 3rd most common cancer in the US. Despite a large amount of work that has concentrated on understanding colon tumor formation, we still do not know the full complement of molecular lesions that are  individually necessary (and together sufficient) to cause colorectal cancer. Neither do we understand why some specific mutations that are relatively rare in other tumors are extremely common in colorectal cancer. As a result,  the race toward personalized and precision-based management plan in colorectal cancer has seen a lost decade with little to nothing that has translated to the cancer clinics after the discovery of the impact of tumor microsatellite instability status in the mid-90's. Big data (gene expression datasets), meanwhile, has accumulated from multiple studies, but has had a 'streetlight effect': where and how we look affects what we see through our own biases. Thus, a lot of what has been accomplished using such big data is justification/ rationalization of  research through the same bias-filled traditional reductionist approach [one protein, pathway at a time based on where one wanted to look]. Which can explain why most pre-clinically identified therapeutic target or biomarkers identified at the bench stumble during translation into clinics. Currently, there is no effective way to extract  meaningful information from such noisy collection of Big data in an unbiased way. ",75000.0,2017-06-01,2018-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,my appointment track does not value intramural funding $. ,0.0,,,,,,No,,Six - Ten
13,127.0,Initial,49.2,Decoding Colon Cancers Using Boolean Principles,Moores Cancer Center,,True,False,False,False,False,Three Specific Aims,Build a virtual colon crypt.,Visualize the altered organization of crypts in colon cancers,Assess the risk of neoplasia in pre-neoplastic lesions of the colon,,,,"Colorectal cancer is the 3rd most common cancer in the US. Despite a large amount of work that has concentrated on understanding colon tumor formation, we still do not know the full complement of molecular lesions that are individually necessary (and together sufficient) to cause colorectal cancer. Neither do we understand why some specific mutations that are relatively rare in other tumors are extremely common in colorectal cancer. As a result, the race toward personalized and precision-based management plan in colorectal cancer has seen a lost decade with little to nothing that has translated to the cancer clinics after the discovery of the impact of tumor microsatellite instability status in the mid-90's. Big data (gene expression datasets), meanwhile, has accumulated from multiple studies, but has had a 'streetlight effect': where and how we look affects what we see through our own biases. Thus, a lot of what has been accomplished using such big data is justification/ rationalization of research through the same bias-filled traditional reductionist approach [one protein, pathway at a time based on where one wanted to look]. Which can explain why most pre-clinically identified therapeutic target or biomarkers identified at the bench stumble during translation into clinics. Currently, there is no effective way to extract meaningful information from such noisy collection of Big data in an unbiased way.",75000.0,2017-06-01,2018-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,Pedal the Cause motivated the students.,,0.0,,,,,None,Yes,2020-135Human-centered drug discovery: A methodology to identify and validate high-value therapeutic targets for human diseases    2019-217 ?Polyp-print?: a methodology to identify which colon polyps are likely to proceed to colorectal cancers,Two
14,128.0,Initial,49.3,Decoding Colon Cancers Using Boolean Principles,Sanford Burnum,,True,False,False,False,False,Three Specific Aims,Build a virtual colon crypt.,Visualize the altered organization of crypts in colon cancers,Assess the risk of neoplasia in pre-neoplastic lesions of the colon,,,,"Colorectal cancer is the 3rd most common cancer in the US. Despite a large amount of work that has concentrated on understanding colon tumor formation, we still do not know the full complement of molecular lesions that are individually necessary (and together sufficient) to cause colorectal cancer. Neither do we understand why some specific mutations that are relatively rare in other tumors are extremely common in colorectal cancer. As a result, the race toward personalized and precision-based management plan in colorectal cancer has seen a lost decade with little to nothing that has translated to the cancer clinics after the discovery of the impact of tumor microsatellite instability status in the mid-90's. Big data (gene expression datasets), meanwhile, has accumulated from multiple studies, but has had a 'streetlight effect': where and how we look affects what we see through our own biases. Thus, a lot of what has been accomplished using such big data is justification/ rationalization of research through the same bias-filled traditional reductionist approach [one protein, pathway at a time based on where one wanted to look]. Which can explain why most pre-clinically identified therapeutic target or biomarkers identified at the bench stumble during translation into clinics. Currently, there is no effective way to extract meaningful information from such noisy collection of Big data in an unbiased way.",75000.0,2017-06-01,2018-05-31,Complete,False,False,True,False,False,False,True,False,False,False,False,False,False,False,False,False,False,No,,Please see description of the atypical situation of my involvement on the project above. ,0.0,,,,,None,No,,Zero
15,193.0,Initial,193.1,Decoding Colon Cancers Using Boolean Principles,Moores Cancer Center,,True,False,False,False,False,Three Specific Aims,Build a virtual colon crypt,Visualize the altered organization of crypts in colon cancers,Assess the risk of neoplasia in pre-neoplastic lesions of the colon,,,,"Colorectal cancer is the 3rd most common cancer in the US. Despite a large amount of work that has concentrated on understanding colon tumor formation, we still do not know the full complement of molecular lesions that are individually necessary (and together sufficient) to cause colorectal cancer. Neither do we understand why some specific mutations that are relatively rare in other tumors are extremely common in colorectal cancer. As a result, the race toward personalized and precision-based management plan in colorectal cancer has seen a lost decade with little to nothing that has translated to the cancer clinics after the discovery of the impact of tumor microsatellite instability status in the mid-90's. Big data (gene expression datasets), meanwhile, has accumulated from multiple studies, but has had a 'streetlight effect': where and how we look affects what we see through our own biases. Thus, a lot of what has been accomplished using such big data is justification/ rationalization of research through the same bias-filled traditional reductionist approach [one protein, pathway at a time based on where one wanted to look]. Which can explain why most pre-clinically identified therapeutic target or biomarkers identified at the bench stumble during translation into clinics. Currently, there is no effective way to extract meaningful information from such noisy collection of Big data in an unbiased way.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
16,194.0,Initial,193.2,Decoding Colon Cancers Using Boolean Principles,Moores Cancer Center,,True,False,False,False,False,Three Specific Aims,Build a virtual colon crypt,Visualize the altered organization of crypts in colon cancers,Assess the risk of neoplasia in pre-neoplastic lesions of the colon,,,,"Colorectal cancer is the 3rd most common cancer in the US. Despite a large amount of work that has concentrated on understanding colon tumor formation, we still do not know the full complement of molecular lesions that are individually necessary (and together sufficient) to cause colorectal cancer. Neither do we understand why some specific mutations that are relatively rare in other tumors are extremely common in colorectal cancer. As a result, the race toward personalized and precision-based management plan in colorectal cancer has seen a lost decade with little to nothing that has translated to the cancer clinics after the discovery of the impact of tumor microsatellite instability status in the mid-90's. Big data (gene expression datasets), meanwhile, has accumulated from multiple studies, but has had a 'streetlight effect': where and how we look affects what we see through our own biases. Thus, a lot of what has been accomplished using such big data is justification/ rationalization of research through the same bias-filled traditional reductionist approach [one protein, pathway at a time based on where one wanted to look]. Which can explain why most pre-clinically identified therapeutic target or biomarkers identified at the bench stumble during translation into clinics. Currently, there is no effective way to extract meaningful information from such noisy collection of Big data in an unbiased way.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
17,195.0,Initial,193.3,Decoding Colon Cancers Using Boolean Principles,Sanford Burnum,,True,False,False,False,False,Three Specific Aims,Build a virtual colon crypt,Visualize the altered organization of crypts in colon cancers,Assess the risk of neoplasia in pre-neoplastic lesions of the colon,,,,"Colorectal cancer is the 3rd most common cancer in the US. Despite a large amount of work that has concentrated  on understanding colon tumor formation, we still do not know the full complement of molecular lesions that are  individually necessary (and together sufficient) to cause colorectal cancer. Neither do we understand why some  specific mutations that are relatively rare in other tumors are extremely common in colorectal cancer. As a result,  the race toward personalized and precision-based management plan in colorectal cancer has seen a lost decade  with little to nothing that has translated to the cancer clinics after the discovery of the impact of tumor  microsatellite instability status in the mid-90's. Big data (gene expression datasets), meanwhile, has accumulated  from multiple studies, but has had a 'streetlight effect': where and how we look affects what we see through our  own biases. Thus, a lot of what has been accomplished using such big data is justification/ rationalization of  research through the same bias-filled traditional reductionist approach [one protein, pathway at a time based on  where one wanted to look]. Which can explain why most pre-clinically identified therapeutic target or biomarkers identified at the bench stumble during translation into clinics. Currently, there is no effective way to extract meaningful information from such noisy collection of Big data in an unbiased way. ",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
18,51.0,Initial,51.1,Deciphering the role of RNA editing in leukemia stem cell generation and pediatric acute leukemia relapse,Moores Cancer Center,,False,False,False,False,True,One Specific Aim,To determine the functional significance of ADAR-mediated RNA editing in LSC-driven ALL relapse.,,,,,,"Acute lymphoblastic leukemia (ALL) is the commonest childhood cancer and leukemia relapse after treatment is an important cause of cancer-related death. Leukemia relapse is caused by a distinct subset of cells called ""leukemia stem cells"" (LSC) that have the unique capacity to maintain themselves for a long period of time while remaining in a dormant state. This enables them to evade elimination by conventional cancer treatments such as chemotherapy and radiotherapy, which preferentially kill rapidly multiplying cells. This project aims to study the signals and pathways that are important in propagating these LSC. Previous work in our lab in chronic myeloid leukemia (CML) has shown that inflammatory signals activate a family of enzymes called adenosine deaminase acting on RNA (ADAR) which generates LSC and leads to progression of CML from an indolent ""chronic phase"" to an aggressive ""blast crisis"" phase that is resistant to treatment. However, the role of ADAR in generating LSC in ALL is not known. Work in our lab showed that there is high expression of ADAR1 in human ALL. Hence, we have established a mouse model of ALL by transferring cells purified from leukemia patient's bone marrow into immune-deficient mice. We will perform latest molecular tests that will allow us to track the functional activity of ADAR1 in LSC in live mice that harbor human ALL. This will enable us to understand how ADAR mediates LSC maintenance and dormancy, thereby revealing novel targets that may be utilized in elimination of the LSC that drives leukemia relapse. have very limited therapeutic options.",75000.0,2017-06-01,2018-05-31,Complete,False,False,True,False,True,False,True,False,False,False,False,False,False,False,False,False,False,Yes,Pedal the cause helped us to recruit five faculty members because of the extraordinary discoveries that it fueled.,,2.0,Ruxolitinib with or without navitoxlax (Abbvie),2.0,Ruxolitinib with or without BET inhibitors (CPI),2.0,Aspera Biomedicines,Yes,Please see justia patents:  https://patents.justia.com/search?q=Catriona+jamieson,More than Ten
19,130.0,Initial,51.2,Deciphering the role of RNA editing in leukemia stem cell generation and pediatric acute leukemia relapse,Rady Children's,,False,False,False,False,True,One Specific Aim,To determine the functional significance of ADAR-mediated RNA editing in LSC-driven ALL relapse.,,,,,,"Acute lymphoblastic leukemia (ALL) is the commonest childhood cancer and leukemia relapse after treatment is an important cause of cancer-related death. Leukemia relapse is caused by a distinct subset of cells called ""leukemia stem cells"" (LSC) that have the unique capacity to maintain themselves for a long period of time while remaining in a dormant state. This enables them to evade elimination by conventional cancer treatments such as chemotherapy and radiotherapy, which preferentially kill rapidly multiplying cells. This project aims to study the signals and pathways that are important in propagating these LSC. Previous work in our lab in chronic myeloid leukemia (CML) has shown that inflammatory signals activate a family of enzymes called adenosine deaminase acting on RNA (ADAR) which generates LSC and leads to progression of CML from an indolent ""chronic phase"" to an aggressive ""blast crisis"" phase that is resistant to treatment. However, the role of ADAR in generating LSC in ALL is not known. Work in our lab showed that there is high expression of ADAR1 in human ALL. Hence, we have established a mouse model of ALL by transferring cells purified from leukemia patient's bone marrow into immune-deficient mice. We will perform latest molecular tests that will allow us to track the functional activity of ADAR1 in LSC in live mice that harbor human ALL. This will enable us to understand how ADAR mediates LSC maintenance and dormancy, thereby revealing novel targets that may be utilized in elimination of the LSC that drives leukemia relapse. have very limited therapeutic options.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
20,198.0,Initial,198.1,Deciphering the role of RNA editing in leukemia stem cell generation and pediatric acute leukemia relapse,Rady Children's,,False,False,False,False,True,One Specific Aim,Deciphering the Role of RNA Editing in Leukemia Stem Cell Generation and Pediatric Acute Leukemia Relapse    Specific Aim  To determine the functional significance of ADAR-mediated RNA editing in LSC-driven ALL relapse.  ,,,,,,"Acute lymphoblastic leukemia (ALL) is the commonest childhood cancer and leukemia relapse after treatment is an important cause of cancer-related death. Leukemia relapse is caused by a distinct subset of cells called ""leukemia stem cells"" (LSC) that have the unique capacity to maintain themselves for a long period of time while remaining in a dormant state. This enables them to evade elimination by conventional cancer treatments such as chemotherapy and radiotherapy, which preferentially kill rapidly multiplying cells. This project aims to study the signals and pathways that are important in propagating these LSC. Previous work in our lab in chronic myeloid leukemia (CML) has shown that inflammatory signals activate a family of enzymes called adenosine deaminase acting on RNA (ADAR) which generates LSC and leads to progression of CML from an indolent ""chronic phase"" to an aggressive ""blast crisis"" phase that is resistant to treatment. However, the role of ADAR in generating LSC in ALL is not known. Work in our lab showed that there is high expression of ADAR1 in human ALL. Hence we have established a mouse model of ALL by transferring cells purified from leukemia patient's bone marrow into immune-deficient mice. We will perform latest molecular tests that will allow us to track the functional activity of ADAR1 in LSC in live mice that harbor human ALL. This will enable us to understand how ADAR mediates LSC maintenance and dormancy, thereby revealing novel targets that may be utilized in elimination of the LSC that drives leukemia relapse. ",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
21,199.0,Initial,198.2,Deciphering the role of RNA editing in leukemia stem cell generation and pediatric acute leukemia relapse,UCSD - not a member of Moores Cancer Center,,False,False,False,False,True,One Specific Aim,Deciphering the Role of RNA Editing in Leukemia Stem Cell Generation and Pediatric Acute Leukemia Relapse    Specific Aim  To determine the functional significance of ADAR-mediated RNA editing in LSC-driven ALL relapse.  ,,,,,,"Acute lymphoblastic leukemia (ALL) is the commonest childhood cancer and leukemia relapse after treatment is an important cause of cancer-related death. Leukemia relapse is caused by a distinct subset of cells called ""leukemia stem cells"" (LSC) that have the unique capacity to maintain themselves for a long period of time while remaining in a dormant state. This enables them to evade elimination by conventional cancer treatments such as chemotherapy and radiotherapy, which preferentially kill rapidly multiplying cells. This project aims to study the signals and pathways that are important in propagating these LSC. Previous work in our lab in chronic myeloid leukemia (CML) has shown that inflammatory signals activate a family of enzymes called adenosine deaminase acting on RNA (ADAR) which generates LSC and leads to progression of CML from an indolent ""chronic phase"" to an aggressive ""blast crisis"" phase that is resistant to treatment. However, the role of ADAR in generating LSC in ALL is not known. Work in our lab showed that there is high expression of ADAR1 in human ALL. Hence we have established a mouse model of ALL by transferring cells purified from leukemia patient's bone marrow into immune-deficient mice. We will perform latest molecular tests that will allow us to track the functional activity of ADAR1 in LSC in live mice that harbor human ALL. This will enable us to understand how ADAR mediates LSC maintenance and dormancy, thereby revealing novel targets that may be utilized in elimination of the LSC that drives leukemia relapse. ",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
22,53.0,Initial,53.1,Identification of therapeutic targets of B-ALL using Boolean logic,Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,Develop a computational model of differentiation in B-ALL.,Predict and validate risk stratification in B-ALL patient samples.,,,,,"B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. Almost all children can be cured of this disease using standard treatment options. Reducing toxicity, rate of infections, and behavioral changes are the main goals in developing next-generation targeted therapies. B-ALL cells possess the ability to go through a series of intermediate steps towards a less aggressive state. The early steps along this path contain the most aggressive cell types that can be targeted to cure the disease. Molecular or epigenetic drivers that  characterize the most aggressive state is poorly understood. We have developed mathematical tools to understand logical rules of gene expression patterns of these aggressive cell types. This will help us to develop targeted therapies for B-ALL.",75000.0,2017-06-01,2018-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,Pedal the Cause motivated people to focus on research.,,0.0,,,,,None,No,,One
23,133.0,Initial,53.2,Identification of therapeutic targets of B-ALL using Boolean logic,Rady Children's,,False,False,False,False,True,Two Specific Aims,Develop a computational model of differentiation in B-ALL.,Predict and validate risk stratification in B-ALL patient samples.,,,,,"B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. Almost all children can be cured of this disease using standard treatment options. Reducing toxicity, rate of infections, and behavioral changes are the main goals in developing next-generation targeted therapies. B-ALL cells possess the ability to go through a series of intermediate steps towards a less aggressive state. The early steps along this path contain the most aggressive cell types that can be targeted to cure the disease. Molecular or epigenetic drivers that characterize the most aggressive state is poorly understood. We have developed mathematical tools to understand logical rules of gene expression patterns of these aggressive cell types. This will help us to develop targeted therapies for B-ALL.",75000.0,2017-06-01,2018-05-31,Complete,False,False,False,False,True,True,False,False,False,False,False,False,False,False,False,False,False,No,,,1.0,Discovery and translation of precursor B-cell Acute Lymphoblastic Leukemia (B-ALL) stem cell targets,25.0,,,Not applicable,No,,One
24,203.0,Initial,203.1,Identification of therapeutic targets of B-ALL using Boolean logic,UCSD - not a member of Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,Develop a computational model of differentiation in B-ALL.,Predict and validate risk stratification in B-ALL patient samples.,,,,,"B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. Almost all children can be cured of this disease using standard treatment options. Reducing toxicity, rate of infections, and behavioral changes are the main goals in developing next-generation targeted therapies. B-ALL cells possess the ability to go through a series of intermediate steps towards a less aggressive state. The early steps along this path contain the most aggressive cell types that can be targeted to cure the disease. Molecular or epigenetic drivers that  characterize the most aggressive state is poorly understood. We have developed mathematical tools to understand logical rules of gene expression patterns of these aggressive cell types. This will help us to develop targeted therapies for B-ALL.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
25,204.0,Initial,203.2,Identification of therapeutic targets of B-ALL using Boolean logic,Rady Children's,,False,False,False,False,True,Two Specific Aims,Develop a computational model of differentiation in B-ALL.,Predict and validate risk stratification in B-ALL patient samples.,,,,,"B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. Almost all children can be cured of this disease using standard treatment options. Reducing toxicity, rate of infections, and behavioral changes are the main goals in developing next-generation targeted therapies. B-ALL cells possess the ability to go through a series of intermediate steps towards a less aggressive state. The early steps along this path contain the most aggressive cell types that can be targeted to cure the disease. Molecular or epigenetic drivers that  characterize the most aggressive state is poorly understood. We have developed mathematical tools to understand logical rules of gene expression patterns of these aggressive cell types. This will help us to develop targeted therapies for B-ALL.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
26,54.0,Initial,54.1,Developing targeted therapy for Ewing sarcoma metastasis,Moores Cancer Center,,False,False,False,False,True,One Specific Aim,Determine the effects of targeting the neural crest migration pathway via PDGFR inhibition on Ewing sarcoma metastasis.,,,,,,"Ewing's sarcoma is a malignant tumor that commonly appears in a bone. It usually occurs between 10-20 years of age. About 25% of patients present with clinically detectable metastatic disease. Because of the possibility of undiagnosed metastatic disease, chemotherapy, surgery and radiation therapy are applied for all  patients. Despite aggressive therapy, almost no improvement has been seen in patients with metastatic disease (80% mortality). The failure to stop Ewing's sarcoma metastasis is due to the lack of understanding about the molecular pathways that regulate its spreading. To address this unmet need, we hypothesize that a  group of genes that regulate the generation and function of a specialized group of embryonic stem cells (neural crest cells) are reactivated to allow Ewing's sarcoma cells to metastasize. Our previous study show that expression of one such gene (Twist1) is associated with metastasis and poor survival in Ewing's sarcoma patients. Therefore, we propose to examine Twist1 and other genes regulated by Twist1 in Ewing sarcoma metastasis and to test whether drugs targeting these genes will block metastasis with higher specificity and fewer side effects than conventional therapy.  In the short term, the proposed research provides new prognostic markers to identify high-risk Ewing sarcoma  patients for personalized treatment options. In the long term, the proposed research could lead to novel therapeutic regimens that reduce morbidity from ineffective conventional therapies and save the lives of countless children affected with metastatic Ewing's sarcoma.",75000.0,2017-06-01,2018-05-31,Complete,False,False,False,False,False,False,False,False,True,False,False,False,False,False,False,False,False,No,,,0.0,,,,,No.,No,,One
27,134.0,Initial,54.2,Developing targeted therapy for Ewing sarcoma metastasis,Rady Children's,,False,False,False,False,True,One Specific Aim,Determine the effects of targeting the neural crest migration pathway via PDGFR inhibition on Ewing sarcoma metastasis.,,,,,,"Ewing's sarcoma is a malignant tumor that commonly appears in a bone. It usually occurs between 10-20 years of age. About 25% of patients present with clinically detectable metastatic disease. Because of the possibility of undiagnosed metastatic disease, chemotherapy, surgery and radiation therapy are applied for all patients. Despite aggressive therapy, almost no improvement has been seen in patients with metastatic disease (80% mortality). The failure to stop Ewing's sarcoma metastasis is due to the lack of understanding about the molecular pathways that regulate its spreading. To address this unmet need, we hypothesize that a group of genes that regulate the generation and function of a specialized group of embryonic stem cells (neural crest cells) are reactivated to allow Ewing's sarcoma cells to metastasize. Our previous study show that expression of one such gene (Twist1) is associated with metastasis and poor survival in Ewing's sarcoma patients. Therefore, we propose to examine Twist1 and other genes regulated by Twist1 in Ewing sarcoma metastasis and to test whether drugs targeting these genes will block metastasis with higher specificity and fewer side effects than conventional therapy.  In the short term, the proposed research provides new prognostic markers to identify high-risk Ewing sarcoma patients for personalized treatment options. In the long term, the proposed research could lead to novel therapeutic regimens that reduce morbidity from ineffective conventional therapies and save the lives of countless children affected with metastatic Ewing's sarcoma.",75000.0,2017-06-01,2018-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,Through this grant I was able to continue my research efforts in Ewing sarcoma to complement my clinical practice in Pediatric Solid Tumors. This grant also led to a large collaborative effort on Ewing Sarcoma. ,,0.0,,,,,,No,,One
28,205.0,Initial,205.1,Developing targeted therapy for Ewing sarcoma metastasis,UCSD - not a member of Moores Cancer Center,,False,False,False,False,True,One Specific Aim,Determine the effects of targeting the neural crest migration pathway via PDGFR inhibition on Ewing sarcoma metastasis.,,,,,,"Ewing's sarcoma is a malignant tumor that commonly appears in a bone. It usually occurs between 10-20 years of age. About 25% of patients present with clinically detectable metastatic disease. Because of the possibility of undiagnosed metastatic disease, chemotherapy, surgery and radiation therapy are applied for all  patients. Despite aggressive therapy, almost no improvement has been seen in patients with metastatic disease (80% mortality). The failure to stop Ewing's sarcoma metastasis is due to the lack of understanding about the molecular pathways that regulate its spreading. To address this unmet need, we hypothesize that a  group of genes that regulate the generation and function of a specialized group of embryonic stem cells (neural crest cells) are reactivated to allow Ewing's sarcoma cells to metastasize. Our previous study show that expression of one such gene (Twist1) is associated with metastasis and poor survival in Ewing's sarcoma patients. Therefore, we propose to examine Twist1 and other genes regulated by Twist1 in Ewing sarcoma metastasis and to test whether drugs targeting these genes will block metastasis with higher specificity and fewer side effects than conventional therapy.   In the short term, the proposed research provides new prognostic markers to identify high-risk Ewing sarcoma patients for personalized treatment options. In the long term, the proposed research could lead to novel  therapeutic regimens that reduce morbidity from ineffective conventional therapies and save the lives of countless children affected with metastatic Ewing's sarcoma.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
29,206.0,Initial,205.2,Developing targeted therapy for Ewing sarcoma metastasis,UCSD - not a member of Moores Cancer Center,,False,False,False,False,True,One Specific Aim,Determine the effects of targeting the neural crest migration pathway via PDGFR inhibition on Ewing sarcoma metastasis.,,,,,,"years of age. About 25% of patients present with clinically detectable metastatic disease. Because of the possibility of undiagnosed metastatic disease, chemotherapy, surgery and radiation therapy are applied for all patients. Despite aggressive therapy, almost no improvement has been seen in patients with metastatic  disease (80% mortality). The failure to stop Ewing's sarcoma metastasis is due to the lack of understanding about the molecular pathways that regulate its spreading. To address this unmet need, we hypothesize that a group of genes that regulate the generation and function of a specialized group of embryonic stem cells (neural crest cells) are reactivated to allow Ewing's sarcoma cells to metastasize. Our previous study show that expression of one such gene (Twist1) is associated with metastasis and poor survival in Ewing's sarcoma patients. Therefore, we propose to examine Twist1 and other genes regulated by Twist1 in Ewing sarcoma metastasis and to test whether drugs targeting these genes will block metastasis with higher specificity and fewer side effects than conventional therapy.  In the short term, the proposed research provides new prognostic markers to identify high-risk Ewing sarcoma patients for personalized treatment options. In the long term, the proposed research could lead to novel  therapeutic regimens that reduce morbidity from ineffective conventional therapies and save the lives of countless children affected with metastatic Ewing's sarcoma.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
30,45.0,Initial,45.1,Oncogenic Regulation of B-Lymphomagenesis by the Chromatin Modulator DOT1L,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Defining the role of DOT1L in B-lymphoma pathogenesis,Determining the mechanistic basis of  DOT1L activity in B-lymphoma ,,,,,"The epigenome is an exciting new frontier for therapeutic intervention in human disease, because unlike genomic abnormalities that are difficult to reverse therapeutically, abnormal epigenetic changes are amenable to reversal using chemical compounds. Our collaborative proposal aims to identify and characterize a novel, actionable, epigenetic vulnerability in B-lymphomas where safer curative treatment options are needed.",74881.0,2017-06-01,2018-05-31,Complete,False,False,False,False,False,False,False,False,False,False,False,False,False,False,True,True,False,Yes,"Pedal the Cause was critical to recruit and retain my most productive postdoctoral researcher, enabling us to reach our research goals. ",,0.0,,,,,None,No,,One
31,123.0,Initial,45.2,Oncogenic Regulation of B-Lymphomagenesis by the Chromatin Modulator DOT1L,Sanford Burnum,,False,True,False,False,False,Two Specific Aims,Defining the role of DOT1L in B-lymphoma pathogenesis,Determining the mechanistic basis of DOT1L activity in B-lymphoma,,,,,"The epigenome is an exciting new frontier for therapeutic intervention in human disease, because unlike genomic abnormalities that are difficult to reverse therapeutically, abnormal epigenetic changes are amenable to reversal using chemical compounds. Our collaborative proposal aims to identify and characterize a novel, actionable, epigenetic vulnerability in B-lymphomas where safer curative treatment options are needed.",74881.0,2017-06-01,2018-05-31,Complete,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,True,False,Yes,"Pedal the cause helped me to get my first large award from the American Cancer Society, which provided an opportunity for me to do high-risk, high-reward research.",,0.0,,,,,None,No,,One
32,185.0,Initial,185.1,Oncogenic Regulation of B-Lymphomagenesis by the Chromatin Modulator DOT1L,Sanford Burnum,,False,True,False,False,False,Two Specific Aims,Defining the role of DOT1L in B-lymphoma pathogenesis,Determining the mechanistic basis of  DOT1L activity in B-lymphoma,,,,,"The epigenome is an exciting new frontier for therapeutic intervention in human disease, because unlike genomic abnormalities that are difficult to reverse therapeutically, abnormal epigenetic changes are amenable to reversal using chemical compounds. Our collaborative proposal aims to identify and characterize a novel, actionable, epigenetic vulnerability in B-lymphomas where safer curative treatment options are needed.",74881.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
33,186.0,Initial,185.2,Oncogenic Regulation of B-Lymphomagenesis by the Chromatin Modulator DOT1L,UCSD - not a member of Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Defining the role of DOT1L in B-lymphoma pathogenesis,Determining the mechanistic basis of  DOT1L activity in B-lymphoma ,,,,,"The epigenome is an exciting new frontier for therapeutic intervention in human disease, because unlike  genomic abnormalities that are difficult to reverse therapeutically, abnormal epigenetic changes are amenable  to reversal using chemical compounds. Our collaborative proposal aims to identify and characterize a novel,  actionable, epigenetic vulnerability in B-lymphomas where safer curative treatment options are needed.",74881.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
34,48.0,Initial,48.1,Targeting cellular mechanotransduction in breast cancer metastasis,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Determine the role of EPHA2 in cellular mechanotransduction in response to matrix stiffness.,Determine the involvement of EPHA2 and Lyn in invasion and metastasis in tumor xenografts in mice and in human breast cancer progression.,,,,,"Breast tumors are frequently detected through physical palpation due to their apparent ""hardness"" compared to the soft normal mammary tissue. The ""hardness"" of breast tumors correlates with distant metastasis and poor outcome in breast cancer patients. Recent studies show that breast tumors show a 10-50-fold increase of mechanical force exerted on tumor cells compared to normal breast tissues and that mechanical force generated by increasing hardness of breast tumors promotes breast cancer metastasis. However, it is unknown how mechanical force impacts breast cancer metastasis and whether therapeutic targeting of this regulatory mechanism could halt breast cancer progression and metastasis.  Our ongoing studies have identified two druggable candidate proteins that are likely to play essential roles in promoting breast tumor invasion and metastasis in response to high matrix rigidities in the tumor microenvironment. In this proposal, we aim to further characterize these two proteins in this novel metastasis regulatory pathway and determine whether therapeutic targeting these two proteins could inhibit breast cancer invasion of surrounding normal tissue and the formation of metastases. In the short term, the proposed research provides new prognostic markers to identify high-risk breast cancer patients for personalized treatment options. In the long term, the proposed research could lead to novel therapeutic regimens targeting cellular mechanotransduction for high-risk breast cancer patients with dense and stiff breast tumors.",75000.0,2017-06-01,2018-05-31,Complete,False,False,True,False,False,False,False,False,True,False,False,False,False,False,False,False,False,Yes,The seed fund allow us to published and obtained an RO1 MPI grant to support new students.,,0.0,,,,,No.,No,,One
35,126.0,Initial,48.2,Targeting cellular mechanotransduction in breast cancer metastasis,Sanford Burnum,,False,True,False,False,False,Two Specific Aims,Determine the role of EPHA2 in cellular mechanotransduction in response to matrix stiffness.,Determine the involvement of EPHA2 and Lyn in invasion and metastasis in tumor xenografts in mice and in human breast cancer progression.,,,,,"Breast tumors are frequently detected through physical palpation due to their apparent ""hardness"" compared to the soft normal mammary tissue. The ""hardness"" of breast tumors correlates with distant metastasis and poor outcome in breast cancer patients. Recent studies show that breast tumors show a 10-50-fold increase of mechanical force exerted on tumor cells compared to normal breast tissues and that mechanical force generated by increasing hardness of breast tumors promotes breast cancer metastasis. However, it is unknown how mechanical force impacts breast cancer metastasis and whether therapeutic targeting of this regulatory mechanism could halt breast cancer progression and metastasis.  Our ongoing studies have identified two druggable candidate proteins that are likely to play essential roles in promoting breast tumor invasion and metastasis in response to high matrix rigidities in the tumor microenvironment. In this proposal, we aim to further characterize these two proteins in this novel metastasis regulatory pathway and determine whether therapeutic targeting these two proteins could inhibit breast cancer invasion of surrounding normal tissue and the formation of metastases. In the short term, the proposed research provides new prognostic markers to identify high-risk breast cancer patients for personalized treatment options. In the long term, the proposed research could lead to novel therapeutic regimens targeting cellular mechanotransduction for high-risk breast cancer patients with dense and stiff breast tumors.",75000.0,2017-06-01,2018-05-31,Complete,False,False,False,False,False,False,False,False,True,False,False,False,False,False,False,False,False,Yes,Enabled initial work that eventually led to a high profile publication and NIH R01 grant.,,0.0,,,,,,No,,One
36,189.0,Initial,189.1,Targeting cellular mechanotransduction in breast cancer metastasis,UCSD - not a member of Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Determine the role of EPHA2 in cellular mechanotransduction in response to matrix stiffness.,Determine the involvement of EPHA2 and Lyn in invasion and metastasis in tumor xenografts in mice and in human breast cancer progression.,,,,,"Breast tumors are frequently detected through physical palpation due to their apparent ""hardness"" compared to the soft normal mammary tissue. The ""hardness"" of breast tumors correlates with distant metastasis and poor outcome in breast cancer patients. Recent studies show that breast tumors show a 10-50-fold increase of mechanical force exerted on tumor cells compared to normal breast tissues and that mechanical force generated by increasing hardness of breast tumors promotes breast cancer metastasis. However, it is unknown how mechanical force impacts breast cancer metastasis and whether therapeutic targeting of this regulatory mechanism could halt breast cancer progression and metastasis. Our ongoing studies have identified two druggable candidate proteins that are likely to play essential roles in promoting breast tumor invasion and metastasis in response to high matrix rigidities in the tumor microenvironment. In this proposal, we aim to further characterize these two proteins in this novel metastasis regulatory pathway and determine whether therapeutic targeting these two proteins could inhibit breast cancer invasion of surrounding normal tissue and the formation of metastases. In the short term, the proposed research provides new prognostic markers to identify high-risk breast cancer patients for personalized treatment options. In the long term, the proposed research could lead to novel therapeutic regimens targeting cellular mechanotransduction for high-risk breast cancer patients with dense and stiff breast tumors.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
37,190.0,Initial,189.2,Targeting cellular mechanotransduction in breast cancer metastasis,Sanford Burnum,,False,True,False,False,False,Two Specific Aims,Determine the role of EPHA2 in cellular mechanotransduction in response to matrix stiffness.,Determine the involvement of EPHA2 and Lyn in invasion and metastasis in tumor xenografts in mice and in human breast cancer progression.,,,,,"Breast tumors are frequently detected through physical palpation due to their apparent ""hardness"" compared to the soft normal mammary tissue. The ""hardness"" of breast tumors correlates with distant metastasis and poor outcome in breast cancer patients. Recent studies show that breast tumors show a 10-50-fold increase of mechanical force exerted on tumor cells compared to normal breast tissues and that mechanical force generated by increasing hardness of breast tumors promotes breast cancer metastasis. However, it is unknown how mechanical force impacts breast cancer metastasis and whether therapeutic targeting of this regulatory mechanism could halt breast cancer progression and metastasis. Our ongoing studies have identified two druggable candidate proteins that are likely to play essential roles in promoting breast tumor invasion and metastasis in response to high matrix rigidities in the tumor microenvironment. In this proposal, we aim to further characterize these two proteins in this novel metastasis regulatory pathway and determine whether therapeutic targeting these two proteins could inhibit breast cancer invasion of surrounding normal tissue and the formation of metastases. In the short term, the proposed research provides new prognostic markers to identify high-risk breast cancer patients for personalized treatment options. In the long term, the proposed research could lead to novel therapeutic regimens targeting cellular mechanotransduction for high-risk breast cancer patients with dense and stiff breast tumors.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
38,161.0,Initial,161.1,Therapeutic Reprogramming of Pancreatic Cancer Stroma Via Modulation of p62 and p53 (YEAR 1),Salk Institute,,False,True,False,False,False,Two Specific Aims,1a. Effect of p62 or p53 stromal deficiency on PDAC progression in vivo.    1b. Human organotypic studies to explore the role of p62 and p53 deficient CAFs in PDAC progression.  ,Identify modulators of p62 or p35 activity in the tumor stroma.,,,,,"Pancreatic cancer remains the most deadly common cancer in the U.S. with a 5-year survival rate of 6%. Despite the fact that fewer persons are diagnosed with pancreatic cancer than many other cancers, this high death rate will likely make it the number 2 cancer killer by 2020. Clearly, new therapies for this disease are desperately needed. A unique feature of pancreatic cancer is that the cancer cells embed themselves within a hard matrix consisting of scar-like tissue and non-cancerous cells that help produce this scar-like tissue. Based on many scientific studies, it appears that these non-cancerous cells help to provide the cancer cells with nutrients and act as a protective barrier, effectively shielding the cancer cells from intended therapies such as chemotherapy drugs. Researchers have now attempted to target the accumulation or even destroy this scar tissue using a variety of approaches, though none have been successful to date. In fact, some approaches have caused pancreatic cancer to grow faster in mouse models of the disease. Our laboratories have identified that the non-cancerous cells present in pancreatic tumors have lost the function of 2 proteins, p53 and p62, that normally act to suppress cancer development. We believe that restoring the function of these proteins may act to ""reprogram"" these cells so that they can no longer support the growth of pancreatic cancer or maintain this barrier to drug penetration. We propose to study how losing the function of the p53 and p62 proteins affects the growth and spread of pancreatic cancer. Next we will use new tools developed by our group to rapidly screen through a very large number of drugs in order to identify those which can restore p53 and p62 function. By identifying such drugs, we will then be in a position to test them as part of a new treatment approach to pancreatic cancer.",300000.0,2015-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
39,162.0,Initial,161.2,Therapeutic Reprogramming of Pancreatic Cancer Stroma Via Modulation of p62 and p53 (YEAR 1),Sanford Burnum,,False,True,False,False,False,Two Specific Aims,1a. Effect of p62 or p53 stromal deficiency on PDAC progression in vivo.    1b. Human organotypic studies to explore the role of p62 and p53 deficient CAFs in PDAC progression.  ,Identify modulators of p62 or p35 activity in the tumor stroma.,,,,,"Pancreatic cancer remains the most deadly common cancer in the U.S. with a 5-year survival rate of 6%. Despite the fact that fewer persons are diagnosed with pancreatic cancer than many other cancers, this high death rate will likely make it the number 2 cancer killer by 2020. Clearly, new therapies for this disease are desperately needed. A unique feature of pancreatic cancer is that the cancer cells embed themselves within a hard matrix consisting of scar-like tissue and non-cancerous cells that help produce this scar-like tissue. Based on many scientific studies, it appears that these non-cancerous cells help to provide the cancer cells with nutrients and act as a protective barrier, effectively shielding the cancer cells from intended therapies such as chemotherapy drugs. Researchers have now attempted to target the accumulation or even destroy this scar tissue using a variety of approaches, though none have been successful to date. In fact, some approaches have caused pancreatic cancer to grow faster in mouse models of the disease. Our laboratories have identified that the non-cancerous cells present in pancreatic tumors have lost the function of 2 proteins, p53 and p62, that normally act to suppress cancer development. We believe that restoring the function of these proteins may act to ""reprogram"" these cells so that they can no longer support the growth of pancreatic cancer or maintain this barrier to drug penetration. We propose to study how losing the function of the p53 and p62 proteins affects the growth and spread of pancreatic cancer. Next we will use new tools developed by our group to rapidly screen through a very large number of drugs in order to identify those which can restore p53 and p62 function. By identifying such drugs, we will then be in a position to test them as part of a new treatment approach to pancreatic cancer.",300000.0,2015-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
40,163.0,Initial,161.3,Therapeutic Reprogramming of Pancreatic Cancer Stroma Via Modulation of p62 and p53 (YEAR 1),Sanford Burnum,,False,True,False,False,False,Two Specific Aims,1a. Effect of p62 or p53 stromal deficiency on PDAC progression in vivo.    1b. Human organotypic studies to explore the role of p62 and p53 deficient CAFs in PDAC progression.  ,Identify modulators of p62 or p35 activity in the tumor stroma.,,,,,"Pancreatic cancer remains the most deadly common cancer in the U.S. with a 5-year survival rate of 6%. Despite the fact that fewer persons are diagnosed with pancreatic cancer than many other cancers, this high death rate will likely make it the number 2 cancer killer by 2020. Clearly, new therapies for this disease are desperately needed. A unique feature of pancreatic cancer is that the cancer cells embed themselves within a hard matrix consisting of scar-like tissue and non-cancerous cells that help produce this scar-like tissue. Based on many scientific studies, it appears that these non-cancerous cells help to provide the cancer cells with nutrients and act as a protective barrier, effectively shielding the cancer cells from intended therapies such as chemotherapy drugs. Researchers have now attempted to target the accumulation or even destroy this scar tissue using a variety of approaches, though none have been successful to date. In fact, some approaches have caused pancreatic cancer to grow faster in mouse models of the disease. Our laboratories have identified that the non-cancerous cells present in pancreatic tumors have lost the function of 2 proteins, p53 and p62, that normally act to suppress cancer development. We believe that restoring the function of these proteins may act to ""reprogram"" these cells so that they can no longer support the growth of pancreatic cancer or maintain this barrier to drug penetration. We propose to study how losing the function of the p53 and p62 proteins affects the growth and spread of pancreatic cancer. Next we will use new tools developed by our group to rapidly screen through a very large number of drugs in order to identify those which can restore p53 and p62 function. By identifying such drugs, we will then be in a position to test them as part of a new treatment approach to pancreatic cancer.",300000.0,2015-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
41,164.0,Initial,161.4,Therapeutic Reprogramming of Pancreatic Cancer Stroma Via Modulation of p62 and p53 (YEAR 1),UCSD - not a member of Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,1a. Effect of p62 or p53 stromal deficiency on PDAC progression in vivo.    1b. Human organotypic studies to explore the role of p62 and p53 deficient CAFs in PDAC progression.  ,Identify modulators of p62 or p35 activity in the tumor stroma.,,,,,"Pancreatic cancer remains the most deadly common cancer in the U.S. with a 5-year survival rate of 6%. Despite the fact that fewer persons are diagnosed with pancreatic cancer than many other cancers, this high death rate will likely make it the number 2 cancer killer by 2020. Clearly, new therapies for this disease are desperately needed. A unique feature of pancreatic cancer is that the cancer cells embed themselves within a hard matrix consisting of scar-like tissue and non-cancerous cells that help produce this scar-like tissue. Based on many scientific studies, it appears that these non-cancerous cells help to provide the cancer cells with nutrients and act as a protective barrier, effectively shielding the cancer cells from intended therapies such as chemotherapy drugs. Researchers have now attempted to target the accumulation or even destroy this scar tissue using a variety of approaches, though none have been successful to date. In fact, some approaches have caused pancreatic cancer to grow faster in mouse models of the disease. Our laboratories have identified that the non-cancerous cells present in pancreatic tumors have lost the function of 2 proteins, p53 and p62, that normally act to suppress cancer development. We believe that restoring the function of these proteins may act to ""reprogram"" these cells so that they can no longer support the growth of pancreatic cancer or maintain this barrier to drug penetration. We propose to study how losing the function of the p53 and p62 proteins affects the growth and spread of pancreatic cancer. Next we will use new tools developed by our group to rapidly screen through a very large number of drugs in order to identify those which can restore p53 and p62 function. By identifying such drugs, we will then be in a position to test them as part of a new treatment approach to pancreatic cancer.",300000.0,2015-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
42,46.0,Initial,46.1,An over-expressed GPCR in pancreatic cancer associated fibroblasts as a novel therapeutic target,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Define PCAF activities in response to GPCR activation of low pH.,Develop and validate an assay to find inhibitors of GPR68 and use this assay in a pilot screen of the SBP library of compounds.,,,,,"Pancreatic ductal adenocarcinoma (PDAC) is the most common and deadly form of pancreatic cancer with >93% of PDAC patients dying less than 5 years after their diagnosis.  Part of the difficulty in treating PDAC is its characteristic dense scarring (""fibrosis"").  This scarring is generated by pancreatic cancer associated fibroblasts (PCAFs).  This project seeks to build on our recent discovery that PCAFs have high expression of a novel protein on their cell surface.  This protein, known as a GPCR, is activated by the acidic (low pH) environment that exist in pancreatic cancers.  When activated by this low pH, the PCAFs communicate with the PDC cells to enhance their growth.  In this project, UCSD investigators will conduct studies to define additional responses produced by exposure of CAFs to low pH and with Sandford-Burnham-Prebys Cancer Center/Medical Discovery Institute (SBP), will assess ""libraries"" (collections) of chemical compounds, certain of which are predicted to antagonize the GPCR we identified and which, as a result, should block the production of scarring and stimulation of PDAC growth by the PCAFs.  These studies that combine efforts at UCSD with those at SBP thus focus on the ""tumor microenvironment"" in which PDAC cells and PCAFs interact and will test the idea that a drug that blocks a special type of GPCR present in PCAF cells can provide a novel way to assist in the treatment PDAC tumors and thus ma be a new way to improve the outcome of this very deadly type of cancer.",75000.0,2017-05-01,2018-04-30,Complete,False,False,True,False,False,False,False,False,False,False,False,False,False,False,True,False,False,Yes,Data from the Pedal the Cause project encouraged a post-doc to join our lab and initiate subsequent experiments on GPR68.,,0.0,,,,,No name yet but in the process of founding a company through UCSD with Autobahn Labs.,Yes,"A PCT was submitted in 2018: ""GPCRs in Cancer-Associated Fibroblasts"",",Four
43,124.0,Initial,46.2,An over-expressed GPCR in pancreatic cancer associated fibroblasts as a novel therapeutic target,Sanford Burnum,,False,True,False,False,False,Two Specific Aims,Define PCAF activities in response to GPCR activation of low pH.,Develop and validate an assay to find inhibitors of GPR68 and use this assay in a pilot screen of the SBP library of compounds.,,,,,"Pancreatic ductal adenocarcinoma (PDAC) is the most common and deadly form of pancreatic cancer with >93% of PDAC patients dying less than 5 years after their diagnosis.  Part of the difficulty in treating PDAC is its characteristic dense scarring (""fibrosis"").  This scarring is generated by pancreatic cancer associated fibroblasts (PCAFs).  This project seeks to build on our recent discovery that PCAFs have high expression of a novel protein on their cell surface.  This protein, known as a GPCR, is activated by the acidic (low pH) environment that exist in pancreatic cancers.  When activated by this low pH, the PCAFs communicate with the PDC cells to enhance their growth.  In this project, UCSD investigators will conduct studies to define additional responses produced by exposure of CAFs to low pH and with Sandford-Burnham-Prebys Cancer Center/Medical Discovery Institute (SBP), will assess ""libraries"" (collections) of chemical compounds, certain of which are predicted to antagonize the GPCR we identified and which, as a result, should block the production of scarring and stimulation of PDAC growth by the PCAFs.  These studies that combine efforts at UCSD with those at SBP thus focus on the ""tumor microenvironment"" in which PDAC cells and PCAFs interact and will test the idea that a drug that blocks a special type of GPCR present in PCAF cells can provide a novel way to assist in the treatment PDAC tumors and thus may be a new way to improve the outcome of this very deadly type of cancer.",75000.0,2017-05-01,2018-04-30,Complete,False,False,False,False,False,False,False,False,False,False,False,False,False,False,True,False,False,No,,"no role in recruitment, retention or advancement",0.0,,,,,None,No,,Three
44,188.0,Initial,187.2,An over-expressed GPCR in pancreatic cancer associated fibroblasts as a novel therapeutic target,Sanford Burnum,,False,True,False,False,False,Two Specific Aims,Define PCAF activities in response to GPCR activation by low pH.,Develop and validate an assay to find inhibitors of GPR68 and use this assay in a pilot screen of the SBP library of compounds.,,,,,"Pancreatic ductal adenocarcinoma (PDAC) is the most common and deadly form of pancreatic cancer with <93% of PDAC patients dying less than 5 years after their diagnosis.  Part of the difficulty in treating PDAC is its characteristic dense scarring (""fibrosis"").  This scarring is generated by pancreatic cancer associated fibroblasts (PCAFs).  This project seeks to build on our recent discovery that PCAFs have high expression of novel protein on their cell surface.  This protein, known as a GPCR, is activated by the acidic (low pH) environment that exists in pancreatic cancers.  When activated by this low pH, the PCAFs communicate with the PDAC cells to enhance their growth.  In this project, UCSD investigators will conduct studies to define additional responses produced by exposure of CAFs to low pH and with Sanford-Burnham-Prebys Cancer Center/Medical Discovery Institute (SBP), will assess ""libraries"" (collections) of chemical compounds, certain of which are predicted to antagonize the GPCR we identified and which, as a result, should block the production of scarring and stimulation of PDAC growth by the PCAFs.  These studies that combine efforts at UCSD with those at SBP thus focus on the ""tumor microenvironment"" in which PDAC cells and PCAFs interact and will test the idea that a drug that blocks a special type of GPCR present in PCAF cells can provide a novel way to assist in the treatment PDAC tumors and thus may be a new way to improve the outcome of this very deadly type of cancer.",75000.0,2017-05-01,2018-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
45,25.0,Initial,25.1,FEN1 Nuclease-Targeted Therapy for Ewing Sarcoma,Moores Cancer Center,,False,False,False,False,True,Three Specific Aims,To Determine the Response of a Panel of Ewing Sarcoma Cell Lines to FEN1 Inhibitor,To Investigate the Response of Ewing Sarcoma Cell Lines to Genetic Ablation of FEN1 ,To Investigate the Role of EWS-FLI1 Fusion Gene in Causing FEN1-Dependency,,,,"Ewing sarcoma (ES) is a bone cancer that affects children and young adults. Despite aggressive treatment survival remains poor because of resistance to chemotherapy. Our study will investigate a new drug target, FEN1, to overcome resistance to current therapy.  FEN1 is an enzyme that helps with DNA replication. Others have shown that ES cells behave like BRCAdeficient cells, which we know are hypersensitive to FEN1 inhibition. ES cells are also sensitive to removal of FEN1 by a process that uses CRISPR to knockout genes. Further, we have found that ES cells from at least  one patient are hypersensitive to our FEN1 inhibitor, SMD2485.  To explore the possibility of treating ES with FEN1 inhibitors, we will measure the effects of SMD2485 in a panel of ES cells. We will compare the effects of SMD2485 to that of Olaparib (PARP inhibitor) and traditional chemotherapy. Patients that are refractory to chemotherapy are often also resistant to PARP inhibitors. By  comparing the responses to SMD2485, Olaparib, and chemo drugs, we will determine if FEN1 inhibition is efficacious in treating chemo resistant ES cells. We will silence, by using RNA interference, the abnormal EWS-FLI1 that drives ES. One of EWS-FLI1's many functions is to cause BRCA-deficiency, which then causes ES cells to be sensitive to FEN1 inhibitors. We will determine how silencing EWS-FLI1 will affect the responses  of ES cells to SMD2485, Olaparib, and chemo drugs.  This project will provide the necessary pre-clinical data for evaluating FEN1 as a drug target to treat Ewing sarcoma. ",99988.0,2019-06-01,2020-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,"The Pedal the Cause funding was instrumental for us to launch this new collaborative, translational, cancer research project and to win an NCI multi-PI R01 to support this project for 5 years. ",,0.0,,,,,None,No,,Zero
46,89.0,Initial,25.2,FEN1 Nuclease-Targeted Therapy for Ewing Sarcoma,Moores Cancer Center,,False,False,False,False,True,Three Specific Aims,To Determine the Response of a Panel of Ewing Sarcoma Cell Lines to FEN1 Inhibitor,To Investigate the Response of Ewing Sarcoma Cell Lines to Genetic Ablation of FEN1 ,To Investigate the Role of EWS-FLI1 Fusion Gene in Causing FEN1-Dependency,,,,"Ewing sarcoma (ES) is a bone cancer that affects children and young adults. Despite aggressive treatment, survival remains poor because of resistance to chemotherapy. Our study will investigate a new drug target, FEN1, to overcome resistance to current therapy. FEN1 is an enzyme that helps with DNA replication. Others have shown that ES cells behave like BRCAdeficient cells, which we know are hypersensitive to FEN1 inhibition. ES cells are also sensitive to removal of FEN1 by a process that uses CRISPR to knockout genes. Further, we have found that ES cells from at least one patient are hypersensitive to our FEN1 inhibitor, SMD2485. To explore the possibility of treating ES with FEN1 inhibitors, we will measure the effects of SMD2485 in a panel of ES cells. We will compare the effects of SMD2485 to that of Olaparib (PARP inhibitor) and traditional chemotherapy. Patients that are refractory to chemotherapy are often also resistant to PARP inhibitors. By comparing the responses to SMD2485, Olaparib, and chemo drugs, we will determine if FEN1 inhibition is efficacious in treating chemo resistant ES cells. We will silence, by using RNA interference, the abnormal EWS-FLI1 that drives ES. One of EWS-FLI1's many functions is to cause BRCA-deficiency, which then causes ES cells to be sensitive to FEN1 inhibitors. We will determine how silencing EWS-FLI1 will affect the responses of ES cells to SMD2485, Olaparib, and chemo drugs.  This project will provide the necessary pre-clinical data for evaluating FEN1 as a drug target to treat Ewing sarcoma.",99988.0,2019-06-01,2020-05-31,Complete,False,False,False,False,False,False,True,False,False,False,False,False,False,False,False,False,False,No,,It was an important for initiating a research project.,0.0,,,,,0.0,No,,Zero
47,90.0,Initial,25.3,FEN1 Nuclease-Targeted Therapy for Ewing Sarcoma,Moores Cancer Center,,False,False,False,False,True,Three Specific Aims,To Determine the Response of a Panel of Ewing Sarcoma Cell Lines to FEN1 Inhibitor,To Investigate the Response of Ewing Sarcoma Cell Lines to Genetic Ablation of FEN1 ,To Investigate the Role of EWS-FLI1 Fusion Gene in Causing FEN1-Dependency,,,,"Ewing sarcoma (ES) is a bone cancer that affects children and young adults. Despite aggressive treatment, survival remains poor because of resistance to chemotherapy. Our study will investigate a new drug target, FEN1, to overcome resistance to current therapy. FEN1 is an enzyme that helps with DNA replication. Others have shown that ES cells behave like BRCAdeficient cells, which we know are hypersensitive to FEN1 inhibition. ES cells are also sensitive to removal of FEN1 by a process that uses CRISPR to knockout genes. Further, we have found that ES cells from at least one patient are hypersensitive to our FEN1 inhibitor, SMD2485. To explore the possibility of treating ES with FEN1 inhibitors, we will measure the effects of SMD2485 in a panel of ES cells. We will compare the effects of SMD2485 to that of Olaparib (PARP inhibitor) and traditional chemotherapy. Patients that are refractory to chemotherapy are often also resistant to PARP inhibitors. By comparing the responses to SMD2485, Olaparib, and chemo drugs, we will determine if FEN1 inhibition is efficacious in treating chemo resistant ES cells. We will silence, by using RNA interference, the abnormal EWS-FLI1 that drives ES. One of EWS-FLI1's many functions is to cause BRCA-deficiency, which then causes ES cells to be sensitive to FEN1 inhibitors. We will determine how silencing EWS-FLI1 will affect the responses of ES cells to SMD2485, Olaparib, and chemo drugs.  This project will provide the necessary pre-clinical data for evaluating FEN1 as a drug target to treat Ewing sarcoma.",99988.0,2019-06-01,2020-05-31,Complete,False,False,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,,0.0,,,,,None,No,,Zero
48,125.0,Initial,47.2,"Identification of genes critical for the production of T cells from human pluripotent stem cells for development of ""off-the-shelf"" T cell immunotherapies",Sanford Burnum,,False,False,True,False,False,Two Specific Aims,Use a genome-wide CRISPR-Cas9 screen in hESC cells to identify genes whose disruption leads to the development of effector T cells.,Validate and assess tumor-killing capacity of clonal hESC-derived T cells.,,,,,"While anti-cancer therapies continue to improve, too many patients still do not respond to conventional therapies and die from their malignancy. A promising new therapy involves the use of the patient's own white blood cells, known as T cells, being removed and engineered to specifically target tumors before being reintroduced to the patient. While this cancer immunotherapy approach appears to work well for some cancers, it is a laborious and expensive process. An ideal solution is to produce ""off the shelf"" T cells which can be genetically altered to kill tumors. Human pluripotent stem cells can multiply without limit, differentiate into T cells, and be engineered to avoid being rejected by the immune systems of different patients, making them an ideal source universal donor cells. While previous studies have demonstrated derivation of T cells from human pluripotent stem cells, the process is inefficient. In this proposal, we will use genetic screening to individually disrupt genes in stem cells and then derive specific T cells capable of killing tumors. We will select these tumor killing cells and then use DNA sequencing to discern which genes are disrupted in the desired population. These genes can then be studied individually to derive stem cell lines, which will reliably give rise to T cells capable of killing tumors. These cells can then be modified to both avoid host rejection and target specific tumors. These universal donor ""off the shelf"" T cells will then be suitable to treat cancers in multiple patients.",75000.0,2017-06-01,2018-05-31,Complete,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,True,False,No,,"It was beneficial to the recruitment of personnel on the project but did not affect my personal recruitment, retention, or advancement.",0.0,,,,,,No,,Zero
49,191.0,Initial,191.1,"Identification of genes critical for the production of T cells from human pluripotent stem cells for development of ""off-the-shelf"" T cell immunotherapies",UCSD - not a member of Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,Use a genome-wide CRISPR-Cas9 screen in hESC cells to identify genes whose disruption leads to the development of effector T cells,Validate and assess tumor killing capacity of clonal hESC-derived T cells,,,,,"While anti-cancer therapies continue to improve, too many patients still do not respond to conventional therapies and die from their malignancy. A promising new therapy involves the use of the patient's own white blood cells, known as T cells, being removed and engineered to specifically target tumors before being reintroduced to the patient. While this cancer immunotherapy approach appears to work well for some cancers, it is a laborious and expensive process. An ideal solution is to produce ""off the shelf"" T cells which can be genetically altered to kill tumors. Human pluripotent stem cells can multiply without limit, differentiate into T cells, and be engineered to avoid being rejected by the immune systems of different patients, making them an ideal source universal donor cells. While previous studies have demonstrated derivation of T cells from human pluripotent stem cells, the process is inefficient. In this proposal we will use genetic screening to individually disrupt genes in stem cells and then derive specific T cells capable of killing tumors. We will select these tumor killing cells and then use DNA sequencing to discern which genes are disrupted in the desired population.  These genes can then be studied individually to derive stem cell lines which will reliably give rise to T cells capable of killing tumors. These cells can then be modified to both avoid host rejection and target specific tumors. These universal donor ""off the shelf"" T cells will then be suitable to treat cancers in multiple patients.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
50,192.0,Initial,191.2,"Identification of genes critical for the production of T cells from human pluripotent stem cells for development of ""off-the-shelf"" T cell immunotherapies",Sanford Burnum,,False,False,True,False,False,Two Specific Aims,Use a genome-wide CRISPR-Cas9 screen in hESC cells to identify genes whose disruption leads to the development of effector T cells,Validate and assess tumor killing capacity of clonal hESC-derived T cells,,,,,"While anti-cancer therapies continue to improve, too many patients still do not respond to conventional therapies and die from their malignancy. A promising new therapy involves the use of the patient's own white blood cells, known as T cells, being removed and engineered to specifically target tumors before being reintroduced to the patient. While this cancer immunotherapy approach appears to work well for some cancers, it is a laborious and expensive process. An ideal solution is to produce ""off the shelf"" T cells which can be genetically altered to kill tumors. Human pluripotent stem cells can multiply without limit, differentiate into T cells, and be engineered to avoid being rejected by the immune systems of different patients, making them an ideal source universal donor cells. While previous studies have demonstrated derivation of T cells from human pluripotent stem cells, the process is inefficient. In this proposal we will use genetic screening to individually disrupt genes in stem cells and then derive specific T cells capable of killing tumors. We will select these tumor killing cells and then use DNA sequencing to discern which genes are disrupted in the desired population.  These genes can then be studied individually to derive stem cell lines which will reliably give rise to T cells capable of killing tumors. These cells can then be modified to both avoid host rejection and target specific tumors. These universal donor ""off the shelf"" T cells will then be suitable to treat cancers in multiple patients.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
51,129.0,Initial,50.2,Tissue-specific role of SMARCB1 in pediatric Rhabdoid tumors,Rady Children's,,False,False,False,False,True,Two Specific Aims,Determine cellular constraints on the ability of SMARCB1 inactivation to initiate tumorigenesis.,Investigate mechanisms underlying tissue-specific effects of SMARCB1 deletion. ,,,,,"This project aims to identify the mechanisms underlying initiation of pediatric rhabdoid tumors of the kidney and atypical teratoid rhabdoid tumors (ATRT) of the brain, which result from deletion of the SMARCB1 gene. To determine why SMARCB1 deletion initiates tumors only in certain tissues and developmental stages the project will investigate differences in the effect of eliminating SMARCB1 expression on cells of different tissue types and attempt to identify potential therapeutic targets which could aid in the treatment of patients with these lethal childhood tumors, which currently have very limited therapeutic options.",75000.0,2017-06-01,2018-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,,0.0,,,,,,No,,One
52,196.0,Initial,196.1,Tissue-specific role of SMARCB1 in pediatric Rhabdoid tumors,UCSD - not a member of Moores Cancer Center,,False,False,False,False,True,Two Specific Aims, Determine cellular constraints on the ability of SMARCB1 inactivation to initiate tumorigenesis.,Investigate mechanisms underlying tissue-specific effects of SMARCB1 deletion.,,,,,"This project aims to identify the mechanisms underlying initiation of pediatric rhabdoid tumors of the kidney and atypical teratoid rhabdoid tumors (ATRT) of the brain, which result from deletion of the SMARCB1 gene. To  determine why SMARCB1 deletion initiates tumors only in certain tissues and developmental stages the project will investigate differences in the effect of eliminating SMARCB1 expression on cells of different tissue  types and attempt to identify potential therapeutic targets which could aid in the treatment of patients with these lethal childhood tumors, which currently have very limited therapeutic options.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
53,197.0,Initial,196.2,Tissue-specific role of SMARCB1 in pediatric Rhabdoid tumors,UCSD - not a member of Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,Determine cellular constraints on the ability of SMARCB1 inactivation to initiate tumorigenesis.,Investigate mechanisms underlying tissue-specific effects of SMARCB1 deletion.,,,,,"This project aims to identify the mechanisms underlying initiation of pediatric rhabdoid tumors of the kidney and atypical teratoid rhabdoid tumors (ATRT) of the brain, which result from deletion of the SMARCB1 gene. To  determine why SMARCB1 deletion initiates tumors only in certain tissues and developmental stages the project will investigate differences in the effect of eliminating SMARCB1 expression on cells of different tissue  types and attempt to identify potential therapeutic targets which could aid in the treatment of patients with these lethal childhood tumors, which currently have very limited therapeutic options.",75000.0,2017-06-01,2018-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
54,34.0,Initial,34.1,Understanding and Targeting NRF2 in Pancreatic Cancer,Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,Determine how NRF2 shapes pancreatic cancer cell metabolism.,Examine the ability of MDM2 inhibitors to induce PDAC regression in KrasG12D;Nrf2Act mice  and PDX-bearing mice.,Examine whether bioreactive prodrugs that are specifically activated by the NRF2 target  NQO1 induce regression of mouse and human PDAC.,,,,"We have identified a protein that is called NRF2, whose expression is elevated in the pancreas of patients suffering from chronic pancreatitis, an inflammatory disease that greatly increases pancreatic cancer risk. Importantly, NRF2 expression remains elevated in established pancreatic cancer. In preclinical studies we  found that inhibition of NRF2 expression slows down development of pancreatic cancer in mice subjected to either acute or chronic pancreatitis. These results suggest that developing drugs to lower NRF2 or kill cells with elevated NRF2 may be used to prevent pancreatic cancer in high-risk individuals and may also be effective  against established pancreatic cancer. To better understand how NRF2 accelerates the development of pancreatic cancer and provide us with an experimental system suitable for testing of NRF2 targeting drugs, we  generated a new mouse model in which the formation of pancreatic cancer is strictly dependent on NRF2. We will use these mice to study how NRF2 controls pancreatic cancer metabolism and determine whether known  drugs that inhibit certain aspects of NRF2's tumorigenic activity can be used to prevent pancreatic cancer. We will also asses the therapeutic potential of a new class of prodrugs whose conversion to fully toxic anticancer  drugs is NRF2-dependent. We expect such drugs to selectively kill pancreatic cancer cells that possess high NRF2 activity while sparing normal cells in which NRF2 expression is low. These studies will contribute to development of new procedures for prevention and treatment of pancreatic cancer, the deadliest common human  malignancy.",125000.0,2018-06-01,2019-05-31,Complete,False,False,True,False,False,False,False,False,False,False,False,False,False,False,False,False,True,No,,,0.0,,,,,None.,Yes,"Track Code: 2020-263-2PCT  Application Number: PCT/2021/013203  Status: Pending: Active  Country of Filing: United States  Inventors: Michael Karin, Hua Su  Title: Combination Therapy for Pancreatic Cancer",Three
55,103.0,Initial,34.2,Understanding and Targeting NRF2 in Pancreatic Cancer,Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,Determine how NRF2 shapes pancreatic cancer cell metabolism.,Examine the ability of MDM2 inhibitors to induce PDAC regression in KrasG12D;Nrf2Act mice and PDX-bearing mice.,Examine whether bioreactive prodrugs that are specifically activated by the NRF2 target NQO1 induce regression of mouse and human PDAC.,,,,"We have identified a protein that is called NRF2, whose expression is elevated in the pancreas of patients suffering from chronic pancreatitis, an inflammatory disease that greatly increases pancreatic cancer risk. Importantly, NRF2 expression remains elevated in established pancreatic cancer. In preclinical studies we found that inhibition of NRF2 expression slows down development of pancreatic cancer in mice subjected to either acute or chronic pancreatitis. These results suggest that developing drugs to lower NRF2 or kill cells with elevated NRF2 may be used to prevent pancreatic cancer in high-risk individuals and may also be effective against established pancreatic cancer. To better understand how NRF2 accelerates the development of pancreatic cancer and provide us with an experimental system suitable for testing of NRF2 targeting drugs, we generated a new mouse model in which the formation of pancreatic cancer is strictly dependent on NRF2. We will use these mice to study how NRF2 controls pancreatic cancer metabolism and determine whether known drugs that inhibit certain aspects of NRF2's tumorigenic activity can be used to prevent pancreatic cancer. We will also asses the therapeutic potential of a new class of prodrugs whose conversion to fully toxic anticancer drugs is NRF2-dependent. We expect such drugs to selectively kill pancreatic cancer cells that possess high NRF2 activity while sparing normal cells in which NRF2 expression is low. These studies will contribute to development of new procedures for prevention and treatment of pancreatic cancer, the deadliest common human malignancy.",125000.0,2018-06-01,2019-05-31,Complete,False,False,True,False,False,False,True,False,False,False,False,False,False,False,False,False,False,No,,,0.0,,,,,None,No,,Two
56,104.0,Initial,34.3,Understanding and Targeting NRF2 in Pancreatic Cancer,Sanford Burnum,,False,True,False,False,False,Three Specific Aims,Determine how NRF2 shapes pancreatic cancer cell metabolism.,Examine the ability of MDM2 inhibitors to induce PDAC regression in KrasG12D;Nrf2Act mice and PDX-bearing mice.,Examine whether bioreactive prodrugs that are specifically activated by the NRF2 target NQO1 induce regression of mouse and human PDAC.,,,,"We have identified a protein that is called NRF2, whose expression is elevated in the pancreas of patients suffering from chronic pancreatitis, an inflammatory disease that greatly increases pancreatic cancer risk. Importantly, NRF2 expression remains elevated in established pancreatic cancer. In preclinical studies we found that inhibition of NRF2 expression slows down development of pancreatic cancer in mice subjected to either acute or chronic pancreatitis. These results suggest that developing drugs to lower NRF2 or kill cells with elevated NRF2 may be used to prevent pancreatic cancer in high-risk individuals and may also be effective against established pancreatic cancer. To better understand how NRF2 accelerates the development of pancreatic cancer and provide us with an experimental system suitable for testing of NRF2 targeting drugs, we generated a new mouse model in which the formation of pancreatic cancer is strictly dependent on NRF2. We will use these mice to study how NRF2 controls pancreatic cancer metabolism and determine whether known drugs that inhibit certain aspects of NRF2's tumorigenic activity can be used to prevent pancreatic cancer. We will also asses the therapeutic potential of a new class of prodrugs whose conversion to fully toxic anticancer drugs is NRF2-dependent. We expect such drugs to selectively kill pancreatic cancer cells that possess high NRF2 activity while sparing normal cells in which NRF2 expression is low. These studies will contribute to development of new procedures for prevention and treatment of pancreatic cancer, the deadliest common human malignancy.",125000.0,2018-06-01,2019-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
57,154.0,Initial,154.1,"Highly selective, synthetic, cleavage specificity-based nanobiosensors for tumorigenic and anti-tumorigenic MMPs",Sanford Burnum,,True,False,False,False,False,Two Specific Aims,"Design and test the QD-FRET MMP-8 and MMP-9 nanosensors in vitro, in cell-based tests and in selected cancer biopsies","Demonstrate low levels, if any, of the off-target activities of the nanosensors using a panel of the purified MMP constructs",,,,,"There is consensus among professionals that matrix metalloproteinases (MMPs), the specialized enzymes produced in cancer, are promising drug target. Evidence suggests that 1) enhanced activities of MMPs are important to malignancies, 2) measuring just one individual protease is unlikely to be representative of the  proteolytic environment of the tumor, 3) no diagnostic/theranostic tests are currently available to detect elevation in MMP activity levels in a tumor, and 4) the development of a simple, widely available MMP diagnostic test could dramatically change the provision of care, especially in outpatient settings. Confirmation  that a tumor has high activity levels of certain individual MMPs could better target protease-modulating therapies and improve outcomes. Despite of their urgent need and significant value for cancer patients, MMP biosensors are currently unavailable. As a result, physicians are blindfolded and incapable of selecting optimal  treatment regiments for patients. To overcome these deficiencies, we have designed and are now testing the unique fully-synthetic nanobiosensors which allow the read-out of the individual MMPs in cells/tissues. The biosensor prototype we have already obtained holds a great promise that, following the required optimization and fine-tuning, these biosensors may be a foundation for the supremely selective and efficient, real-world diagnostic/theranostic tests to detect high MMP activity levels in a tumor for the implement of specific treatment. As a result of our work, clinicians will be armed with a multitude of novel diagnostic/prognostic  molecular tools, which can then be used to rationally design a knowledge-based personalized medicine treatment for the individual patients.",75000.0,2015-05-01,2016-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
58,155.0,Initial,154.2,"Highly selective, synthetic, cleavage specificity-based nanobiosensors for tumorigenic and anti-tumorigenic MMPs",UCSD - not a member of Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,"Design and test the QD-FRET MMP-8 and MMP-9 nanosensors in vitro, in cell-based tests and in selected cancer biopsies","Demonstrate low levels, if any, of the off-target activities of the nanosensors using a panel of the purified MMP constructs",,,,,"There is consensus among professionals that matrix metalloproteinases (MMPs), the specialized enzymes produced in cancer, are promising drug target. Evidence suggests that 1) enhanced activities of MMPs are important to malignancies, 2) measuring just one individual protease is unlikely to be representative of the proteolytic environment of the tumor, 3) no diagnostic/theranostic tests are currently available to detect elevation in MMP activity levels in a tumor, and 4) the development of a simple, widely available MMP diagnostic test could dramatically change the provision of care, especially in outpatient settings. Confirmation that a tumor has high activity levels of certain individual MMPs could better target protease-modulating therapies and improve outcomes. Despite of their urgent need and significant value for cancer patients, MMP biosensors are currently unavailable. As a result, physicians are blindfolded and incapable of selecting optimal treatment regiments for patients. To overcome these deficiencies, we have designed and are now testing the unique fully-synthetic nanobiosensors which allow the read-out of the individual MMPs in cells/tissues. The biosensor prototype we have already obtained holds a great promise that, following the required optimization and fine-tuning, these biosensors may be a foundation for the supremely selective and efficient, real-world diagnostic/theranostic tests to detect high MMP activity levels in a tumor for the implement of specific treatment. As a result of our work, clinicians will be armed with a multitude of novel diagnostic/prognostic molecular tools, which can then be used to rationally design a knowledge-based personalized medicine treatment for the individual patients.",75000.0,2015-05-01,2016-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
59,156.0,Initial,154.3,"Highly selective, synthetic, cleavage specificity-based nanobiosensors for tumorigenic and anti-tumorigenic MMPs",UCSD - not a member of Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,"Design and test the QD-FRET MMP-8 and MMP-9 nanosensors in vitro, in cell-based tests and in selected cancer biopsies","Demonstrate low levels, if any, of the off-target activities of the nanosensors using a panel of the purified MMP constructs",,,,,"There is consensus among professionals that matrix metalloproteinases (MMPs), the specialized enzymes produced in cancer, are promising drug target. Evidence suggests that 1) enhanced activities of MMPs are important to malignancies, 2) measuring just one individual protease is unlikely to be representative of the proteolytic environment of the tumor, 3) no diagnostic/theranostic tests are currently available to detect elevation in MMP activity levels in a tumor, and 4) the development of a simple, widely available MMP diagnostic test could dramatically change the provision of care, especially in outpatient settings. Confirmation that a tumor has high activity levels of certain individual MMPs could better target protease-modulating therapies and improve outcomes. Despite of their urgent need and significant value for cancer patients, MMP biosensors are currently unavailable. As a result, physicians are blindfolded and incapable of selecting optimal treatment regiments for patients. To overcome these deficiencies, we have designed and are now testing the unique fully-synthetic nanobiosensors which allow the read-out of the individual MMPs in cells/tissues. The biosensor prototype we have already obtained holds a great promise that, following the required optimization and fine-tuning, these biosensors may be a foundation for the supremely selective and efficient, real-world diagnostic/theranostic tests to detect high MMP activity levels in a tumor for the implement of specific treatment. As a result of our work, clinicians will be armed with a multitude of novel diagnostic/prognostic molecular tools, which can then be used to rationally design a knowledge-based personalized medicine treatment for the individual patients.",75000.0,2015-05-01,2016-04-16,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
60,28.0,Initial,28.1,Targeting CD114 Signaling in Pediatric Medulloblastoma,Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,Evaluate the prognostic relevance of CD114 expression in medulloblastoma (MB)  tumors.,Evaluate the efficacy of targeting intracellular signaling pathways downstream of  CD114 in medulloblastoma (MB) tumors.,,,,,"Children with high-risk, aggressive forms of medulloblastoma (MB) have poor chances of survival despite intensive chemotherapy and significant supportive care, including Granulocyte-Colony Stimulating Factor (GCSF).  New treatments that kill MB cells resistant to chemotherapy are likely to reduce the chances of relapse and improve patient outcomes. We have recently found a small number of MB cells that have the Granulocyte-Colony Stimulating Factor (G-CSF) receptor (also called CD114) on their surface. We have shown that these  CD114-positive cells grow faster after G-CSF treatment and are more resistant to chemotherapy compared to CD114-negative cells. These CD114-positive cells may contribute to the poor outcomes in children with high-risk  MB, and their survival could be promoted by the routine use of G-CSF in children with MB after  chemotherapy. However, the function of CD114 in MB tumors is not known. The goals of this proposal are to determine the function of CD114 in MB tumors and to determine whether CD114 could be a target for new types of MB treatment. We propose experiments determine which MB cells express CD114 in MB tumors and how  CD114 expression contributes to the growth and survival of CD114-positive MB cells. The results of these studies will increase our understanding of the role of CD114 expression and function in MB tumors and will potentially identify new treatments for children with MB.",125000.0,2019-01-01,2019-12-31,Complete,False,False,True,True,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,The availability of funding from Padres Pedal the Cause has been critical in maintaining stable funding to support ongoing research and productivity required for my retention and advancement at UCSD.,,0.0,,,,,none,No,,Two
61,96.0,Initial,28.2,Targeting CD114 Signaling in Pediatric Medulloblastoma,Sanford Burnum,,False,False,False,False,True,Two Specific Aims,Evaluate the prognostic relevance of CD114 expression in medulloblastoma (MB) tumors.,Evaluate the efficacy of targeting intracellular signaling pathways downstream of CD114 in medulloblastoma (MB) tumors.,,,,,"Children with high-risk, aggressive forms of medulloblastoma (MB) have poor chances of survival despite intensive chemotherapy and significant supportive care, including Granulocyte-Colony Stimulating Factor (GCSF). New treatments that kill MB cells resistant to chemotherapy are likely to reduce the chances of relapse and improve patient outcomes. We have recently found a small number of MB cells that have the Granulocyte-Colony Stimulating Factor (G-CSF) receptor (also called CD114) on their surface. We have shown that these CD114-positive cells grow faster after G-CSF treatment and are more resistant to chemotherapy compared to CD114-negative cells. These CD114-positive cells may contribute to the poor outcomes in children with high-risk MB, and their survival could be promoted by the routine use of G-CSF in children with MB after chemotherapy. However, the function of CD114 in MB tumors is not known. The goals of this proposal are to determine the function of CD114 in MB tumors and to determine whether CD114 could be a target for new types of MB treatment. We propose experiments determine which MB cells express CD114 in MB tumors and how CD114 expression contributes to the growth and survival of CD114-positive MB cells. The results of these studies will increase our understanding of the role of CD114 expression and function in MB tumors and will potentially identify new treatments for children with MB.",125000.0,2019-01-01,2019-12-31,Complete,False,False,False,False,False,True,False,False,False,False,False,False,False,False,False,False,False,No,,,0.0,,,,,,No,,One
62,97.0,Initial,28.3,Targeting CD114 Signaling in Pediatric Medulloblastoma,Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,Evaluate the prognostic relevance of CD114 expression in medulloblastoma (MB) tumors.,Evaluate the efficacy of targeting intracellular signaling pathways downstream of CD114 in medulloblastoma (MB) tumors.,,,,,"Children with high-risk, aggressive forms of medulloblastoma (MB) have poor chances of survival despite intensive chemotherapy and significant supportive care, including Granulocyte-Colony Stimulating Factor (GCSF). New treatments that kill MB cells resistant to chemotherapy are likely to reduce the chances of relapse and improve patient outcomes. We have recently found a small number of MB cells that have the Granulocyte-Colony Stimulating Factor (G-CSF) receptor (also called CD114) on their surface. We have shown that these CD114-positive cells grow faster after G-CSF treatment and are more resistant to chemotherapy compared to CD114-negative cells. These CD114-positive cells may contribute to the poor outcomes in children with high-risk MB, and their survival could be promoted by the routine use of G-CSF in children with MB after chemotherapy. However, the function of CD114 in MB tumors is not known. The goals of this proposal are to determine the function of CD114 in MB tumors and to determine whether CD114 could be a target for new types of MB treatment. We propose experiments determine which MB cells express CD114 in MB tumors and how CD114 expression contributes to the growth and survival of CD114-positive MB cells. The results of these studies will increase our understanding of the role of CD114 expression and function in MB tumors and will potentially identify new treatments for children with MB.",125000.0,2019-01-01,2019-12-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
63,26.0,Initial,26.1,Inhibiting Liver Cancer Stem Cells to Improve Response to Thermal Ablation,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,To test the hypothesis that the heat shock from iPTA stimulates hCSC proliferation in a murine model of HCC in the setting of cirrhosis and NASH,To test the hypothesis that combining iPTA with adjuvant NEN inhibits hCSC proliferation,,,,,"Liver cancer, or hepatocellular carcinoma (HCC), is the 5th most common cancer and the world's 2nd leading cause of cancer-related death in adult men. According to the CDC, it is the only cancer for which the incidence and mortality are rising. An increasingly significant cause of HCC is fatty liver disease, for which obesity is a risk factor. Since 71% of Americans are overweight or obese, the number of HCCs is expected to rise. Surgery offers the best hope for a cure, yet most HCC patients are not surgical candidates. The best alternative is percutaneous thermal ablation, a minimally invasive way to destroy the tumor without surgery. Yet when cancer cells are left behind, HCC can recur. The likely source of recurrence is from treatment-resistant cells called ""cancer stem cells"" which become stimulated under the stress conditions induced by percutaneous thermal ablation. No current therapies target these cells. Our study proposes to combine niclosamide ethanolamine, an FDA-approved antiparasitic drug that inhibits cancer stem cells, with percutaneous thermal ablation in mice with fatty liver disease that develop HCC. In the short term, this study will improve our understanding of the effect of percutaneous thermal ablation on HCC cancer stem cells in a singularly clinically-relevant model. In the long term, this study has the potential for rapid translation to clinical trials. If successful in improving outcomes after percutaneous thermal ablation, this combined approach with niclosamide ethanolamine could ultimately curb the mortality from HCC and help countless patients.",125000.0,2019-01-01,2019-12-31,Complete,False,False,False,True,False,True,False,False,True,False,False,False,False,False,False,False,False,Yes,It enabled me to continue and advance my research and foster new collaborations,,0.0,,,,,none,No,,Two
64,92.0,Initial,26.2,Inhibiting Liver Cancer Stem Cells to Improve Response to Thermal Ablation,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,To test the hypothesis that the heat shock from iPTA stimulates hCSC proliferation in a murine model of HCC in the setting of cirrhosis and NASH,To test the hypothesis that combining iPTA with adjuvant NEN inhibits hCSC proliferation,,,,,"Liver cancer, or hepatocellular carcinoma (HCC), is the 5th most common cancer and the world's 2nd leading cause of cancer-related death in adult men. According to the CDC, it is the only cancer for which the incidence and mortality are rising. An increasingly significant cause of HCC is fatty liver disease, for which obesity is a risk factor. Since 71% of Americans are overweight or obese, the number of HCCs is expected to rise. Surgery offers the best hope for a cure, yet most HCC patients are not surgical candidates. The best alternative is percutaneous thermal ablation, a minimally invasive way to destroy the tumor without surgery. Yet when cancer cells are left behind, HCC can recur. The likely source of recurrence is from treatment-resistant cells called ""cancer stem cells"" which become stimulated under the stress conditions induced by percutaneous thermal ablation. No current therapies target these cells. Our study proposes to combine niclosamide ethanolamine, an FDA-approved antiparasitic drug that inhibits cancer stem cells, with percutaneous thermal ablation in mice with fatty liver disease that develop HCC. In the short term, this study will improve our understanding of the effect of percutaneous thermal ablation on HCC cancer stem cells in a singularly clinically-relevant model. In the long term, this study has the potential for rapid translation to clinical trials. If successful in improving outcomes after percutaneous thermal ablation, this combined approach with niclosamide ethanolamine could ultimately curb the mortality from HCC and help countless patients.",125000.0,2019-01-01,2019-12-31,Complete,False,False,True,False,False,False,False,False,True,False,False,False,False,False,False,False,False,Yes,"Two Radiology residents who worked on the project were funded by the Radiology T32 program.  The Pedal funds provided for the experimental supplies, animal costs and research assistant help that allowed them to perform the studies.",,0.0,,,,,,No,,Zero
65,93.0,Initial,26.3,Inhibiting Liver Cancer Stem Cells to Improve Response to Thermal Ablation,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,To test the hypothesis that the heat shock from iPTA stimulates hCSC proliferation in a murine model of HCC in the setting of cirrhosis and NASH,To test the hypothesis that combining iPTA with adjuvant NEN inhibits hCSC proliferation,,,,,"Liver cancer, or hepatocellular carcinoma (HCC), is the 5th most common cancer and the world's 2nd leading cause of cancer-related death in adult men. According to the CDC, it is the only cancer for which the incidence and mortality are rising. An increasingly significant cause of HCC is fatty liver disease, for which obesity is a risk factor. Since 71% of Americans are overweight or obese, the number of HCCs is expected to rise. Surgery offers the best hope for a cure, yet most HCC patients are not surgical candidates. The best alternative is percutaneous thermal ablation, a minimally invasive way to destroy the tumor without surgery. Yet when cancer cells are left behind, HCC can recur. The likely source of recurrence is from treatment-resistant cells called ""cancer stem cells"" which become stimulated under the stress conditions induced by percutaneous thermal ablation. No current therapies target these cells. Our study proposes to combine niclosamide ethanolamine, an FDA-approved antiparasitic drug that inhibits cancer stem cells, with percutaneous thermal ablation in mice with fatty liver disease that develop HCC. In the short term, this study will improve our understanding of the effect of percutaneous thermal ablation on HCC cancer stem cells in a singularly clinically-relevant model. In the long term, this study has the potential for rapid translation to clinical trials. If successful in improving outcomes after percutaneous thermal ablation, this combined approach with niclosamide ethanolamine could ultimately curb the mortality from HCC and help countless patients.",125000.0,2019-01-01,2019-12-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,The fund allowed a BS/MS student complete the proposed experiments.,,0.0,,,,,,No,,Zero
66,27.0,Initial,27.1,Knowledge-based planning and treatment decision-making for gynecologic brachytherapy,Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,"To prepare the ML training pipeline, we will process external beam radiotherapy  images to compute geometric variables for brachytherapy treatment prediction.",We will utilize established ML methods to train a knowledge-based radiation dose prediction model that takes as input pre-BT imaging and outputs BT treatment quality indicators.,,,,,"Brachytherapy is a treatment in which radiation is delivered internally, using a device known as an applicator and/or needles to guide a radioactive source directly into the tumor. Using imaging, this radiation dose can be customized to an individual patient's anatomy, maximizing dose to the tumor while minimizing dose to healthy organs.  Although brachytherapy is an essential component of cervical cancer treatment, centers worldwide are offering less and less brachytherapy. This could be because the treatment process is complex, time  consuming, and requires a very skilled team. Doctors use their experience to decide what applicator and needles to use, and physicians with deep brachytherapy experience are a scarce resource.  Machine learning is an exciting new technique where large amounts of data are input into advanced computer models to automatically make predictions. In this study, we will use data from hundreds of prior patients' treatments to make predictions for an individual patient. The machine learning model will be able to look at images of a patient before brachytherapy, and then predict the best applicator for that patient, as well as the radiation dose he/she will receive. This will help doctors make important decisions about a patient's brachytherapy treatment before they ever enter the operating room!  Without brachytherapy, the chance of survival of a cervical cancer patient is reduced by 12%. The tools developed in this study will improve the quality and efficiency of brachytherapy treatments, so that brachytherapy can be used by more centers worldwide.",71979.0,2019-01-01,2019-12-31,Complete,False,False,False,False,False,False,False,False,False,True,False,False,False,False,False,False,False,Yes,"It allowed me to a hire a programmer just out of undergraduate studies, and pay for part of my post doc. The work funded by the grant was also built on by other future trainees",,0.0,,,,,,No,,Four
67,94.0,Initial,27.2,Knowledge-based planning and treatment decision-making for gynecologic brachytherapy,UCSD - not a member of Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,"To prepare the ML training pipeline, we will process external beam radiotherapy images to compute geometric variables for brachytherapy treatment prediction.",We will utilize established ML methods to train a knowledge-based radiation dose prediction model that takes as input pre-BT imaging and outputs BT treatment quality indicators.,,,,,"Brachytherapy is a treatment in which radiation is delivered internally, using a device known as an applicator and/or needles to guide a radioactive source directly into the tumor. Using imaging, this radiation dose can be customized to an individual patient's anatomy, maximizing dose to the tumor while minimizing dose to healthy organs.  Although brachytherapy is an essential component of cervical cancer treatment, centers worldwide are offering less and less brachytherapy. This could be because the treatment process is complex, time consuming, and requires a very skilled team. Doctors use their experience to decide what applicator and needles to use, and physicians with deep brachytherapy experience are a scarce resource.  Machine learning is an exciting new technique where large amounts of data are input into advanced computer models to automatically make predictions. In this study, we will use data from hundreds of prior patients' treatments to make predictions for an individual patient. The machine learning model will be able to look at images of a patient before brachytherapy, and then predict the best applicator for that patient, as well as the radiation dose he/she will receive. This will help doctors make important decisions about a patient's brachytherapy treatment before they ever enter the operating room! Without brachytherapy, the chance of survival of a cervical cancer patient is reduced by 12%. The tools developed in this study will improve the quality and efficiency of brachytherapy treatments, so that brachytherapy can be used by more centers worldwide.",71979.0,2019-01-01,2019-12-31,Complete,False,False,False,False,False,False,False,False,False,True,False,False,False,False,False,False,False,Yes,"It allowed us to a hire a programmer just out of undergraduate studies, and pay for part of my post doc. The work funded by the grant was also built on by other future trainees.",,0.0,,,,,,No,,Four
68,95.0,Initial,27.3,Knowledge-based planning and treatment decision-making for gynecologic brachytherapy,Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,"To prepare the ML training pipeline, we will process external beam radiotherapy images to compute geometric variables for brachytherapy treatment prediction.",We will utilize established ML methods to train a knowledge-based radiation dose prediction model that takes as input pre-BT imaging and outputs BT treatment quality indicators.,,,,,"Brachytherapy is a treatment in which radiation is delivered internally, using a device known as an applicator and/or needles to guide a radioactive source directly into the tumor. Using imaging, this radiation dose can be customized to an individual patient's anatomy, maximizing dose to the tumor while minimizing dose to healthy organs.  Although brachytherapy is an essential component of cervical cancer treatment, centers worldwide are offering less and less brachytherapy. This could be because the treatment process is complex, time consuming, and requires a very skilled team. Doctors use their experience to decide what applicator and needles to use, and physicians with deep brachytherapy experience are a scarce resource.  Machine learning is an exciting new technique where large amounts of data are input into advanced computer models to automatically make predictions. In this study, we will use data from hundreds of prior patients' treatments to make predictions for an individual patient. The machine learning model will be able to look at images of a patient before brachytherapy, and then predict the best applicator for that patient, as well as the radiation dose he/she will receive. This will help doctors make important decisions about a patient's brachytherapy treatment before they ever enter the operating room! Without brachytherapy, the chance of survival of a cervical cancer patient is reduced by 12%. The tools developed in this study will improve the quality and efficiency of brachytherapy treatments, so that brachytherapy can be used by more centers worldwide.",71979.0,2019-01-01,2019-12-31,Complete,False,False,False,False,False,False,False,False,False,True,False,False,False,False,False,False,False,Yes,Collaboration with Sandra Meyers PhD physics in RAD ONC,,0.0,,,,,none,No,,Four
69,22.0,Initial,22.1,Identification of regulatory programs for glioblastoma cellular hierarchy using single-cell multi-omic profiling,Salk Institute,,False,True,False,False,False,Two Specific Aims,"Identify the regulatory programs that distinguish GSCs and drive GBM cellular heterogeneity  using single-cell multi-omic profiling of transcriptome, methylome and chromatin accessibility.",Uncover the chromatin architecture dynamics of GSCs and across GBM cellular hierarchy using  single-cell joint profiling of methylome and chromatin conformation.,,,,,"Cell type heterogeneity is a major contributor to the therapeutic resistance of glioblastoma. The goal of this project is to understand the molecular identity of different cell types in glioblastoma tumors. Using single-cell strategies, the project will reveal the gene regulatory programs that drive the progression of glioblastoma. ",125000.0,2019-07-15,2020-07-14,Complete,False,False,False,False,False,True,False,False,False,False,False,False,False,False,False,False,False,No,,The project was carried out by my technical staff,0.0,,,,,none,No,,Zero
70,84.0,Initial,22.2,Identification of regulatory programs for glioblastoma cellular hierarchy using single-cell multi-omic profiling,UCSD - not a member of Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,"Identify the regulatory programs that distinguish GSCs and drive GBM cellular heterogeneity using single-cell multi-omic profiling of transcriptome, methylome and chromatin accessibility.",Uncover the chromatin architecture dynamics of GSCs and across GBM cellular hierarchy using single-cell joint profiling of methylome and chromatin conformation.,,,,,"Cell type heterogeneity is a major contributor to the therapeutic resistance of glioblastoma. The goal of this project is to understand the molecular identity of different cell types in glioblastoma tumors. Using single-cell strategies, the project will reveal the gene regulatory programs that drive the progression of glioblastoma.",125000.0,2019-07-15,2020-07-14,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
71,85.0,Initial,22.3,Identification of regulatory programs for glioblastoma cellular hierarchy using single-cell multi-omic profiling,Salk Institute,,False,True,False,False,False,Two Specific Aims,"Identify the regulatory programs that distinguish GSCs and drive GBM cellular heterogeneity using single-cell multi-omic profiling of transcriptome, methylome and chromatin accessibility.",Uncover the chromatin architecture dynamics of GSCs and across GBM cellular hierarchy using single-cell joint profiling of methylome and chromatin conformation.,,,,,"Cell type heterogeneity is a major contributor to the therapeutic resistance of glioblastoma. The goal of this project is to understand the molecular identity of different cell types in glioblastoma tumors. Using single-cell strategies, the project will reveal the gene regulatory programs that drive the progression of glioblastoma.",125000.0,2019-07-15,2020-07-14,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,I think obtaining funding is important for career advancement.,,0.0,,,,,None,No,,Zero
72,179.0,Initial,179.1,The GNAS-PKA Onco-Signaling Network in Colorectal Malignancies,Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,We will define the contribution of the GNAS-PKA pathway to colon cancer progression ,We will perform a structure/function analysis of PKA interacting partners and therapeutic targets.  ,We will establish the PKA oncogenic transcriptional network.  ,,,,"Every year >135,000 Americans and more than 1.35 million people world-wide are diagnosed with colorectal cancer, which includes malignant tumors arising in the large intestine and appendix. With 50,000 deaths each year, colorectal cancer is the second leading cause of cancer deaths in the United States. New approaches are clearly needed to elucidate the underlying biology of colorectal cancer, which will help the development of new and more effective options to prevent and treat this highly prevalent human malignancy. Aspirin and multiple over the counter nonsteroidal anti-inflammatory drugs are effective in preventing colorectal cancer, supporting that chronic inflammation contributes to the development of this cancer type. A molecule known as Protein Kinase A (PKA) is often stimulated by inflammatory mediators in the normal intestine and colorectal tumors. A recent genetic analysis of colorectal cancers revealed multiple genetic alterations that may cause the uncontrolled activation of PKA. Thus, we can hypothesize that persistent PKA activation may promote the growth of cancer cells and render the protective function of aspirin and other anti-inflammatory drugs ineffective. We plan to study what causes the unrestrained activation of PKA in colorectal cancer and how in turn PKA stimulates the growth of cancer cells using newly developed animal models and multiple biochemical approaches. We believe that these studies will increase our understanding of colorectal cancer initiation and progression, will help identify patients at risk of developing this malignancy, and will reveal new molecular targets for therapeutic intervention to prevent and treat this highly prevalent human cancer.",75000.0,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
73,180.0,Initial,179.2,The GNAS-PKA Onco-Signaling Network in Colorectal Malignancies,Salk Institute,,False,True,False,False,False,Three Specific Aims,We will define the contribution of the GNAS-PKA pathway to colon cancer progression ,We will perform a structure/function analysis of PKA interacting partners and therapeutic targets,We will establish the PKA oncogenic transcriptional network.  ,,,,"Every year >135,000 Americans and more than 1.35 million people world-wide are diagnosed with colorectal cancer, which includes malignant tumors arising in the large intestine and appendix. With 50,000 deaths each year, colorectal cancer is the second leading cause of cancer deaths in the United States. New approaches are clearly needed to elucidate the underlying biology of colorectal cancer, which will help the development of new and more effective options to prevent and treat this highly prevalent human malignancy. Aspirin and multiple over the counter nonsteroidal anti-inflammatory drugs are effective in preventing colorectal cancer, supporting that chronic inflammation contributes to the development of this cancer type. A molecule known as Protein Kinase A (PKA) is often stimulated by inflammatory mediators in the normal intestine and colorectal tumors. A recent genetic analysis of colorectal cancers revealed multiple genetic alterations that may cause the uncontrolled activation of PKA. Thus, we can hypothesize that persistent PKA activation may promote the growth of cancer cells and render the protective function of aspirin and other anti-inflammatory drugs ineffective. We plan to study what causes the unrestrained activation of PKA in colorectal cancer and how in turn PKA stimulates the growth of cancer cells using newly developed animal models and multiple biochemical approaches. We believe that these studies will increase our understanding of colorectal cancer initiation and progression, will help identify patients at risk of developing this malignancy, and will reveal new molecular targets for therapeutic intervention to prevent and treat this highly prevalent human cancer.",75000.0,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
74,181.0,Initial,179.3,The GNAS-PKA Onco-Signaling Network in Colorectal Malignancies,UCSD - not a member of Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,We will define the contribution of the GNAS-PKA pathway to colon cancer progression ,We will perform a structure/function analysis of PKA interacting partners and therapeutic targets.  ,We will establish the PKA oncogenic transcriptional network.,,,,"Every year >135,000 Americans and more than 1.35 million people world-wide are diagnosed with colorectal cancer, which includes malignant tumors arising in the large intestine and appendix. With 50,000 deaths each year, colorectal cancer is the second leading cause of cancer deaths in the United States. New approaches are clearly needed to elucidate the underlying biology of colorectal cancer, which will help the development of new and more effective options to prevent and treat this highly prevalent human malignancy. Aspirin and multiple over the counter nonsteroidal anti-inflammatory drugs are effective in preventing colorectal cancer, supporting that chronic inflammation contributes to the development of this cancer type. A molecule known as Protein Kinase A (PKA) is often stimulated by inflammatory mediators in the normal intestine and colorectal tumors. A recent genetic analysis of colorectal cancers revealed multiple genetic alterations that may cause the uncontrolled activation of PKA. Thus, we can hypothesize that persistent PKA activation may promote the growth of cancer cells and render the protective function of aspirin and other anti-inflammatory drugs ineffective. We plan to study what causes the unrestrained activation of PKA in colorectal cancer and how in turn PKA stimulates the growth of cancer cells using newly developed animal models and multiple biochemical approaches. We believe that these studies will increase our understanding of colorectal cancer initiation and progression, will help identify patients at risk of developing this malignancy, and will reveal new molecular targets for therapeutic intervention to prevent and treat this highly prevalent human cancer.",75000.0,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
75,6.0,Initial,6.1,UCSD-UCSF Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer,Moores Cancer Center,,False,False,False,False,False,Three Specific Aims,Improve outcomes for HNSCC by expanding our understanding of immune-cancer interactions through rational co-targeting and enhancing T cell specific responses.,"Leverage our administrative, biostatistics, computational biology, tissue biospecimen, and institutional resources and expertise to optimize our translation of novel findings from the SPORE to collaborative groups, and national and international cooperative venues.","Develop emerging, novel, high quality translational science and investigators using our SPORE developmental research and career enhancement programs to support qualified junior, women, minority, and transitioning investigators.",,,,"Cancer immunotherapies have led to major treatment breakthroughs for a number of different cancers, but the majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses are often not durable. Generally, this is explained by an insufficient reversal of immune-suppressive mechanisms and, concurrently, an inadequate augmentation of existing anticancer immunity. Collectively, our multi-institutional group of internationally recognized investigators in the field of translation head and neck cancer immune-oncology research has undertaken several interdisciplinary approaches to address this outstanding problem and improve the outcomes for head and neck cancer patients. Specifically, we have demonstrated that responses to immunotherapies are augmented by simultaneously co-targeting cancer cell vulnerabilities and immune effector cells and by reversing the immune-suppressive landscape imposed by established cancers both locally within the tumor and systemically within the patient.With this team award, we propose the following principal projects in head and neck cancer: 1) co-targeting cancer and immune cell signaling networks for precision immunotherapy; 2) enhancing the response to immunotherapies by suppressing the transcription factor STAT3; and 3) investigating the use of engineered interleukin 7 to reverse lymphopenia to enhance immunotherapy. Our short term goal is that this Team Science Award will support the development and submission (in 2021) of an application from UCSD and UCSF for a Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer with the overall goal of improving the treatment of head and neck cancer through translating exceptional science from the laboratory to the clinic and back.",200000.0,2021-07-01,2022-06-30,Complete,False,False,True,False,True,False,True,False,False,False,False,False,False,False,False,False,False,Yes,Opportunity to develop an immune modulatory approach for oral cancer prevention,,1.0,Metformin for oral cancer prevention 2.0,80.0,Neoadjuvant Immunoradiotherapy in Head & Neck Cancer ,,No,No,,Two
76,61.0,Initial,6.2,UCSD-UCSF Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,Improve outcomes for HNSCC by expanding out understanding of immune-cancer interactions through rational co-targeting and enhancing T cell specific responses.,"Leverage our administrative, biostatistics, computational biology, tissue biospecimen, and institutional resources and expertise to optimize our translation of novel findings from the SPORE to collaborative groups, and national and international cooperative venues.",,,,,"Cancer immunotherapies have led to major treatment breakthroughs for a number of different cancers, but the majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses are often not durable. Generally, this is explained by an insufficient reversal of immune-suppressive mechanisms and, concurrently, an inadequate augmentation of existing anticancer immunity. Collectively, our multi-institutional group of internationally recognized investigators in the field of translation head and neck cancer immune-oncology research has undertaken several interdisciplinary approaches to address this outstanding problem and improve the outcomes for head and neck cancer patients. Specifically, we have demonstrated that responses to immunotherapies are augmented by simultaneously co-targeting cancer cell vulnerabilities and immune effector cells and by reversing the immune-suppressive landscape imposed by established cancers both locally within the tumor and systemically within the patient.With this team award, we propose the following principal projects in head and neck cancer: 1) co-targeting cancer and immune cell signaling networks for precision immunotherapy; 2) enhancing the response to immunotherapies by suppressing the transcription factor STAT3; and 3) investigating the use of engineered interleukin 7 to reverse lymphopenia to enhance immunotherapy. Our short term goal is that this Team Science Award will support the development and submission (in 2021) of an application from UCSD and UCSF for a Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer with the overall goal of improving the treatment of head and neck cancer through translating exceptional science from the laboratory to the clinic and back.",200000.0,2021-07-01,2022-06-30,Complete,False,False,True,True,True,True,False,False,True,True,True,False,False,False,False,False,False,No,,,1.0,,0.0,,,,No,,Two
77,62.0,Initial,6.3,UCSD-UCSF Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,"Leverage our administrative, biostatistics, computational biology, tissue biospecimen, and institutional resources and expertise to optimize our translation of novel findings from the SPORE to collaborative groups, and national and international cooperative venues.","Develop emerging, novel, high quality translational science and investigators using our SPORE developmental research and career enhancement programs to support qualified junior, women, minority, and transitioning investigators. ",,,,,"Cancer immunotherapies have led to major treatment breakthroughs for a number of different cancers, but the majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses are often not durable. Generally, this is explained by an insufficient reversal of immune-suppressive mechanisms and, concurrently, an inadequate augmentation of existing anticancer immunity. Collectively, our multi-institutional group of internationally recognized investigators in the field of translation head and neck cancer immune-oncology research has undertaken several interdisciplinary approaches to address this outstanding problem and improve the outcomes for head and neck cancer patients. Specifically, we have demonstrated that responses to immunotherapies are augmented by simultaneously co-targeting cancer cell vulnerabilities and immune effector cells and by reversing the immune-suppressive landscape imposed by established cancers both locally within the tumor and systemically within the patient.With this team award, we propose the following principal projects in head and neck cancer: 1) co-targeting cancer and immune cell signaling networks for precision immunotherapy; 2) enhancing the response to immunotherapies by suppressing the transcription factor STAT3; and 3) investigating the use of engineered interleukin 7 to reverse lymphopenia to enhance immunotherapy. Our short term goal is that this Team Science Award will support the development and submission (in 2021) of an application from UCSD and UCSF for a Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer with the overall goal of improving the treatment of head and neck cancer through translating exceptional science from the laboratory to the clinic and back.",200000.0,2021-07-01,2022-06-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
78,17.0,Initial,17.1,Improved Echocardiographic Diagnosis of Anthracycline-Related Cardiac Dysfunction Using Global Longitudinal Strain,Rady Children's,,False,False,False,False,True,Two Specific Aims,To determine the utility of GLS in conjunction with 2D echo-LVEF in the diagnosis of CTRCD.,To explore the association of MRI-LVEF with GLS and 3D echo-LVEF.,,,,,"Due to high survival rates and long life expectancy after a childhood cancer diagnosis, there is a large and growing population of nearly 500,000 childhood cancer survivors in the United States, a majority of whom were exposed to anthracycline chemotherapy. Although highly effective at treating cancer, anthracyclines damage the heart and result in high rates of heart dysfunction and heart failure in survivors. Childhood cancer survivors are periodically screened for the development of heart dysfunction. However, standard ultrasound-based heart function screening measurements are inaccurate and may fail to correctly diagnose a substantial percentage of affected individuals; more accurate screening methods are needed.  We propose to study the role of global longitudinal strain, a more sensitive ultrasound-based measure of heart function, in the diagnosis of heart dysfunction in childhood cancer survivors. Using a comparison to heart  function measured by magnetic resonance imaging (the most accurate method available), we will determine whether global longitudinal strain can aid in screening procedures in survivors. In the short-term, our study has  the potential to improve heart function screening accuracy in childhood cancer survivors. In the long-term, we intend to build upon these results in future studies that combine the most accurate ultrasound-based methods to optimize early detection and treatment of heart failure in childhood cancer survivors.",99992.0,2020-09-01,2021-08-30,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,"Pedal the Cause funding has allowed me to generate preliminary data and have protected time to submit multiple grant proposals, with one career development award application resubmission currently under review and another planned resubmission this summer.",,0.0,,,,,,No,,Four
79,78.0,Initial,17.2,Improved Echocardiographic Diagnosis of Anthracycline-Related Cardiac Dysfunction Using Global Longitudinal Strain,Other,City of Hope,False,False,False,False,True,Two Specific Aims,To determine the utility of GLS in conjunction with 2D echo-LVEF in the diagnosis of CTRCD.,To explore the association of MRI-LVEF with GLS and 3D echo-LVEF.,,,,,"Due to high survival rates and long life expectancy after a childhood cancer diagnosis, there is a large and growing population of nearly 500,000 childhood cancer survivors in the United States, a majority of whom were exposed to anthracycline chemotherapy. Although highly effective at treating cancer, anthracyclines damage the heart and result in high rates of heart dysfunction and heart failure in survivors. Childhood cancer survivors are periodically screened for the development of heart dysfunction. However, standard ultrasound-based heart function screening measurements are inaccurate and may fail to correctly diagnose a substantial percentage of affected individuals; more accurate screening methods are needed. We propose to study the role of global longitudinal strain, a more sensitive ultrasound-based measure of heart function, in the diagnosis of heart dysfunction in childhood cancer survivors. Using a comparison to heart function measured by magnetic resonance imaging (the most accurate method available), we will determine whether global longitudinal strain can aid in screening procedures in survivors. In the short-term, our study has the potential to improve heart function screening accuracy in childhood cancer survivors. In the long-term, we intend to build upon these results in future studies that combine the most accurate ultrasound-based methods to optimize early detection and treatment of heart failure in childhood cancer survivors.",99992.0,2020-09-01,2021-08-30,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,This is not applicable to me. It's more applicable for Dr. Narayan,0.0,,,,,,No,,One
80,79.0,Initial,17.3,Improved Echocardiographic Diagnosis of Anthracycline-Related Cardiac Dysfunction Using Global Longitudinal Strain,Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,To determine the utility of GLS in conjunction with 2D echo-LVEF in the diagnosis of CTRCD.,To explore the association of MRI-LVEF with GLS and 3D echo-LVEF.,,,,,"Due to high survival rates and long life expectancy after a childhood cancer diagnosis, there is a large and growing population of nearly 500,000 childhood cancer survivors in the United States, a majority of whom were exposed to anthracycline chemotherapy. Although highly effective at treating cancer, anthracyclines damage the heart and result in high rates of heart dysfunction and heart failure in survivors. Childhood cancer survivors are periodically screened for the development of heart dysfunction. However, standard ultrasound-based heart function screening measurements are inaccurate and may fail to correctly diagnose a substantial percentage of affected individuals; more accurate screening methods are needed. We propose to study the role of global longitudinal strain, a more sensitive ultrasound-based measure of heart function, in the diagnosis of heart dysfunction in childhood cancer survivors. Using a comparison to heart function measured by magnetic resonance imaging (the most accurate method available), we will determine whether global longitudinal strain can aid in screening procedures in survivors. In the short-term, our study has the potential to improve heart function screening accuracy in childhood cancer survivors. In the long-term, we intend to build upon these results in future studies that combine the most accurate ultrasound-based methods to optimize early detection and treatment of heart failure in childhood cancer survivors.",99992.0,2020-09-01,2021-08-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
81,169.0,Initial,169.1,Epigenetic basis of platinum drug resistance in ovarian cancer,UCSD - not a member of Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,Identify regions differentially methylated in carboplatin resistant cells.,Validate resistance-associated regulatory changes at single cell resolution.,,,,,"Platinum drug resistance is a serious clinical problem affecting thousands of patients every year. Patients treated for ovarian cancer receive platinum-based chemotherapy, but 85% of the patients who initially responded eventually relapse and the recurrent tumor is resistant to the treatment. With the modern tools of precision medicine and genomics, we now have a chance to understand better how the tumor cells adapt to and escape the treatment. We will use an experimental system we developed to obtain platinum sensitive and resistant cells that have the exact same DNA sequence. We will look at their entire genome to see how it is being modified as the cells become resistant to the treatment. The location of these modifications in the genome will reveal cellular processes that are mediating the resistance. Importantly, we will check if these changes are different in every cell within a population of cells, which can explain why tumors can rapidly adapt to the treatment and become resistant. This research is likely to result in molecular assays to predict which tumor is more likely to become resistant and how soon. It may also lead to the identification of therapies to prevent or delay the onset of the platinum resistance.",75000.0,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
82,170.0,Initial,169.2,Epigenetic basis of platinum drug resistance in ovarian cancer,Salk Institute,,True,False,False,False,False,Two Specific Aims,Identify regions differentially methylated in carboplatin resistant cells.,Validate resistance-associated regulatory changes at single cell resolution.,,,,,"Platinum drug resistance is a serious clinical problem affecting thousands of patients every year. Patients treated for ovarian cancer receive platinum-based chemotherapy, but 85% of the patients who initially responded eventually relapse and the recurrent tumor is resistant to the treatment. With the modern tools of precision medicine and genomics, we now have a chance to understand better how the tumor cells adapt to and escape the treatment. We will use an experimental system we developed to obtain platinum sensitive and resistant cells that have the exact same DNA sequence. We will look at their entire genome to see how it is being modified as the cells become resistant to the treatment. The location of these modifications in the genome will reveal cellular processes that are mediating the resistance. Importantly, we will check if these changes are different in every cell within a population of cells, which can explain why tumors can rapidly adapt to the treatment and become resistant. This research is likely to result in molecular assays to predict which tumor is more likely to become resistant and how soon. It may also lead to the identification of therapies to prevent or delay the onset of the platinum resistance.",75000.0,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
83,171.0,Initial,169.3,Epigenetic basis of platinum drug resistance in ovarian cancer,UCSD - not a member of Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,Identify regions differentially methylated in carboplatin resistant cells.,Validate resistance-associated regulatory changes at single cell resolution.,,,,,"Platinum drug resistance is a serious clinical problem affecting thousands of patients every year. Patients treated for ovarian cancer receive platinum-based chemotherapy, but 85% of the patients who initially responded eventually relapse and the recurrent tumor is resistant to the treatment. With the modern tools of precision medicine and genomics, we now have a chance to understand better how the tumor cells adapt to and escape the treatment. We will use an experimental system we developed to obtain platinum sensitive and resistant cells that have the exact same DNA sequence. We will look at their entire genome to see how it is being modified as the cells become resistant to the treatment. The location of these modifications in the genome will reveal cellular processes that are mediating the resistance. Importantly, we will check if these changes are different in every cell within a population of cells, which can explain why tumors can rapidly adapt to the treatment and become resistant. This research is likely to result in molecular assays to predict which tumor is more likely to become resistant and how soon. It may also lead to the identification of therapies to prevent or delay the onset of the platinum resistance.",75000.0,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
84,9.0,Initial,9.1,New Therapies for Myeloid Leukemia,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Determine if inhibitory Tspan3 mAb impairs the growth of diverse types of indolent and aggressive myeloid leukemia  ,Identify biomarkers predictive of response to Tspan3 inhibition.,,,,,"Acute Myelogenous Leukemia (AML) is a cancer marked by rapid and uncontrolled growth of immature cells of the myeloid lineage. Although it is the most common acute leukemia in adults, current treatments, which include chemotherapy and bone marrow transplantation, are largely ineffective, leading to relapse and death in  most patients. AML also occurs in children, and pediatric AML has a much poorer outcome than other childhood leukemias. In light of these issues, AML represents a disease with a significant unmet medical need. Given that  there have been no new therapies for AML in the last 30-40 years, identifying new approaches to target AML is critically important. At a cellular level, AML is heterogeneous and has been shown to be driven by cancer stem cells. Thus strategies aimed at inhibiting cancer stem cell growth and renewal may target the fundamental  propagative abilities of the tumor and allow development of a more targeted therapy. Importantly, AML can often arise from early stage myeloid disorders such as myelodysplastic syndrome (MDS) or myeloproliferative  neoplasms (MPN), thus also providing an opportunity to block its progression at earlier stages. Our goal is to develop a new therapeutic agent that can block growth and progression of these myeloid disorders. To this end we have developed antibodies that target a protein required for AML growth. We will test whether these antibodies can block progression of MDS/MPN to AML and improve outcomes. If successful, these exciting studies could to lead to a new treatment strategy for myeloid leukemia.",200000.0,2020-02-01,2021-01-31,Complete,False,False,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,timeline not applicable,0.0,,,,,,No,,Zero
85,65.0,Initial,9.2,New Therapies for Myeloid Leukemia,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Determine if inhibitory Tspan3 mAb impairs the growth of diverse types of indolent and aggressive myeloid leukemia.,Identify biomarkers predictive of response to Tspan3 inhibition.,,,,,"Acute Myelogenous Leukemia (AML) is a cancer marked by rapid and uncontrolled growth of immature cells of the myeloid lineage. Although it is the most common acute leukemia in adults, current treatments, which include chemotherapy and bone marrow transplantation, are largely ineffective, leading to relapse and death in  most patients. AML also occurs in children, and pediatric AML has a much poorer outcome than other childhood leukemias. In light of these issues, AML represents a disease with a significant unmet medical need. Given that  there have been no new therapies for AML in the last 30-40 years, identifying new approaches to target AML is critically important. At a cellular level, AML is heterogeneous and has been shown to be driven by cancer stem cells. Thus strategies aimed at inhibiting cancer stem cell growth and renewal may target the fundamental  propagative abilities of the tumor and allow development of a more targeted therapy. Importantly, AML can often arise from early stage myeloid disorders such as myelodysplastic syndrome (MDS) or myeloproliferative  neoplasms (MPN), thus also providing an opportunity to block its progression at earlier stages. Our goal is to develop a new therapeutic agent that can block growth and progression of these myeloid disorders. To this end we have developed antibodies that target a protein required for AML growth. We will test whether these antibodies can block progression of MDS/MPN to AML and improve outcomes. If successful, these exciting studies could to lead to a new treatment strategy for myeloid leukemia.  ",200000.0,2020-02-01,2021-01-31,Complete,False,False,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,,0.0,,,,,,No,,Zero
86,66.0,Initial,9.3,New Therapies for Myeloid Leukemia,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Determine if inhibitory Tspan3 mAb impairs the growth of diverse types of indolent and aggressive myeloid leukemia.,Identify biomarkers predictive of response to Tspan3 inhibition.,,,,,"Acute Myelogenous Leukemia (AML) is a cancer marked by rapid and uncontrolled growth of immature cells of the myeloid lineage. Although it is the most common acute leukemia in adults, current treatments, which include chemotherapy and bone marrow transplantation, are largely ineffective, leading to relapse and death in  most patients. AML also occurs in children, and pediatric AML has a much poorer outcome than other childhood leukemias. In light of these issues, AML represents a disease with a significant unmet medical need. Given that  there have been no new therapies for AML in the last 30-40 years, identifying new approaches to target AML is critically important. At a cellular level, AML is heterogeneous and has been shown to be driven by cancer stem cells. Thus strategies aimed at inhibiting cancer stem cell growth and renewal may target the fundamental  propagative abilities of the tumor and allow development of a more targeted therapy. Importantly, AML can often arise from early stage myeloid disorders such as myelodysplastic syndrome (MDS) or myeloproliferative  neoplasms (MPN), thus also providing an opportunity to block its progression at earlier stages. Our goal is to develop a new therapeutic agent that can block growth and progression of these myeloid disorders. To this end we have developed antibodies that target a protein required for AML growth. We will test whether these antibodies can block progression of MDS/MPN to AML and improve outcomes. If successful, these exciting studies could to lead to a new treatment strategy for myeloid leukemia.  ",200000.0,2020-02-01,2021-01-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,My role on this project is to help with patient samples from ,0.0,,,,,,No,,Zero
87,174.0,Initial,174.1,Mechanisms Linking Prolonged Nightly Fasting with Cancer Risk,UCSD - not a member of Moores Cancer Center,,True,False,False,False,False,Three Specific Aims,fasting insulin concentration and glycemic regulation,inflammation (CRP),"body mass index, sleep duration and quality, and physical activity",,,,"Obesity is epidemic, thus, identification and validation of feasible, efficacious approaches to reducing-obesity related cancer risk are needed. This is a proposal to examine whether in humans, a long nightly fasting interval  can reduce the risk of cancer. Research in rodents indicates that this type of time-restricted feeding can protect against obesity, high insulin levels, fatty liver, and inflammation; all of which can increase cancer risk. Data from human studies are limited, but also suggest positive effects on these markers of cancer risk. The  hypothesis of this study is that a regular pattern of prolonged nightly fasting (13 or more hours per night) will improve factors that may increase the risk of common cancers. Specifically, we propose to test whether in comparison to a short fasting interval, a 13+ hour nightly fasting interval is associated with lower blood glucose  levels, lower inflammation, lower levels of obesity, and improved sleep. As exploratory aims, we will investigate the association of prolonged nightly fasting with metabolites in the blood, such as sugars and fats. We will also  examine the association of nightly fasting with the gut microbiome, which may help us understand how a prolonged nightly fast could improve health. If habitual prolonged nightly fasting improves metabolic health and  reduces cancer risk, this would be an important discovery in cancer prevention that could improve the health of US adults.",75000.0,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
88,175.0,Initial,174.2,Mechanisms Linking Prolonged Nightly Fasting with Cancer Risk,UCSD - not a member of Moores Cancer Center,,True,False,False,False,False,Three Specific Aims,fasting insulin concentration and glycemic regulation,inflammation (CRP),"body mass index, sleep duration and quality, and physical activity",,,,"Obesity is epidemic, thus, identification and validation of feasible, efficacious approaches to reducing-obesity related cancer risk are needed. This is a proposal to examine whether in humans, a long nightly fasting interval can reduce the risk of cancer. Research in rodents indicates that this type of time-restricted feeding can protect against obesity, high insulin levels, fatty liver, and inflammation; all of which can increase cancer risk. Data from human studies are limited, but also suggest positive effects on these markers of cancer risk. The hypothesis of this study is that a regular pattern of prolonged nightly fasting (13 or more hours per night) will  improve factors that may increase the risk of common cancers. Specifically, we propose to test whether in comparison to a short fasting interval, a 13+ hour nightly fasting interval is associated with lower blood glucose levels, lower inflammation, lower levels of obesity, and improved sleep. As exploratory aims, we will investigate the association of prolonged nightly fasting with metabolites in the blood, such as sugars and fats. We will also examine the association of nightly fasting with the gut microbiome, which may help us understand how a prolonged nightly fast could improve health. If habitual prolonged nightly fasting improves metabolic health and reduces cancer risk, this would be an important discovery in cancer prevention that could improve the health of  US adults.",75000.0,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
89,176.0,Initial,174.3,Mechanisms Linking Prolonged Nightly Fasting with Cancer Risk,Salk Institute,,True,False,False,False,False,Three Specific Aims,fasting insulin concentration and glycemic regulation,inflammation (CRP),"body mass index, sleep duration and quality, and physical activity",,,,"Obesity is epidemic, thus, identification and validation of feasible, efficacious approaches to reducing-obesity related cancer risk are needed. This is a proposal to examine whether in humans; a long nightly fasting interval can reduce the risk of cancer. Research in rodents indicates that this type of time-restricted feeding can protect against obesity, high insulin levels, fatty liver, and inflammation; all of which can increase cancer risk. Data from human studies are limited, but also suggest positive effects on these markers of cancer risk. The hypothesis of this study is that a regular pattern of prolonged nightly fasting (13 or more hours per night) will improve factors that may increase the risk of common cancers. Specifically, we propose to test whether in comparison to a short fasting interval, a 13+ hour nightly fasting interval is associated with lower blood glucose levels, lower inflammation, lower levels of obesity, and improved sleep. As exploratory aims, we will investigate the association of prolonged nightly fasting with metabolites in the blood, such as sugars and fats. We will also examine the association of nightly fasting with the gut microbiome, which may help us understand how a prolonged nightly fast could improve health. If habitual prolonged nightly fasting improves metabolic health and reduces cancer risk, this would be an important discovery in cancer prevention that could improve the health of US adults.",75000.0,2016-05-01,2016-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
90,11.0,Initial,11.1,Precision Interception of Gastric Cancers,Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,Network-guided target Identification and prioritization.,Validation of network-prioritized targets using pre-clinical animal models of GC initiation and  progression.,Phase '0' proof-of-concept trials testing the efficacy of drugs for intercepting GC initiation and  progression using human organoid-based disease models.,,,,"A team of researchers comprised of engineers, cancer biologists, and physician-scientists have joined forces to intercept the devastating disease that is Gastric Cancer (GC). GCs often present as advanced disease and kill silently. Fortunately, this disease has well known triggers, e.g., the cancer-causing bug, Helicobacter pylori (Hp)  and some poorly understood, but definite pre-cancerous states that are typically not treatable by surgery but could be specifically intercepted with medical treatment. Currently, no such treatment exists; this team seeks to  change just that.  This team is deploying a new set of mathematical tools for finding precise drugs that prevent GCs and utilizing human stem-cell based disease models for target validation. The team has already created the first-ever map of how GCs begin and has defined the most important steps of GC progression that could be precisely intercepted with drugs. Going forward, their goal is to validate ~3-6 new drugs, some aimed for prevention and others for halting metastatic disease.  There are 2 reasons why this team is likely to succeed where others have failed:  First, when it comes to drug discovery in GC, this team employs precise and unbiased AI-based approaches to expose previously unknown and undefined intermediate stages before GCs and reveal how to stop  progression.  Second, when it comes to drug testing, this team has developed human models that are reverse engineered with the GC-causing bug, the stomach lining and the immune cells to mimic the human ""stomach-in-a-dish"".  These human-relevant models are expected to enable rapidly translation of discoveries.",125000.0,2020-07-01,2021-06-30,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,,0.0,,,,,,No,,One
91,69.0,Initial,11.2,Precision Interception of Gastric Cancers,Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,Network-guided target Identification and prioritization.,Validation of network-prioritized targets using pre-clinical animal models of GC initiation and  progression.,Phase '0' proof-of-concept trials testing the efficacy of drugs for intercepting GC initiation and  progression using human organoid-based disease models.,,,,"A team of researchers comprised of engineers, cancer biologists, and physician-scientists have joined forces to intercept the devastating disease that is Gastric Cancer (GC). GCs often present as advanced disease and kill silently. Fortunately, this disease has well known triggers, e.g., the cancer-causing bug, Helicobacter pylori (Hp) and some poorly understood, but definite pre-cancerous states that are typically not treatable by surgery but could be specifically intercepted with medical treatment. Currently, no such treatment exists; this team seeks to change just that.  This team is deploying a new set of mathematical tools for finding precise drugs that prevent GCs and utilizing human stem-cell based disease models for target validation. The team has already created the first-ever map of how GCs begin and has defined the most important steps of GC progression that could be precisely intercepted with drugs. Going forward, their goal is to validate ~3-6 new drugs, some aimed for prevention and others for halting metastatic disease.  There are 2 reasons why this team is likely to succeed where others have failed:  First, when it comes to drug discovery in GC, this team employs precise and unbiased AI-based approaches to expose previously unknown and undefined intermediate stages before GCs and reveal how to stop progression.  Second, when it comes to drug testing, this team has developed human models that are reverse engineered with the GC-causing bug, the stomach lining and the immune cells to mimic the human ""stomach-in-a-dish"".  These human-relevant models are expected to enable rapidly translation of discoveries.",125000.0,2020-07-01,2021-06-30,Complete,False,False,True,False,False,False,False,False,True,False,False,False,False,False,False,False,False,Yes,I was recently promoted to Professor Step 9.,,0.0,,,,,N/A.,No,,Two
92,137.0,Initial,11.3,Precision Interception of Gastric Cancers,Sanford Burnum,,False,True,False,False,False,Three Specific Aims,Network-guided target identification and prioritization.,Validation of network-prioritized targets using pre-clinical animal models of GC initiation and progression.,Phase '0' proof-of-concept trials testing the efficacy of drugs for intercepting GC initiation and progression using human organoid-based disease models.,,,,"A team of researchers comprised of engineers, cancer biologists, and physician-scientists have joined forces to intercept the devastating disease that is Gastric Cancer (GC). GCs often present as advanced disease and kill silently. Fortunately, this disease has well known triggers, e.g., the cancer-causing bug, Helicobacter pylori (Hp) and some poorly understood, but definite pre-cancerous states that are typically not treatable by surgery but could be specifically intercepted with medical treatment. Currently, no such treatment exists; this team seeks to change just that.  This team is deploying a new set of mathematical tools for finding precise drugs that prevent GCs and utilizing human stem-cell based disease models for target validation. The team has already created the first-ever map of how GCs begin and has defined the most important steps of GC progression that could be precisely intercepted with drugs. Going forward, their goal is to validate ~3-6 new drugs, some aimed for prevention and others for halting metastatic disease.  There are 2 reasons why this team is likely to succeed where others have failed:  First, when it comes to drug discovery in GC, this team employs precise and unbiased AI-based approaches to expose previously unknown and undefined intermediate stages before GCs and reveal how to stop progression.  Second, when it comes to drug testing, this team has developed human models that are reverse engineered with the GC-causing bug, the stomach lining and the immune cells to mimic the human ""stomach-in-a-dish"".  These human-relevant models are expected to enable rapidly translation of discoveries.",125000.0,2020-07-01,2021-06-30,Incomplete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
93,12.0,Initial,12.1,Examination of inhibitors of the ULK1 autophagy kinase as therapeutics in NSCLC,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,To test ULK1 inhibitor +/- standard of care for NSCLC cell lines in cell culture to examine if autophagy inhibitor reverses chemo- or TKI-resistant phenotype,To test ULK1 inhibitor +/- standard of care chemotherapy or TKIs in NSCLC PDX  xenografts in mice,,,,,"Lung cancer is the number 1 cause of cancer deaths per year, causing more deaths annually as colon, breast, and prostate cancer combined. One of the reasons underpinning the high mortality rate of lung cancer is the rapid development of therapeutic resistance to chemotherapies, as well as resistance to targeted therapies in those select patients for which genetically targeted therapies are applicable. ULK1 is a key enzyme in a cellular  process known as autophagy. Autophagy is normally used in cells to survive starvation conditions by recycling internal stores of nutrients, but autophagy gets upregulated in tumor cells, especially in response to therapy. We and other hypothesize that autophagy allows lung cancer cells to evade cell death in response to chemo- and targeted therapies, causing resistance. We have very recently developed new orally available small molecule inhibitors of ULK1, which we have shown suppress autophagy and work without toxicity in animal models. Here  we propose here to test our new ULK1 inhibitors in the first-of-its-kind study for the treatment of lung cancer, and further to specifically to see if they will re-sensitize human tumor samples to standard therapies. We believe autophagy inhibitors have unique promise against a broad set of lung cancers, when used in combination with existing therapeutics.",125000.0,2020-07-01,2021-06-30,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,Provided an opportunity for continue research goals.,,0.0,,,,,none,No,,One
94,70.0,Initial,12.2,Examination of inhibitors of the ULK1 autophagy kinase as therapeutics in NSCLC,Sanford Burnum,,False,True,False,False,False,Two Specific Aims,To test ULK1 inhibitor +/- standard of care for NSCLC cell lines in cell culture to examine if autophagy inhibitor reverses chemo- or TKI-resistant phenotype,To test ULK1 inhibitor +/- standard of care chemotherapy or TKIs in NSCLC PDX xenografts in mice,,,,,"Lung cancer is the number 1 cause of cancer deaths per year, causing more deaths annually as colon, breast, and prostate cancer combined. One of the reasons underpinning the high mortality rate of lung cancer is the rapid development of therapeutic resistance to chemotherapies, as well as resistance to targeted therapies in those select patients for which genetically targeted therapies are applicable. ULK1 is a key enzyme in a cellular  process known as autophagy. Autophagy is normally used in cells to survive starvation conditions by recycling internal stores of nutrients, but autophagy gets upregulated in tumor cells, especially in response to therapy. We and other hypothesize that autophagy allows lung cancer cells to evade cell death in response to chemo- and targeted therapies, causing resistance. We have very recently developed new orally available small molecule inhibitors of ULK1, which we have shown suppress autophagy and work without toxicity in animal models. Here  we propose here to test our new ULK1 inhibitors in the first-of-its-kind study for the treatment of lung cancer, and further to specifically to see if they will re-sensitize human tumor samples to standard therapies. We believe autophagy inhibitors have unique promise against a broad set of lung cancers, when used in combination with existing therapeutics.  ",125000.0,2020-07-01,2021-06-30,Complete,False,False,False,False,False,False,False,False,False,False,False,False,False,False,True,False,False,Yes,A new graduate student joined my lab in 2021 and a main reason for his interest in pursuing graduate studies with me was our work on autophagy in cancer.,,0.0,,,,,"Endeavor Biomedicines licensed this program and pursuing the lead ULKi candidate, now renamed ENV-201",No,,Two
95,71.0,Initial,12.3,Examination of inhibitors of the ULK1 autophagy kinase as therapeutics in NSCLC,Salk Institute,,False,True,False,False,False,Two Specific Aims,To test ULK1 inhibitor +/- standard of care for NSCLC cell lines in cell culture to examine if autophagy inhibitor reverses chemo- or TKI-resistant phenotype,To test ULK1 inhibitor +/- standard of care chemotherapy or TKIs in NSCLC PDX xenografts in mice,,,,,"Lung cancer is the number 1 cause of cancer deaths per year, causing more deaths annually as colon, breast, and prostate cancer combined. One of the reasons underpinning the high mortality rate of lung cancer is the rapid development of therapeutic resistance to chemotherapies, as well as resistance to targeted therapies in those select patients for which genetically targeted therapies are applicable. ULK1 is a key enzyme in a cellular  process known as autophagy. Autophagy is normally used in cells to survive starvation conditions by recycling internal stores of nutrients, but autophagy gets upregulated in tumor cells, especially in response to therapy. We and other hypothesize that autophagy allows lung cancer cells to evade cell death in response to chemo- and targeted therapies, causing resistance. We have very recently developed new orally available small molecule inhibitors of ULK1, which we have shown suppress autophagy and work without toxicity in animal models. Here  we propose here to test our new ULK1 inhibitors in the first-of-its-kind study for the treatment of lung cancer, and further to specifically to see if they will re-sensitize human tumor samples to standard therapies. We believe autophagy inhibitors have unique promise against a broad set of lung cancers, when used in combination with existing therapeutics.  ",125000.0,2020-07-01,2021-06-30,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,I was already tenured and Director of the Salk Cancer Center at the time of the award so this does not apply ,0.0,,,,,"Endeavor Biomedicines licensed this program and pursuing the lead ULKi candidate, now renamed ENV-201",No,,Two
96,13.0,Initial,13.1,Neoantigen-specific T cell responses in exceptional responders to immunotherapy in NSCLC,Salk Institute,,False,False,True,False,False,Two Specific Aims,To identify NeoAntigen (NeoAg)-specific CD4+ and CD8+ T cells in NSCLC patients prior to and after  anti-PD-1 therapy.,To characterize the TCR repertoires of NeoAg-specific T cells prior to and after a-PD-1 therapy.,,,,,"A breakthrough in cancer treatment are drugs aimed to revitalize our immune system to  attack cancer, also known as immunotherapies. However, the majority of patients are non-responders or their cancer develops resistance months after initially responding to therapy (progressors). A few patients on the other hand, are 'exceptional responders' who experience complete cures with tumors melting away  within months. In order to find a ""true"" cure for cancer, it is critical to understand why some patients' tumors completely regress and others do not. This pilot project will address this question in a way that has not been investigated before by comparing the immune responses induced between 'exceptional responders',  'progressors' and 'non-responders'. By definition, tumors are created by mutations that allow it to outgrow normal tissue. These mutations create 'neoantigens' that could potentially induce immune reactions. Many have tried to identify biomarkers that correlate with positive outcomes, but no study has systematically  compared the number or quality of tumor-reactive T cells across these groups to correlate with clinical outcome. We have a time-series of blood samples collected from more than 20 patients with metastatic lung cancer treated with a form of immunotherapy called KEYTRUDA (pembrolizumab) who vary in their responses to treatment. Importantly, we have cryopreserved many T cells from each patient that we can  use to enumerate tumor-reactive T cells between patients with different outcomes. This type of analysis may provide the best understanding of patient responses to immunotherapy to date.",125000.0,2020-07-01,2021-06-30,Complete,False,False,False,False,False,True,True,False,False,False,True,False,False,False,False,False,False,No,,"I was recruited to Salk prior to the obtaining funding from Pedal the Cause. Despite this, the funding we are using for this project is important as it would be difficult to obtain elsewhere.",0.0,,,,,,No,,Zero
97,72.0,Initial,13.2,Neoantigen-specific T cell responses in exceptional responders to immunotherapy in NSCLC,LJI,,False,False,True,False,False,Two Specific Aims,To identify NeoAntigen (NeoAg)-specific CD4+ and CD8+ T cells in NSCLC patients prior to and after anti-PD-1 therapy.,To characterize the TCR repertoires of NeoAg-specific T cells prior to and after a-PD-1 therapy.,,,,,"A breakthrough in cancer treatment are drugs aimed to revitalize our immune system to attack cancer, also known as immunotherapies. However, the majority of patients are non-responders or their cancer develops resistance months after initially responding to therapy (progressors). A few patients on the other hand, are 'exceptional responders' who experience complete cures with tumors melting away within months. In order to find a ""true"" cure for cancer, it is critical to understand why some patients' tumors completely regress and others do not. This pilot project will address this question in a way that has not been investigated before by comparing the immune responses induced between 'exceptional responders', 'progressors' and 'non-responders'. By definition, tumors are created by mutations that allow it to outgrow normal tissue. These mutations create 'neoantigens' that could potentially induce immune reactions. Many have tried to identify biomarkers that correlate with positive outcomes, but no study has systematically compared the number or quality of tumor-reactive T cells across these groups to correlate with clinical outcome. We have a time-series of blood samples collected from more than 20 patients with metastatic lung cancer treated with a form of immunotherapy called KEYTRUDA (pembrolizumab) who vary in their responses to treatment. Importantly, we have cryopreserved many T cells from each patient that we can use to enumerate tumor-reactive T cells between patients with different outcomes. This type of analysis may provide the best understanding of patient responses to immunotherapy to date.  ",125000.0,2020-07-01,2021-06-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
98,73.0,Initial,13.3,Neoantigen-specific T cell responses in exceptional responders to immunotherapy in NSCLC,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,To identify NeoAntigen (NeoAg)-specific CD4+ and CD8+ T cells in NSCLC patients prior to and after anti-PD-1 therapy.,To characterize the TCR repertoires of NeoAg-specific T cells prior to and after a-PD-1 therapy.,,,,,"A breakthrough in cancer treatment are drugs aimed to revitalize our immune system to attack cancer, also known as immunotherapies. However, the majority of patients are non-responders or their cancer develops resistance months after initially responding to therapy (progressors). A few patients on the other hand, are 'exceptional responders' who experience complete cures with tumors melting away within months. In order to find a ""true"" cure for cancer, it is critical to understand why some patients' tumors completely regress and others do not. This pilot project will address this question in a way that has not been investigated before by comparing the immune responses induced between 'exceptional responders', 'progressors' and 'non-responders'. By definition, tumors are created by mutations that allow it to outgrow normal tissue. These mutations create 'neoantigens' that could potentially induce immune reactions. Many have tried to identify biomarkers that correlate with positive outcomes, but no study has systematically compared the number or quality of tumor-reactive T cells across these groups to correlate with clinical outcome. We have a time-series of blood samples collected from more than 20 patients with metastatic lung cancer treated with a form of immunotherapy called KEYTRUDA (pembrolizumab) who vary in their responses to treatment. Importantly, we have cryopreserved many T cells from each patient that we can use to enumerate tumor-reactive T cells between patients with different outcomes. This type of analysis may provide the best understanding of patient responses to immunotherapy to date.",125000.0,2020-07-01,2021-06-30,Complete,False,False,False,False,False,True,True,False,False,False,True,False,False,False,False,False,False,No,,"I was recruited to Salk prior to the obtaining funding from Pedal the Cause. Despite this, the funding we are using for this project is important as it would be difficult to obtain elsewhere. ",0.0,,,,,No companies,No,,Zero
99,14.0,Initial,14.1,Defining the mechanisms of pancreatic cancer susceptibility in patient-derived organoid models,Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,Delineate unique molecular features of chronic pancreatitis patient-derived organoids.,Define transformation potential in the background of pancreatitis.,,,,,"Pancreatic cancer (PDA) is a deadly malignancy. Most PDA patients are diagnosed with late-stage disease and no longer benefit from surgery, the only curative treatment for this disease. Early detection would greatly increase the number of patients who receive this life-saving surgery. Unfortunately, diagnostic tests with the necessary specificity for pancreatic cancer are not available. This is due in part to the difficulty in discriminating between pancreatic cancer and pancreatitis. Pancreatitis is a common type of pancreatic inflammation that resolves naturally in most patients and has a low mortality rate. However, it shares several features with PDA, including the development of fibrotic scar tissue, making it difficult to distinguish between patients with pancreatitis and PDA. We propose to make models from pancreatitis patients that will enable in depth comparison to a collection of models already generated from normal pancreas and pancreatic cancer patients. This will facilitate the discovery of biomarkers that are unique to pancreatic cancer and can be used for early detection.  Several populations exhibit elevated risk for developing pancreatic cancer. Patients with chronic pancreatitis are at 3.5-fold higher risk than the general population and patients with hereditary pancreatitis have a 40-55% lifetime risk of developing PDA. However, the underlying cause of this increased risk is largely unknown. To develop prevention approached for this at-risk patient population, we need a better understanding of why they have increased susceptibility to cancer. Therefore, we will use the models we generate from pancreatitis patients to uncover the source of pancreatic cancer risk.",125000.0,2020-07-01,2021-06-30,Complete,False,False,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,This is an important project for our research program because chronic pancreatitis is an under-studied disease.  We have a multi-disciplinary pancreatitis clinic program and need to take advantage of this resource.  ,,0.0,,,,,None,No,,Zero
100,75.0,Initial,14.3,Defining the mechanisms of pancreatic cancer susceptibility in patient-derived organoid models,UCSD - not a member of Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,Delineate unique molecular features of chronic pancreatitis patient-derived organoids.,Define transformation potential in the background of pancreatitis.,,,,,"Pancreatic cancer (PDA) is a deadly malignancy. Most PDA patients are diagnosed with late-stage disease and no longer benefit from surgery, the only curative treatment for this disease. Early detection would greatly increase the number of patients who receive this life-saving surgery. Unfortunately, diagnostic tests with the necessary specificity for pancreatic cancer are not available. This is due in part to the difficulty in discriminating between pancreatic cancer and pancreatitis. Pancreatitis is a common type of pancreatic inflammation that resolves naturally in most patients and has a low mortality rate. However, it shares several features with PDA, including the development of fibrotic scar tissue, making it difficult to distinguish between patients with pancreatitis and PDA. We propose to make models from pancreatitis patients that will enable in depth comparison to a collection of models already generated from normal pancreas and pancreatic cancer patients. This will facilitate the discovery of biomarkers that are unique to pancreatic cancer and can be used for early detection.  Several populations exhibit elevated risk for developing pancreatic cancer. Patients with chronic pancreatitis are at 3.5-fold higher risk than the general population and patients with hereditary pancreatitis have a 40-55% lifetime risk of developing PDA. However, the underlying cause of this increased risk is largely unknown. To develop prevention approached for this at-risk patient population, we need a better understanding of why they have increased susceptibility to cancer. Therefore, we will use the models we generate from pancreatitis patients to uncover the source of pancreatic cancer risk.",125000.0,2020-07-01,2021-06-30,Complete,False,False,True,False,False,False,False,False,False,False,False,True,False,False,False,False,False,Yes,It is an important part of my advancement and has helped me establish a strong collaboration. ,,0.0,,,,,,No,,One
101,136.0,Initial,14.2,Defining the mechanisms of pancreatic cancer susceptibility in patient-derived organoid models,Salk Institute,,False,False,False,False,False,,,,,,,,,125000.0,2020-07-01,2021-06-30,Incomplete,False,False,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,This funding was important for my midterm evaluation towards my promotion and to lay the ground work for an ongoing collaboration.,,0.0,,,,,,No,,One
102,159.0,Initial,159.1,In Vivo Modeling of Anti-Tumor Responses of Human Melanoma Patients and their Responses to Checkpoint Immunotherapy,Sanford Burnum,,False,False,True,False,False,Two Specific Aims,To assess the anti-tumor responses of melanoma patient T cells in HLA-matched NSG mice. ,"To address the impact of immunotherapy with mAbs specific for PD-1, CTLA-4, and PSGL-1 on anti-tumor immunity, individually or in combinations.",,,,,"Melanoma skin cancer is a deadly disease that kills many patients after the cancer spreads. Current therapies are not effective, and many patients have very few treatment options after metastasis occurs. Recently, immunotherapies have been developed to augment immune cell function to kill tumors. Even though these  immunotherapies are effective in some patients, many others are nonresponsive. There is therefore a pressing need to predict whether a patient will or will not respond to these drugs so that effective personalized treatment options can be offered. The overall goal of our research is to examine a patient's immune system in avatar mice. These mice can carry a patient's own immune and tumor cells. The goal of this project is to test a patient's immune system against their tumors to determine whether they will have a productive response with  clinically available drugs. We will test a new potential drug, an antibody against PSGL-1, and examine whether this therapy restores immune system function that results in tumor destruction. These studies are important  since they will be tools that can be used for personalized medicine. A patient's immune system will first be tested in mice and results will provide their physicians personalized results so that they can design an optimal treatment regimen to combat melanoma growth. These studies are highly significant because if they show promise in melanoma, these tools can be further applied to combat other cancers in humans. ",75000.0,2015-05-01,2016-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
103,160.0,Initial,159.2,In Vivo Modeling of Anti-Tumor Responses of Human Melanoma Patients and their Responses to Checkpoint Immunotherapy,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,To assess the anti-tumor responses of melanoma patient T cells in HLA-matched NSG mice.,"To address the impact of immunotherapy with mAbs specific for PD-1, CTLA-4, and PSGL-1 on anti-tumor immunity, individually or in combinations.",,,,,"Melanoma skin cancer is a deadly disease that kills many patients after the cancer spreads. Current therapies are not effective, and many patients have very few treatment options after metastasis occurs. Recently, immunotherapies have been developed to augment immune cell function to kill tumors. Even though these immunotherapies are effective in some patients, many others are nonresponsive. There is therefore a pressing need to predict whether a patient will or will not respond to these drugs so that effective personalized treatment options can be offered. The overall goal of our research is to examine a patient's immune system in avatar mice. These mice can carry a patient's own immune and tumor cells. The goal of this project is to test a patient's immune system against their tumors to determine whether they will have a productive response with clinically available drugs. We will test a new potential drug, an antibody against PSGL-1, and examine whether this therapy restores immune system function that results in tumor destruction. These studies are important since they will be tools that can be used for personalized medicine. A patient's immune system will first be tested in mice and results will provide their physicians personalized results so that they can design an optimal treatment regimen to combat melanoma growth. These studies are highly significant because if they show promise in melanoma, these tools can be further applied to combat other cancers in humans.",75000.0,2015-05-01,2016-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
104,138.0,Initial,138.1,A Novel Role for Histidine Kinase Activity in Neuroblastoma Pathogenesis,Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,Determine the prognostic relevance of NME1 expression in neuroblastoma tumors.,Evaluate the functional role of NME1 histidine kinase activity in neuroblastoma tumor growth and metastasis.,,,,,"Children with aggressive neuroblastoma have poor cure rates despite intensive treatment, and new treatments are needed.  Treatments that inhibit important proteins and pathways in neuroblastoma are likely to be more effective with fewer side effects.  In our initial experiments, we have identified an association between expression of the NME1 gene and the survival rates of children with neuroblastoma.  NME1 can act as a histidine kinase, by adding phosphate to the amino acid histidine in other proteins in neuroblastoma cells, representing a previously undiscovered way for cells to control the function of proteins required for neuroblastoma growth and survival.  We propose to evaluate the associations of NME1 expression in tumor samples from children with neuroblastoma with the survival rates and other tumor features, and we will explore how MNE1 functions to affect neuroblastoma growth, survival, and spread.  The results of these studies will likely new proteins that could serve as targets for new types of treatment, leading to improved success of neuroblastoma therapy and improved chances of survival for children with neuroblastoma.",100000.0,2018-06-01,2019-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,The availability of funding from Padres Pedal the Cause has been critical in maintaining stable funding to support ongoing research and productivity required for my retention and advancement at UCSD.,,0.0,,,,,none,No,,Two
105,139.0,Initial,138.2,A Novel Role for Histidine Kinase Activity in Neuroblastoma Pathogenesis,Salk Institute,,False,False,False,False,True,Two Specific Aims,Determine the prognostic relevance of NME1 expression in neuroblastoma tumors.,Evaluate the functional role of NME1 histidine kinase activity in neuroblastoma tumor growth and metastasis.,,,,,"Children with aggressive neuroblastoma have poor cure rates despite intensive treatment, and new treatments are needed.  Treatments that inhibit important proteins and pathways in neuroblastoma are likely to be more effective with fewer side effects.  In our initial experiments, we have identified an association between expression of the NME1 gene and the survival rates of children with neuroblastoma.  NME1 can act as a histidine kinase, by adding phosphate to the amino acid histidine in other proteins in neuroblastoma cells, representing a previously undiscovered way for cells to control the function of proteins required for neuroblastoma growth and survival.  We propose to evaluate the associations of NME1 expression in tumor samples from children with neuroblastoma with the survival rates and other tumor features, and we will explore how MNE1 functions to affect neuroblastoma growth, survival, and spread.  The results of these studies will likely new proteins that could serve as targets for new types of treatment, leading to improved success of neuroblastoma therapy and improved chances of survival for children with neuroblastoma.",100000.0,2018-06-01,2019-05-31,Complete,False,False,False,False,False,False,False,False,False,False,False,False,False,True,False,False,False,,,,0.0,,,,,None,No,,One
106,177.0,Initial,177.1,Detecting Correlates of Vaccine Responses in Allogeneic Hematopoietic Stem Cell Transplant Recipients ,UCSD - not a member of Moores Cancer Center,,True,False,False,False,False,Three Specific Aims,"Determine the dynamics of the antibody response to Prevnar-13 and tetanus, diphtheria, and pertussis vaccination in HCT recipients. ",Determine the dynamics of germinal center activity in the post HCT period by assessing circulating CXCL13 levels and circulating Tfh cells.  ,Determine the vaccine-specific CD4+ T cell responses in HCT recipients.,,,,"Vaccines decrease the risk of infection by working with the body's natural defenses to develop immunity, or protection against disease. Patients with cancer and other diseases that affect the immune system may lose immunity to those diseases against which they have previously been vaccinated, and also may have reduced ability to develop immunity to a new vaccination.  Hematopoietic cell transplant (HCT) is a procedure that replaces defective or damaged cells in patients whose normal blood cells have been affected by cancer. Intense chemotherapy or radiation is used to kill the patient's defective stem cells, including immune cells. Hematopoietic cells collected from another donor (allogeneic) are used to reestablish the bone marrow and its ability to generate immunity. Upon engraftment of these new stem cells, transplant recipients have a nave immune system and are at risk for infection. They subsequently undergo a rigorous vaccination schedule, similar to the pediatric vaccination schedule, in the hopes of reestablishing immunity to certain infections.  Our goal is to measure immune markers associated with vaccine responses in HCT recipients in order to improve vaccination strategies. We will do this by measuring vaccine-specific immunity before and after vaccination with the pneumococcal and Tdap vaccines, which are given at standardized times in the year after HCT. Ultimately, this effort is expected to lead to better vaccination strategies which will in turn lead to decreased infections due to vaccine-preventable diseases in this vulnerable patient population as well as contribute to our understanding of immune recovery after HCT.  ",74999.51,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
107,178.0,Initial,177.2,Detecting Correlates of Vaccine Responses in Allogeneic Hematopoietic Stem Cell Transplant Recipients ,LJI,,True,False,False,False,False,Three Specific Aims,"Determine the dynamics of the antibody response to Prevnar-13 and tetanus, diphtheria, and pertussis vaccination in HCT recipients. ",Determine the dynamics of germinal center activity in the post HCT period by assessing circulating CXCL13 levels and circulating Tfh cells.  ,Determine the vaccine-specific CD4+ T cell responses in HCT recipients. ,,,,"Vaccines decrease the risk of infection by working with the body's natural defenses to develop immunity, or protection against disease. Patients with cancer and other diseases that affect the immune system may lose immunity to those diseases against which they have previously been vaccinated, and also may have reduced ability to develop immunity to a new vaccination.  Hematopoietic cell transplant (HCT) is a procedure that replaces defective or damaged cells in patients whose normal blood cells have been affected by cancer. Intense chemotherapy or radiation is used to kill the patient's defective stem cells, including immune cells. Hematopoietic cells collected from another donor (allogeneic) are used to reestablish the bone marrow and its ability to generate immunity. Upon engraftment of these new stem cells, transplant recipients have a nave immune system and are at risk for infection. They subsequently undergo a rigorous vaccination schedule, similar to the pediatric vaccination schedule, in the hopes of reestablishing immunity to certain infections.  Our goal is to measure immune markers associated with vaccine responses in HCT recipients in order to improve vaccination strategies. We will do this by measuring vaccine-specific immunity before and after vaccination with the pneumococcal and Tdap vaccines, which are given at standardized times in the year after HCT. Ultimately, this effort is expected to lead to better vaccination strategies which will in turn lead to decreased infections due to vaccine-preventable diseases in this vulnerable patient population as well as contribute to our understanding of immune recovery after HCT.  ",74999.51,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
108,114.0,Initial,39.2,A Phase 1b Safety and Feasibility Study of Personalized Immunotherapy in Adults with Advanced Cancers,LJI,,False,False,True,False,False,Three Specific Aims,Conduct a phase 1b clinical trial to assess dose-limiting toxicities and adverse events from a personalized pSLP vaccine administered with an anti-PD1 antibody.,Characterize the vaccine contribution to T cell responses. We will enroll patients in two cohorts administering the vaccine either concurrently or sequentially with an anti-PD1 antibody.,Determine the extent of epitope spreading secondary to vaccine and anti-PD1 therapy.,,,,"Immunotherapy has produced a paradigm shift in the way we approach and manager cancer.  In the last few years we have seen unprecedented improvements in cancer survival stemming from immunotherapy with corresponding expedited drug approvals by the FDA.  These agents are generally well tolerated and can have deep and enduring responses once immune recognition of the tumor has occurred.  Unfortunately, over 80% of cancer patients do not benefit from current immunotherapies because the available drugs are ineffective at inducing immune rejection of the tumor.  Accordingly, we hypothesized that if a patient's immune system is stimulated to recognize their cancer then a vigorous anti-tumor response can be achieved.  Over the last four years, we have developed a method of identifying targets in a patient's cancer that can be seen by their immune system, so called ""neoantigens"".  We are now taking this discovery to the clinic by conducting a clinical trial using a personalized neoantigen vaccine in combination with standard immunotherapy.  The clinical trial will test the feasibility of creating truly individualized cancer vaccines and demonstrating the efficacy of this approach at inducing immune responses against a patient's cancer.  This study will lay the groundwork for larger trials for patients with metastatic cancer.  This study will lay the groundwork for larger trials for patients with metastatic cancer, irrespective of the primary tumor site, and for studies testing the effectiveness of personalized cancer vaccines at preventing cancer reoccurrence after definitive therapy.  This work will usher in a new era of transformational immunotherapy that is precise, tailored to the patient, and with little to no side effects.",150000.0,2019-01-01,2019-12-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
109,115.0,Initial,39.3,A Phase 1b Safety and Feasibility Study of Personalized Immunotherapy in Adults with Advanced Cancers,Moores Cancer Center,,False,False,True,False,False,Three Specific Aims,Conduct a phase 1b clinical trial to assess dose-limiting toxicities and adverse events from a personalized pSLP vaccine administered with an anti-PD1 antibody.,Characterize the vaccine contribution to T cell responses. We will enroll patients in two cohorts administering the vaccine either concurrently or sequentially with an anti-PD1 antibody.,Determine the extent of epitope spreading secondary to vaccine and anti-PD1 therapy.,,,,"Immunotherapy has produced a paradigm shift in the way we approach and manager cancer.  In the last few years we have seen unprecedented improvements in cancer survival stemming from immunotherapy with corresponding expedited drug approvals by the FDA.  These agents are generally well tolerated and can have deep and enduring responses once immune recognition of the tumor has occurred.  Unfortunately, over 80% of cancer patients do not benefit from current immunotherapies because the available drugs are ineffective at inducing immune rejection of the tumor.  Accordingly, we hypothesized that if a patient's immune system is stimulated to recognize their cancer then a vigorous anti-tumor response can be achieved.  Over the last four years, we have developed a method of identifying targets in a patient's cancer that can be seen by their immune system, so called ""neoantigens"".  We are now taking this discovery to the clinic by conducting a clinical trial using a personalized neoantigen vaccine in combination with standard immunotherapy.  The clinical trial will test the feasibility of creating truly individualized cancer vaccines and demonstrating the efficacy of this approach at inducing immune responses against a patient's cancer.  This study will lay the groundwork for larger trials for patients with metastatic cancer.  This study will lay the groundwork for larger trials for patients with metastatic cancer, irrespective of the primary tumor site, and for studies testing the effectiveness of personalized cancer vaccines at preventing cancer reoccurrence after definitive therapy.  This work will usher in a new era of transformational immunotherapy that is precise, tailored to the patient, and with little to no side effects.",150000.0,2019-01-01,2019-12-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
110,142.0,Initial,142.1,Protein Kinase C as a Novel Biomarker and Target in Pancreatic Cancer,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Does enhancing PKC protein levels inhibit viability and growth of patient-derived PDAC organoids?,What is the mechanism by which high PKC protein level confers a survival advantage in PDAC?,,,,,"Pancreatic cancer remains one of the deadliest and most aggressive types of cancer, with a five-year survival rate of 9%. We recently discovered that the levels of two proteins predict survival outcome. One protein, PKC, is a tumor suppressor and the other protein, PHLPP1, is its negative regulator that controls how much PKC is  present. We found that in pancreatic cancer, high PHLPP1/low PKC correlated with poor prognosis: in a cohort of 105 patients, none survived longer than five years. But 50% of patients with low PHLPP1/high PKC survived longer than 5 years. This proposal Aims to set the stage for clinicians to one day use a pancreatic cancer patient's PHLPP1/PKC levels as a predictor for prognosis, and for researchers to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC as a means to treat the disease.",200000.0,2020-01-15,2021-01-14,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
111,143.0,Initial,142.2,Protein Kinase C as a Novel Biomarker and Target in Pancreatic Cancer,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Does enhancing PKC protein levels inhibit viability and growth of patient-derived PDAC organoids?,What is the mechanism by which high PKC protein level confers a survival advantage in PDAC?,,,,,"Pancreatic cancer remains one of the deadliest and most aggressive types of cancer, with a five-year survival rate of 9%. We recently discovered that the levels of two proteins predict survival outcome. One protein, PKC, is a tumor suppressor and the other protein, PHLPP1, is its negative regulator that controls how much PKC is  present. We found that in pancreatic cancer, high PHLPP1/low PKC correlated with poor prognosis: in a cohort of 105 patients, none survived longer than five years. But 50% of patients with low PHLPP1/high PKC survived longer than 5 years. This proposal Aims to set the stage for clinicians to one day use a pancreatic cancer patient's PHLPP1/PKC levels as a predictor for prognosis, and for researchers to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC as a means to treat the disease.",200000.0,2020-01-15,2021-01-14,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
112,140.0,Initial,140.1,Targeting fibroblast heterogeneity to improve surgical outcomes in pancreatic cancer,Salk Institute,,False,True,False,False,False,Two Specific Aims,Improving outcomes for fluorescence-guided surgical resection and photo-immunotherapy  treatment using VDR agonist therapies.,Determine the contribution of fibroblast heterogeneity to VDR-driven therapeutic responses.,,,,,"Currently, the only curative treatment for pancreatic cancer is surgical resection. However, for the majority of patients that undergo surgery, some cancer cells are inadvertently left behind and tumors regrow. The recent development of fluorescence-guided surgery and photoimmunotherapy techniques have tremendous potential to capture these remaining tumor cells and allow surgeons to achieve truly curative resections where patients  remain disease free. Importantly, these revolutionary new approaches rely on the delivery of labeled drugs to  tumors. One major roadblock for their successful application in pancreatic cancer comes from the presence of  a cellular support network (or ""stroma"") that surrounds the tumor, forming a physical barrier that hides tumor cells and prevents drugs from reaching them. This stromal response is largely driven by a collection of cells known as cancer associated fibroblasts (CAFs). In breakthrough studies, we have found that therapeutically  targeting the Vitamin D Receptor (VDR) in CAFs can destabilize this stromal barrier. Here, we will use mouse models that accurately mimic human disease to test if VDR-targeted therapies can aid fluorescence-guided surgery and photoimmunotherapy to improve surgical success rates. In addition, we will use recent advances in single cell genomic analyses to understand precisely how VDR-targeted therapies impact the different types  of CAFs that establish stromal barriers for drug delivery. In summary, by combining VDR-targeted therapies with fluorescence-guided surgery and photoimmunotherapy, we believe we are poised to dramatically enhance  the success of surgical resection, paving the way for increased patient survival of this deadly disease.",125000.0,2018-06-18,2019-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
113,141.0,Initial,140.2,Targeting fibroblast heterogeneity to improve surgical outcomes in pancreatic cancer,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Improving outcomes for fluorescence-guided surgical resection and photo-immunotherapy  treatment using VDR agonist therapies.,Determine the contribution of fibroblast heterogeneity to VDR-driven therapeutic responses.,,,,,"Currently, the only curative treatment for pancreatic cancer is surgical resection. However, for the majority of patients that undergo surgery, some cancer cells are inadvertently left behind and tumors regrow. The recent development of fluorescence-guided surgery and photoimmunotherapy techniques have tremendous potential to capture these remaining tumor cells and allow surgeons to achieve truly curative resections where patients  remain disease free. Importantly, these revolutionary new approaches rely on the delivery of labeled drugs to tumors. One major roadblock for their successful application in pancreatic cancer comes from the presence of  a cellular support network (or ""stroma"") that surrounds the tumor, forming a physical barrier that hides tumor cells and prevents drugs from reaching them. This stromal response is largely driven by a collection of cells known as cancer associated fibroblasts (CAFs). In breakthrough studies, we have found that therapeutically  targeting the Vitamin D Receptor (VDR) in CAFs can destabilize this stromal barrier. Here, we will use mouse models that accurately mimic human disease to test if VDR-targeted therapies can aid fluorescence-guided surgery and photoimmunotherapy to improve surgical success rates. In addition, we will use recent advances in single cell genomic analyses to understand precisely how VDR-targeted therapies impact the different types  of CAFs that establish stromal barriers for drug delivery. In summary, by combining VDR-targeted therapies with fluorescence-guided surgery and photoimmunotherapy, we believe we are poised to dramatically enhance  the success of surgical resection, paving the way for increased patient survival of this deadly disease.",125000.0,2018-06-01,2019-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
114,157.0,Initial,157.1,Cytotoxic Breast Cancer Treatment Effects on Aging,Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,To compare the change of laboratory-based blood measures of telomere function and cellular senescence in 20 newly diagnosed postmenopausal breast cancer patients from before and at the conclusion of IV chemotherapy.,"To investigate the effects of breast cancer chemotherapy on repeated detailed measures of  physical fitness, balance, body composition, physical function and neurocognitive exams.",,,,,"With a growing aging U.S. population and an expected increase in cancer survivorship projected to affect >60% of those over the age of 65, there is concern that the effects of cancer treatments on physiologic reserve may carry long-term undesirable health consequences. Studies have shown that adult childhood cancer  survivors are at marked increased risk of developing frailty and chronic health conditions at younger ages than would normally be expected. Whether accelerated aging affects patients diagnosed with breast cancer, the  most common type of cancer to affect women, is unknown. To answer this question, we have brought together a multi-disciplinary team of expert basic scientists, clinician researchers, exercise physiologists, geriatricians  and cancer physician specialists to test the hypothesis of accelerated aging in post-menopausal women recently diagnosed with stage II to III breast cancer. Together we will conduct an integrated effort to understand what anti-cancer therapies do, not only with respect to healthy cells, but also to overall health and  function. This study is not only novel, but also unique in its scope of attempting to bridge the latest in scientific advances on the cellular level to the whole patient. Our ultimate goal is to better understand whether or not chemotherapy may contribute to accelerated aging in breast cancer patients, and if so, identify and target  modifiable factors to decrease the risk of not only developing recurrence, but also to maximize long-term healthy function and quality of life in these women as they age.",75000.0,2015-05-01,2016-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
115,158.0,Initial,157.2,Cytotoxic Breast Cancer Treatment Effects on Aging,Salk Institute,,True,False,False,False,False,Two Specific Aims,To compare the change of laboratory-based blood measures of telomere function and cellular senescence in 20 newly diagnosed postmenopausal breast cancer patients from before and at the conclusion of IV chemotherapy.,"To investigate the effects of breast cancer chemotherapy on repeated detailed measures of  physical fitness, balance, body composition, physical function and neurocognitive exams.  ",,,,,"With a growing aging U.S. population and an expected increase in cancer survivorship projected to affect >60% of those over the age of 65, there is concern that the effects of cancer treatments on physiologic reserve may carry long-term undesirable health consequences. Studies have shown that adult childhood cancer survivors are at marked increased risk of developing frailty and chronic health conditions at younger ages than would normally be expected. Whether accelerated aging affects patients diagnosed with breast cancer, the most common type of cancer to affect women, is unknown. To answer this question, we have brought together a multi-disciplinary team of expert basic scientists, clinician researchers, exercise physiologists, geriatricians and cancer physician specialists to test the hypothesis of accelerated aging in post-menopausal women recently diagnosed with stage II to III breast cancer. Together we will conduct an integrated effort to understand what anti-cancer therapies do, not only with respect to healthy cells, but also to overall health and function. This study is not only novel, but also unique in its scope of attempting to bridge the latest in scientific advances on the cellular level to the whole patient. Our ultimate goal is to better understand whether or not chemotherapy may contribute to accelerated aging in breast cancer patients, and if so, identify and target modifiable factors to decrease the risk of not only developing recurrence, but also to maximize long-term healthy function and quality of life in these women as they age.",75000.0,2015-05-01,2016-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
116,144.0,Initial,144.1,Small molecule screen for inhibitors of the GOLPH3 pathway,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Use the current moderate throughput assay to screen known FDA approved drugs for activity against the GOLPH3 pathway,Re-tool the assay for a HTS in the CLS C3 shared core,,,,,"To more effectively combat cancer we need new therapies directed at new targets. We have discovered a new signaling pathway involving a protein called GOLPH3 that drives a high fraction of cancers that together account for the majority of cancer deaths. This GOLPH3 pathway is unlike other pathways that drive cancer,  and so inhibitors of the pathway provide a unique approach to cancer treatment. Our published data suggest that inhibition of the GOLPH3 pathway is likely to have therapeutic benefit. We have developed and validated a  screening assay to test compounds for their ability to inhibit the GOLPH3 pathway. Here we propose to team up with the Chemical Library Screening C3 Shared Core Facility to further develop the assay for use in a high  throughput screen to identify a set of potent inhibitors targeting different steps in the GOLPH3 pathway to serve as lead compounds for novel cancer therapeutics.",75000.0,2014-05-01,2015-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
117,145.0,Initial,144.2,Small molecule screen for inhibitors of the GOLPH3 pathway,Sanford Burnum,,False,True,False,False,False,Two Specific Aims,Use the current moderate throughput assay to screen known FDA approved drugs for activity against the GOLPH3  pathway,Re-tool the assay for a HTS in the CLS C3 shared core,,,,,"To more effectively combat cancer we need new therapies directed at new targets. We have discovered a new signaling pathway involving a protein called GOLPH3 that drives a high fraction of cancers that together account for the majority of cancer deaths. This GOLPH3 pathway is unlike other pathways that drive cancer, and so inhibitors of the pathway provide a unique approach to cancer treatment. Our published data suggest that inhibition of the GOLPH3 pathway is likely to have therapeutic benefit. We have developed and validated a screening assay to test compounds for their ability to inhibit the GOLPH3 pathway. Here we propose to team up with the Chemical Library Screening C3 Shared Core Facility to further develop the assay for use in a high throughput screen to identify a set of potent inhibitors targeting different steps in the GOLPH3 pathway to serve as lead compounds for novel cancer therapeutics.",75000.0,2014-05-01,2015-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
118,172.0,Initial,172.1,Targeting Stem Cell Signals in Cancer Development and Progression,UCSD - not a member of Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Perform high throughput screening of targeted libraries,Test the efficacy of compounds on AML growth,,,,,"To identify new therapeutic targets for cancer, we have focused on stem cell programs that are reactivated in cancer. Recently, we demonstrated that the stem cell signal Musashi (Msi) is highly upregulated during leukemia development and that its blockade can inhibit tumor growth and progression. This work was important because it identified a new role for Msi as a key regulator of cancer progression in vivo and as an  early indicator of poor prognosis. We have now extended these findings to other cancers, and shown that Msi2 is also upregulated in many solid cancers as they progress to higher grades, and is required for growth and maintenance of these cancers. These data suggest that targeting Msi may provide a new strategy for therapy.  To move this work forward to the clinic, we now propose to develop inhibitors of Msi and test their efficacy against cancer growth. These studies have the potential to identify a new class of therapeutics for cancers that are largely unresponsive to current therapies.",75000.0,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
119,173.0,Initial,172.2,Targeting Stem Cell Signals in Cancer Development and Progression,Sanford Burnum,,False,True,False,False,False,Two Specific Aims,Perform high throughput screening of targeted libraries,Test the efficacy of compounds on AML growth,,,,,"To identify new therapeutic targets for cancer, we have focused on stem cell programs that are reactivated in cancer. Recently, we demonstrated that the stem cell signal Musashi (Msi) is highly upregulated during leukemia development and that its blockade can inhibit tumor growth and progression. This work was important because it identified a new role for Msi as a key regulator of cancer progression in vivo and as an early indicator of poor prognosis. We have now extended these findings to other cancers, and shown that Msi2 is also upregulated in many solid cancers as they progress to higher grades, and is required for growth and maintenance of these cancers. These data suggest that targeting Msi may provide a new strategy for therapy.  To move this work forward to the clinic, we now propose to develop inhibitors of Msi and test their efficacy against cancer growth. These studies have the potential to identify a new class of therapeutics for cancers that are largely unresponsive to current therapies.",75000.0,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
120,146.0,Initial,146.1,Applying p38 MAPK inhibitors to tackle breast cancer metastasis,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Investigate the mechanisms through which Ubc13 and p38 control BCa metastasis and (MIC).,Define metastasis gene signatures that are controlled by Ubc13 and p38.,,,,,"The spread of cancer cells from the primary tumor to distant organs, termed metastasis, is the leading cause of cancer-related death. In the clinic, removal of early diagnosed primary breast cancer, even when the tumor is very small, cannot prevent metastatic recurrence many years later. It remains a big challenge to conduct  metastasis-preventing trials on patients with early stage breast cancer using long term survival and reduction of metastatic load as endpoints, because such studies are lengthy and require a large number of patients,  many of which have good intermediate survival prospects. Consequently, new agents that prevent metastasis from occurring or trigger the regression of already formed metastases are urgent unmet needs. We found that  Ubc13, an enzyme that modifies proteins and controls their ability to transmit signals that stimulate cell proliferation and survival, is important for the metastatic spread of breast cancer. Ubc13 controls metastatic spread through another enzyme called p38. We hypothesize that inhibition of Ubc13 or p38 can be used to prevent BCa metastatic spread and sensitize dormant metastasis initiating cells and existing metastases to chemotherapy. We will investigate in further detail how Ubc13 and p38 control BCa metastasis and define an  Ubc13/p38-dependent metastasis gene signature, which will help in measuring clinical response to Ubc13 or p38. These investigations will provide new insights to the control of BCa metastasis by Ubc13 and p38 and will provide a rationale for the clinical testing of Ubc13 or p38 inhibitors as anti -metastatic agents in breast cancer. ",75000.0,2014-08-01,2015-07-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
121,147.0,Initial,146.2,Applying p38 MAPK inhibitors to tackle breast cancer metastasis,Salk Institute,,False,True,False,False,False,Two Specific Aims,Investigate the mechanisms through which Ubc13 and p38 control BCa metastasis and (MIC).,Define metastasis gene signatures that are controlled by Ubc13 and p38.,,,,,"The spread of cancer cells from the primary tumor to distant organs, termed metastasis, is the leading cause of cancer-related death. In the clinic, removal of early diagnosed primary breast cancer, even when the tumor is very small, cannot prevent metastatic recurrence many years later. It remains a big challenge to conduct  metastasis-preventing trials on patients with early stage breast cancer using long term survival and reduction of metastatic load as endpoints, because such studies are lengthy and require a large number of patients,  many of which have good intermediate survival prospects. Consequently, new agents that prevent metastasis from occurring or trigger the regression of already formed metastases are urgent unmet needs. We found that  Ubc13, an enzyme that modifies proteins and controls their ability to transmit signals that stimulate cell proliferation and survival, is important for the metastatic spread of breast cancer. Ubc13 controls metastatic spread through another enzyme called p38. We hypothesize that inhibition of Ubc13 or p38 can be used to prevent BCa metastatic spread and sensitize dormant metastasis initiating cells and existing metastases to chemotherapy. We will investigate in further detail how Ubc13 and p38 control BCa metastasis and define an  Ubc13/p38-dependent metastasis gene signature, which will help in measuring clinical response to Ubc13 or p38. These investigations will provide new insights to the control of BCa metastasis by Ubc13 and p38 and will  provide a rationale for the clinical testing of Ubc13 or p38 inhibitors as anti -metastatic agents in breast cancer. ",75000.0,2014-08-01,2015-07-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
122,148.0,Initial,148.1,Stromal reprogramming to enhance the effectiveness of pancreatic cancer therapy,Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,"Determine the impact of stromal p53 activation on PC cell proliferation, viability and gene  expression.",Determine whether PCs reduce p53 activation in CAFs via secretion of paracrine  factors or through cell:cell interactions.,"Test the therapeutic benefit of stromal reprogramming in an orthotopic,  immunocompetent model of pancreatic cancer. ",,,,"Our project, ""Reprogramming the stroma of pancreatic cancer to enhance effectiveness of cancer therapy"" proposes a new strategy to treat this terrible disease that is the fourth leading cause of cancer death in the United States. Every day, a San Diegan will be diagnosed with pancreatic cancer, yet only 1 in 20 will survive  for 5 years after this diagnosis. Doctors have made impressive strides in treating cancer using ""smart-drugs"" tailored to our improving knowledge of the abnormal genes that drive cancer growth and survival.  Unfortunately, thus far, applying such knowledge to pancreatic cancer hasn't helped. We believe that the lack  of progress is in part due to the fact that pancreatic cancers grow encased in a thick tissue protective layer called the ""activated stroma"". This stroma acts both as a barrier to drug entry and also provides fuel for cancer cell growth. We hypothesize that drugs that ""reprogram"" the stroma to make it more ""normal"" will increase the efficacy of cancer cell therapy. We propose to test one ""smart-drug"" that is in clinical trials to ""reprogram"" the stroma, and a second ""smart-drug"" to make pancreatic cancer cells and their metastases more sensitive to standard chemotherapy drugs. This innovative outside-in strategy will combat the barriers posed by pancreatic cancer, and could have significant community impact by reducing death and suffering caused by this deadly  cancer.",74757.0,2014-05-01,2015-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
123,149.0,Initial,148.2,Stromal reprogramming to enhance the effectiveness of pancreatic cancer therapy,Salk Institute,,False,True,False,False,False,Three Specific Aims,"Determine the impact of stromal p53 activation on PC cell proliferation, viability and gene  expression.",Determine whether PCs reduce p53 activation in CAFs via secretion of paracrine  factors or through cell:cell interactions.,"Test the therapeutic benefit of stromal reprogramming in an orthotopic,  immunocompetent model of pancreatic cancer. ",,,,"Our project, ""Reprogramming the stroma of pancreatic cancer to enhance effectiveness of cancer therapy"" proposes a new strategy to treat this terrible disease that is the fourth leading cause of cancer death in the United States. Every day, a San Diegan will be diagnosed with pancreatic cancer, yet only 1 in 20 will survive  for 5 years after this diagnosis. Doctors have made impressive strides in treating cancer using ""smart-drugs"" tailored to our improving knowledge of the abnormal genes that drive cancer growth and survival.  Unfortunately, thus far, applying such knowledge to pancreatic cancer hasn't helped. We believe that the lack  of progress is in part due to the fact that pancreatic cancers grow encased in a thick tissue protective layer called the ""activated stroma"". This stroma acts both as a barrier to drug entry and also provides fuel for cancer cell growth. We hypothesize that drugs that ""reprogram"" the stroma to make it more ""normal"" will increase the efficacy of cancer cell therapy. We propose to test one ""smart-drug"" that is in clinical trials to ""reprogram"" the stroma, and a second ""smart-drug"" to make pancreatic cancer cells and their metastases more sensitive to standard chemotherapy drugs. This innovative outside-in strategy will combat the barriers posed by pancreatic cancer, and could have significant community impact by reducing death and suffering caused by this deadly  cancer. ",74757.0,2014-05-01,2015-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
124,150.0,Initial,150.1,"Targeting imatinib-resistant, KIT-negative cells in human GISTs",Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,"Determine whether imatinib-resistant, KITneg cells are CSCs."," Define the molecular properties of imatinib-resistant, KITneg cells.","Identify strategies for targeting imatinib-resistant, KITneg cells.",,,,"Gastrointestinal Stromal Tumor (GIST) is a cancer that arises from nerve cells that control the movement of muscles in the intestine. Until the late 1990s, cancers like GIST were ""carpet bombed"" with chemotherapy without much success. Therefore, attention turned to ""sniping"" specific targets in tumors. GIST served as a  paradigm for this approach with the discovery that many GISTs have high levels of a protein called KIT. It turned out that imatinib, a drug originally developed for treating leukemia, could attack KIT. This served as the first targeted, personalized therapy for treating any solid tumor. However, it did not completely cure GIST  because some GISTs don't have the KIT target. Even those that do will eventually develop a ""bullet-proof"" form of KIT, which allows the cancer to keep growing/spreading. Therefore, it is critically important to identify new ways to treat GIST that do not depend on KIT. Our preliminary findings suggest that KIT-expressing human GISTs contain a small population of cells that lack KIT, and are therefore resistant to imatinib treatment. We propose to characterize these cells, to study their properties, and to use advanced screening technology to discover new drugs that can specifically target them. These studies have the potential for rapid translational  application because: 1) characterization of drug-resistant GIST cells may identify new methods for predicting patient outcomes; and 2) novel drugs identified in our studies may provide new approaches to treating GIST patients whose tumors become resistant to current therapy.",75000.0,2014-06-01,2015-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
125,151.0,Initial,150.2,"Targeting imatinib-resistant, KIT-negative cells in human GISTs",Sanford Burnum,,False,True,False,False,False,Three Specific Aims,"Determine whether imatinib-resistant, KITneg cells are CSCs.","Define the molecular properties of imatinib-resistant, KITneg cells.","Identify strategies for targeting imatinib-resistant, KITneg cells.",,,,"Gastrointestinal Stromal Tumor (GIST) is a cancer that arises from nerve cells that control the movement of muscles in the intestine. Until the late 1990s, cancers like GIST were ""carpet bombed"" with chemotherapy without much success. Therefore, attention turned to ""sniping"" specific targets in tumors. GIST served as a  paradigm for this approach with the discovery that many GISTs have high levels of a protein called KIT. It turned out that imatinib, a drug originally developed for treating leukemia, could attack KIT. This served as the first targeted, personalized therapy for treating any solid tumor. However, it did not completely cure GIST  because some GISTs don't have the KIT target. Even those that do will eventually develop a ""bullet-proof"" form of KIT, which allows the cancer to keep growing/spreading. Therefore, it is critically important to identify new  ways to treat GIST that do not depend on KIT. Our preliminary findings suggest that KIT-expressing human GISTs contain a small population of cells that lack KIT, and are therefore resistant to imatinib treatment. We  propose to characterize these cells, to study their properties, and to use advanced screening technology to discover new drugs that can specifically target them. These studies have the potential for rapid translational application because: 1) characterization of drug-resistant GIST cells may identify new methods for predicting patient outcomes; and 2) novel drugs identified in our studies may provide new approaches to treating GIST patients whose tumors become resistant to current therapy.",75000.0,2014-06-01,2015-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
126,152.0,Initial,152.1,Demonstrating the Clinical Utility of Whole Exome Sequencing for Cancer Patients,UCSD - not a member of Moores Cancer Center,,True,False,False,False,False,Three Specific Aims,"Successfully sequence the exomes of a UCSD patient, her sister, and both parents",Use state of the art bioinformatics methods to identify a novel breast cancer predisposition  gene(s),"Translate the finding to clinical care by having CLIA-certified confirmation of our research  finding so that the results can be given to the patient and her family to be used for predictive  testing in additional family members, and  If appropriate:  Elucidate the mechanism of cancer initiation and/or progression using functional assays with a view to understanding which oncogenic pathways are implicated for this family.",,,,"Breast cancer in young women often has a genetic cause. The BRCA genes explain some hereditary breast cancer, but there are still many families where a genetic cause is suspected, but never found through routine genetic testing. For this project, we propose to sequence the entire exome (the coding part of the genome) of a  family with a strong suspicion of a hereditary breast cancer gene. Two sisters both had breast cancer in their 30s, but their BRCA testing was normal, and additional breast cancer genetic testing was also normal. We hope to find a new gene that increases the risk of early-onset breast cancer in this family. Once we have identified a potential high-risk gene (or genes), we will examine how that gene works in breast cancer cells in an effort to understand how breast cancer can develop in women at a very young age. This genetic information could be of immediate benefit to this family, and in the longer term other families with unexplained early breast cancer could benefit as well. Our goal is to find a new gene that families with unexplained hereditary breast cancer can be tested for, in order to determine which family members have the gene (and need to be  monitored carefully or undertake breast cancer prevention measures), and which family members did not inherit the gene and are considered to be at average risk.",18288.0,2014-05-01,2015-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
127,153.0,Initial,152.2,Demonstrating the Clinical Utility of Whole Exome Sequencing for Cancer Patients,Salk Institute,,True,False,False,False,False,Three Specific Aims,"Successfully sequence the exomes of a UCSD patient, her sister, and both parents",Use state of the art bioinformatics methods to identify a novel breast cancer predisposition  gene(s),"Translate the finding to clinical care by having CLIA-certified confirmation of our research  finding so that the results can be given to the patient and her family to be used for predictive  testing in additional family members, and  If appropriate:  Elucidate the mechanism of cancer initiation and/or progression using functional assays with a view to understanding which oncogenic pathways are implicated for this family.",,,,"Breast cancer in young women often has a genetic cause. The BRCA genes explain some hereditary breast cancer, but there are still many families where a genetic cause is suspected, but never found through routine genetic testing. For this project, we propose to sequence the entire exome (the coding part of the genome) of a  family with a strong suspicion of a hereditary breast cancer gene. Two sisters both had breast cancer in their 30s, but their BRCA testing was normal, and additional breast cancer genetic testing was also normal. We hope to find a new gene that increases the risk of early-onset breast cancer in this family. Once we have identified a potential high-risk gene (or genes), we will examine how that gene works in breast cancer cells in an effort to understand how breast cancer can develop in women at a very young age. This genetic information could be of immediate benefit to this family, and in the longer term other families with unexplained early breast cancer could benefit as well. Our goal is to find a new gene that families with unexplained hereditary breast cancer can be tested for, in order to determine which family members have the gene (and need to be  monitored carefully or undertake breast cancer prevention measures), and which family members did not inherit the gene and are considered to be at average risk.",18288.0,2014-05-01,2015-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
128,167.0,Initial,167.1,Targeting KRAS mutant lung cancer with biphosphonated/statins and rapamycin analogs,Salk Institute,,False,True,False,False,False,Two Specific Aims,Phase II pilot study of zoledronate in combination with everolimus for metastatic lung adenocarcinomas harboring KRAS mutations. KRAS mutated lung cancer is considered to be an unmet need in thoracic oncology. Multiple prior efforts have failed to produce effective therapy. We propose testing in the clinic a novel combination of zoledronate and everolimus to confirm preclinical data derived from Dr. Verma's laboratory.,"Investigation of bisphosphonates/statins and rapamycin analog combination in lung adenocarcinoma mouse models. 2A. Test zoledronate plus everolimus in PDX model with more mutation combinations (such as KRAS with TP53 or LKB1). In our previous mouse model study, we showed that zoledronate and rapamycin combination is effective against lung adenocarcinomas induced by KRAS G12D mutation and loss of TP53. In this proposed study, we will further test the combination therapy in more PDX models and ask the question if lung tumors with certain mutation combinations are more sensitive to this therapy, thus we can better define the therapeutic indications. 2B. Test simvastatin plus everolimus in lentiviral model and PDX model. Since our preliminary data showed that simvastatin is also a potent inhibitor of protein prenylation, we will test if simvastatin and everolimus combination is effective against KRAS induced lung adenocarcinoma in our lentiviral mouse model. If the result is positive, we will further test the combination in more PDX models as proposed in Aim 2A.",,,,,"Lung cancer is the most common human malignancy and leads to about one-third of all cancer-related deaths. There are three major genetic mutations found in lung adenocarcinomas, EGFR, EML4-ALK and KRAS. The first two have been successfully targeted in the past decade with innovative kinase inhibitors; however, KRAS, which is more common in Caucasians, males and smokers, does not have good therapeutic options to date. Our previous study showed that zoledronate (a drug usually prescribed for bone resorption) could efficiently block a kind of protein modification called prenylation, and thus impair KRAS oncogenic activity. In several mouse lung cancer models, we proved that zoledronate in combination with rapamycin (an immunosuppressing drug usually used for preventing rejection in organ transplantation) could successfully inhibit tumor growth and prolonged mouse survival. Based on this, we propose to test the drug combination in metastatic lung adenocarcinomas harboring KRAS mutations. We will also try to decipher what type of mutation spectrum makes a given tumor more sensitive to this drug combination. On the other hand, we found that statins (drugs prescribed for lowering blood cholesterol) could inhibit protein modification as well, and thus we will also try a statin and rapamycin combination in mouse lung cancer models. With all these efforts, we hope to develop a good combination therapy to combat lung cancers harboring KRAS mutations and demonstrate the power of immediate translation of basic research results into the clinic and thus benefit human patients directly.",75000.0,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
129,168.0,Initial,167.2,Targeting KRAS mutant lung cancer with biphosphonated/statins and rapamycin analogs,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Phase II pilot study of zoledronate in combination with everolimus for metastatic lung adenocarcinomas harboring KRAS mutations. KRAS mutated lung cancer is considered to be an unmet need in thoracic oncology. Multiple prior efforts have failed to produce effective therapy. We propose testing in the clinic a novel combination of zoledronate and everolimus to confirm preclinical data derived from Dr. Verma's laboratory.,"Investigation of bisphosphonates/statins and rapamycin analog combination in lung adenocarcinoma mouse models. 2A. Test zoledronate plus everolimus in PDX model with more mutation combinations (such as KRAS with TP53 or LKB1). In our previous mouse model study, we showed that zoledronate and rapamycin combination is effective against lung adenocarcinomas induced by KRAS G12D mutation and loss of TP53. In this proposed study, we will further test the combination therapy in more PDX models and ask the question if lung tumors with certain mutation combinations are more sensitive to this therapy, thus we can better define the therapeutic indications. 2B. Test simvastatin plus everolimus in lentiviral model and PDX model. Since our preliminary data showed that simvastatin is also a potent inhibitor of protein prenylation, we will test if simvastatin and everolimus combination is effective against KRAS induced lung adenocarcinoma in our lentiviral mouse model. If the result is positive, we will further test the combination in more PDX models as proposed in Aim 2A.",,,,,"Lung cancer is the most common human malignancy and leads to about one-third of all cancer-related deaths. There are three major genetic mutations found in lung adenocarcinomas, EGFR, EML4-ALK and KRAS. The first two have been successfully targeted in the past decade with innovative kinase inhibitors; however, KRAS, which is more common in Caucasians, males and smokers, does not have good therapeutic options to date. Our previous study showed that zoledronate (a drug usually prescribed for bone resorption) could efficiently block a kind of protein modification called prenylation, and thus impair KRAS oncogenic activity. In several mouse lung cancer models, we proved that zoledronate in combination with rapamycin (an immunosuppressing drug usually used for preventing rejection in organ transplantation) could successfully inhibit tumor growth and prolonged mouse survival. Based on this, we propose to test the drug combination in metastatic lung adenocarcinomas harboring KRAS mutations. We will also try to decipher what type of mutation spectrum makes a given tumor more sensitive to this drug combination. On the other hand, we found that statins (drugs prescribed for lowering blood cholesterol) could inhibit protein modification as well, and thus we will also try a statin and rapamycin combination in mouse lung cancer models. With all these efforts, we hope to develop a good combination therapy to combat lung cancers harboring KRAS mutations and demonstrate the power of immediate translation of basic research results into the clinic and thus benefit human patients directly.",75000.0,2016-05-01,2017-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
130,165.0,Initial,165.1,KRAS Addiction and Protein Biomarkers of Response to anti-KRAS Therapy in NSCLC Patient Derived Xenografts,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,"Investigate the effects of mut-KRAS inhibition by siRNA knockdown and our small molecule mut-KRAS inhibitor PHT-7390 in mut-KRAS addicted, non-addicted, and wt-KRAS NSCLC cell  lines.",To investigate the in vivo antitumor and biomarker response of addicted and nonaddicted NSCLC patient derived malignant effusion PDX to the mut-KRAS inhibitor in order to develop a panel of not more than 3 RPPA and IHC biomarkers for testing in future in a clinical trial of mut-KRAS inhibition with PHT-7390.,,,,,"In approximately 25% of lung cancer, the specific gene KRAS may be mutated. Therapies that are uniquely specific for patients who have the KRAS mutation do not exist, and this challenge remains a large unmet need among lung cancer patients. Every year an estimated 39,000 people will die of this molecular form of the disease. In determining the best therapy for patients, there are several challenges to consider. Not all patients with KRAS mutations are uniquely dependent on the KRAS molecular pathway for causing the cancer and, even in patients with the mutation, we currently do not know how to predict who will have the best response to therapy targeted specifically against the mutated KRAS gene. In this project, we seek to identify additional markers that may be used to help determine who will respond to novel KRAS directed therapies. We will use cancer cells  obtained from the fluid that accumulate in the chest and bathes the lungs, inject them into mice so that they may grow and form a tumor, and study proteins that are expressed in the tumors to identify new markers that associate with the dependency of the tumor on mutant KRAS specifically. We will also study a new drug that we have developed to precisely target the KRAS protein complex and test its efficacy in KRAS mutated and pathway dependent cancer cells. This work will be the basis of a future clinical trial to evaluate the new anti-KRAS drug for  patients with KRAS mutations and pathway dependency.",75000.0,2015-05-01,2016-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
131,166.0,Initial,165.2,KRAS Addiction and Protein Biomarkers of Response to anti-KRAS Therapy in NSCLC Patient Derived Xenografts,Sanford Burnum,,False,True,False,False,False,Two Specific Aims,"Investigate the effects of mut-KRAS inhibition by siRNA knockdown and our small molecule mut-KRAS inhibitor PHT-7390 in mut-KRAS addicted, non-addicted, and wt-KRAS NSCLC cell lines.",To investigate the in vivo antitumor and biomarker response of addicted and nonaddicted NSCLC patient derived malignant effusion PDX to the mut-KRAS inhibitor in order to develop a panel of not more than 3 RPPA and IHC biomarkers for testing in future in a clinical trial of mut-KRAS inhibition with PHT-7390.,,,,,"In approximately 25% of lung cancer, the specific gene KRAS may be mutated. Therapies that are uniquely specific for patients who have the KRAS mutation do not exist, and this challenge remains a large unmet need among lung cancer patients. Every year an estimated 39,000 people will die of this molecular form of the disease. In determining the best therapy for patients, there are several challenges to consider. Not all patients with KRAS mutations are uniquely dependent on the KRAS molecular pathway for causing the cancer and, even in patients with the mutation, we currently do not know how to predict who will have the best response to therapy targeted specifically against the mutated KRAS gene. In this project, we seek to identify additional markers that may be used to help determine who will respond to novel KRAS directed therapies. We will use cancer cells  obtained from the fluid that accumulate in the chest and bathes the lungs, inject them into mice so that they may grow and form a tumor, and study proteins that are expressed in the tumors to identify new markers that associate with the dependency of the tumor on mutant KRAS specifically. We will also study a new drug that we have developed to precisely target the KRAS protein complex and test its efficacy in KRAS mutated and pathway dependent cancer cells. This work will be the basis of a future clinical trial to evaluate the new anti-KRAS drug for patients with KRAS mutations and pathway dependency.  ",75000.0,2015-05-01,2016-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
132,3.0,Initial,3.1,Detecting dysregulated genes in neuroblastoma using allele-specific expression,Salk Institute,,False,False,False,False,True,Two Specific Aims,Identify genes that are dysregulated in neuroblastoma through analysis of allele-specific expression (ASE).,Identify and characterize de novo germline and somatic mutations in neuroblastoma tumors,,,,,"Improved knowledge of the genetic mutations that are important for neuroblastoma could lead to advances both in neuroblastoma risk stratification and to new therapeutic approaches. In this study, we propose to identify genes that are inappropriately expressed (i.e. turned off or on) in neuroblastoma tumors using an analysis method known as allele-specific expression. With this approach we will learn how mutations affect genes indirectly by changing their expression instead of the genes themselves. In addition, we will identify mutations in neuroblastoma tumors that occurred in the parents or early in embryonic development. These types of mutations may be more important in neuroblastoma than other cancers because of its extremely early age of onset.",100000.0,2019-07-15,2021-07-14,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,The PPTC funding allowed a postdoctoral researcher in my laboratory to develop and execute this project.,,0.0,,,,,None,No,,One
133,82.0,Initial,3.2,Detecting dysregulated genes in neuroblastoma using allele-specific expression,Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,Identify genes that are dysregulated in neuroblastoma through analysis of allele-specific expression (ASE).,Identify and characterize de novo germline and somatic mutations in neuroblastoma tumors,,,,,"Neuroblastoma is a devastating cancer of the sympathetic nervous system that most commonly affects very young children-90% of patients are diagnosed by 5 years of age and the highest rate of diagnosis in the first month of life. Neuroblastoma patients are currently stratified into low-, intermediate- and high-risk groups based on their age at diagnosis, pattern of metastases, and the genetic mutations in their tumor. Unfortunately the accuracy of risk stratification is hampered by our limited genetic understanding of the mutations that drive disease progression and relapse. Improved knowledge of the genetic mutations that are important for neuroblastoma could lead to advances both in neuroblastoma risk stratification and to new therapeutic approaches. In this study, we propose to identify genes that are inappropriately expressed (i.e. turned off or on) in neuroblastoma tumors using an analysis method known as allele-specific expression. With this approach we will learn how mutations affect genes indirectly by changing their expression instead of the genes themselves. In addition, we will identify mutations in neuroblastoma tumors that occurred in the parents or early in embryonic development. These types of mutations may be more important in neuroblastoma than other cancers because of its extremely early age of onset.",100000.0,2019-07-15,2021-07-14,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,Working on this grant and project has been part of my advancement from assistant to associate professor,,0.0,,,,,none,No,,One
134,42.0,Initial,42.1,Investigating the Efficacy of radium-223 with Olaparib in Men with Metastatic Castration-resistant Prostate Cancer,Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,To investigate the safety and efficacy of radium-223 combined with olaparib compared to radium-223 for men with castration-resistant prostate cancer {CRPC) with bone metastases.,To prospectively characterize germline and somatic molecular alterations in the HR pathway and determine whether these alterations are predictive of meaningful clinical responses to PARP inhibition in patients with mCPRC.,To phenotypically and molecularly profile changes in circulating immune cells in response to radium-223 with or without olaparib.,,,,"Metastatic castration-resistant prostate cancer heralds a lethal disease and represents a major unmet need in clinical practice. Despite the confirmed efficacy of approved agents for men with mCRPC, resistance to treatment is universal. Novel treatments and combinations are imperative to improve outcomes for patients.  Radium-223, an alpha emitting radioisotope, has been shown to prolong overall survival in mCRPC2 . Studies have demonstrated that enhanced DNA repair is a potential resistance mechanism to radiation and impairment of this process, via PARP inhibitors such as olaparib, can promote cell death and delay tumor growth4  5. We hypothesize that the addition of olaparib to radium-223 will improve survival for patients and outcomes may be dependent on tumor DNA repair status which may serve as predictive biomarker of response. To test this hypothesize, we have designed a phase 1/11 open-label randomized clinical trial of standard of care  radium-223 with or without olaparib. To investigate molecular mechanisms of response and resistance to treatment and interrogate molecular aberrations in the DNA repair pathway, patients will undergo a mandatory  baseline and optional progression tumor biopsy. Additionally, lmmunoprofiling of blood and tissue specimens will be performed on a subset of patients to investigate the rationale for combinatorial immunotherapy to radium-223 with or without olaparib. This study has the potential to improve the efficacy of existing  treatment options for mCRPC patients. By harnessing vast advances in technology, genetics, and biomedical research, molecular tumor profiling has the potential to better inform patient selection for a given treatment and transform clinical decision making.",150000.0,2018-11-01,2020-10-31,Complete,False,False,True,True,True,False,True,False,False,False,False,False,False,False,False,False,False,No,,,1.0,A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE) ,72.0,NCI10096 ClinicalTrials.gov Identifier:  NCT03317392  Title:  A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE),,None,No,,Zero
135,119.0,Initial,42.2,Investigating the Efficacy of radium-223 with Olaparib in Men with Metastatic Castration-resistant Prostate Cancer,Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,To investigate the safety and efficacy of radium-223 combined with olaparib compared to radium-223 for men with castration-resistant prostate cancer {CRPC) with bone metastases.,To prospectively characterize germline and somatic molecular alterations in the HR pathway and determine whether these alterations are predictive of meaningful clinical responses to PARP inhibition in patients with mCPRC.,To phenotypically and molecularly profile changes in circulating immune cells in response to radium-223 with or without olaparib.,,,,"Metastatic castration-resistant prostate cancer heralds a lethal disease and represents a major unmet need in clinical practice. Despite the confirmed efficacy of approved agents for men with mCRPC, resistance to treatment is universal. Novel treatments and combinations are imperative to improve outcomes for patients. Radium-223, an alpha emitting radioisotope, has been shown to prolong overall survival in mCRPC2. Studies have demonstrated that enhanced DNA repair is a potential resistance mechanism to radiation and impairment of this process, via PARP inhibitors such as olaparib, can promote cell death and delay tumor growth45. We hypothesize that the addition of olaparib to radium-223 will improve survival for patients and outcomes may be dependent on tumor DNA repair status which may serve as predictive biomarker of response. To test this hypothesize, we have designed a phase 1/11 open-label randomized clinical trial of standard of care radium-223 with or without olaparib. To investigate molecular mechanisms of response and resistance to treatment and interrogate molecular aberrations in the DNA repair pathway, patients will undergo a mandatory baseline and optional progression tumor biopsy. Additionally, lmmunoprofiling of blood and tissue specimens will be performed on a subset of patients to investigate the rationale for combinatorial immunotherapy to radium-223 with or without olaparib. This study has the potential to improve the efficacy of existing treatment options for mCRPC patients. By harnessing vast advances in technology, genetics, and biomedical research, molecular tumor profiling has the potential to better inform patient selection for a given treatment and transform clinical decision-making.",150000.0,2018-11-01,2020-10-31,Complete,False,False,False,True,True,True,False,False,False,False,False,False,False,False,False,False,False,Yes,,,1.0,,,,,None,No,,One
136,31.0,Initial,31.1,Inducing Cytosolic Chromatin Fragments in Cancer Cells to Turn Cold Tumors Hot,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,Identify compounds that induce CCF and anti-tumor cytokines in cancer cells with low basal CCF  signaling.,Determine the in vivo impact of low and high CCF in cancer cells in activating anti-tumor immune  responses.,,,,,"Immune therapy is a method to treat cancer using the body's own immune system. This method works because immune cells such as T cells can infiltrate a tumor mass and specifically destroy cancer cells. For some patients, the T cells can also seek out and destroy cancer cells that have metastasized throughout the body. Additionally, the T cells survive even when the cancer cells have been destroyed and thus can prevent recurrence of cancer. Thus, immune therapy has the potential to produce durable, long-lasting cures for cancer. Unfortunately, not all patients respond to immune therapy. In particular, some patients have ""cold"" tumors that do not contain many immune cells. These tumors resist immune therapy by preventing the infiltration and/or accumulation of T cells  in the tumor mass. This grant seeks to discover new ways to make a cold tumor ""hot"". Specifically, we wish to manipulate the cancer cell to force it to make proteins such as cytokines that recruit immune cells. In essence, our research will turn cancer cells into ""suicide cells"" that act as beacons for anti-tumor immune cells. We envision that our therapy will amplify and broaden the efficacy of current immune therapies and provide long-lasting remissions for a large swath of cancer patients.",124972.0,2018-06-01,2019-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,It helped support my laboratory and provide bridge funding while I secured extramural monies.,,0.0,,,,,None,No,,Zero
137,100.0,Initial,31.2,Inducing Cytosolic Chromatin Fragments in Cancer Cells to Turn Cold Tumors Hot,Sanford Burnum,,False,False,True,False,False,Two Specific Aims,Identify compounds that induce CCF and anti-tumor cytokines in cancer cells with low basal CCF signaling.,Determine the in vivo impact of low and high CCF in cancer cells in activating anti-tumor immune responses.,,,,,"Immune therapy is a method to treat cancer using the body's own immune system. This method works because immune cells such as T cells can infiltrate a tumor mass and specifically destroy cancer cells. For some patients, the T cells can also seek out and destroy cancer cells that have metastasized throughout the body. Additionally, the T cells survive even when the cancer cells have been destroyed and thus can prevent recurrence of cancer. Thus, immune therapy has the potential to produce durable, long-lasting cures for cancer. Unfortunately, not all patients respond to immune therapy. In particular, some patients have ""cold"" tumors that do not contain many immune cells. These tumors resist immune therapy by preventing the infiltration and/or accumulation of T cells  in the tumor mass. This grant seeks to discover new ways to make a cold tumor ""hot"". Specifically, we wish to manipulate the cancer cell to force it to make proteins such as cytokines that recruit immune cells. In essence, our research will turn cancer cells into ""suicide cells"" that act as beacons for anti-tumor immune cells. We envision that our therapy will amplify and broaden the efficacy of current immune therapies and provide long-lasting remissions for a large swath of cancer patients.  ",124972.0,2018-06-01,2019-05-31,Complete,False,False,False,False,False,False,False,False,True,False,False,False,False,False,True,True,False,Yes,Progress made was able to support a successful R21 application for additional funding. Currently in progress. ,,0.0,,,,,none,No,,Zero
138,33.0,Initial,33.1,Enhanced Breast Cancer Risk Prediction from Imputed Gene Expression,Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,Identify genes and regulatory network modules that affect breast cancer risk.  ,Develop a network-informed genetic risk score for breast cancer susceptibility.,,,,,"Early detection remains the strongest determinant of long-term disease-free survival across cancer types, however there is a tradeoff between screening for early detection and the risk of false diagnosis and overtreatment. One strategy to optimize this tradeoff is to stratify individuals by genetic cancer risk and to screen more aggressively in high-risk populations. Genetic risk scores have shown some promise for identifying individuals at risk, however current models use a very simple combination of risk factors and do not account for the complex nature of the underlying biology. In this proposal we will develop new genetic risk scores that incorporate information about (1) the impact of genetic factors on gene expression and (2) the relationship between gene expression and disease risk. This proof-of-principle study will be implemented in breast cancer, but can easily generalize to a number of cancer types and will provide a framework for future studies of cancer risk biology. The long-term goals of this research are to improve our understanding of the genetic mechanisms that drive cancer risk and to enable accurate identification of high-risk individuals that can benefit from additional screening and prevention.",125000.0,2018-06-01,2019-05-31,Complete,False,False,False,False,False,False,True,False,False,False,False,False,False,False,False,False,False,Yes,"This grant was mentioned in my my tenure package  and was counted toward my ability to compete for funding. I received an accelerated promotion, transitioning from Assistant to Associate and skipping a rank. ",,0.0,,,,,,No,,One
139,102.0,Initial,33.2,Enhanced Breast Cancer Risk Prediction from Imputed Gene Expression,Salk Institute,,True,False,False,False,False,Two Specific Aims,Identify genes and regulatory network modules that affect breast cancer risk.,Develop a network-informed genetic risk score for breast cancer susceptibility.,,,,,"Early detection remains the strongest determinant of long-term disease-free survival across cancer types, however there is a tradeoff between screening for early detection and the risk of false diagnosis and overtreatment. One strategy to optimize this tradeoff is to stratify individuals by genetic cancer risk and to screen more aggressively in high-risk populations. Genetic risk scores have shown some promise for identifying individuals at risk, however current models use a very simple combination of risk factors and do not account for the complex nature of the underlying biology. In this proposal we will develop new genetic risk scores that incorporate information about (1) the impact of genetic factors on gene expression and (2) the relationship between gene expression and disease risk. This proof-of-principle study will be implemented in breast cancer, but can easily generalize to a number of cancer types and will provide a framework for future studies of cancer risk biology. The long-term goals of this research are to improve our understanding of the genetic mechanisms that drive cancer risk and to enable accurate identification of high-risk individuals that can benefit from additional screening and prevention.",125000.0,2018-06-01,2019-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,The Carter and McVicker laboratories were able to recruit a co-advised PhD student to initiate this project as a result of the Pedal the Cause funding.,,0.0,,,,,None,No,,One
140,18.0,Initial,18.1,Novel Pathways Regulated by NME1 in Neuroblastoma,Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,Identify and validate genes and intracellular signaling pathways associated with NME1 expression.,Evaluate the functional role of NME1 and NME1-mediated signaling in neuroblastoma cell and tumor growth and spread.,,,,,"Children with aggressive neuroblastoma tumors have poor rates of survival and cure despite intensive treatment, and new therapies are needed. Treatments that block the actions of important proteins and pathways in neuroblastoma tumors are likely to be more effective with fewer side effects. We have identified an association between the levels of the NME1 gene and the rates of survival of children with neuroblastoma, and we have also identified an association between the levels of the NME1 gene and signaling pathways that potentially control neuroblastoma cell growth and spread, suggesting that NME1 may be a good candidate target for new neuroblastoma treatments. We propose to determine the genes and pathways in neuroblastoma cells that are controlled by NME1 and to explore how NME1 expression levels and activity affect neuroblastoma tumor cell growth, survival, and spread. The results of these studies will likely identify new proteins that could serve as targets for new types of treatment, leading to improved success of neuroblastoma therapy and improved chances of survival for children with neuroblastoma.",100000.0,2020-07-01,2021-06-30,Complete,False,False,False,True,False,False,False,False,False,False,False,False,False,False,True,False,False,Yes,The availability of funding from Padres Pedal the Cause was critical in maintaining stable funding to support ongoing research and productivity required for my retention and advancement at UCSD.,,0.0,,,,,none,No,,Two
141,80.0,Initial,18.2,Novel Pathways Regulated by NME1 in Neuroblastoma,Salk Institute,,False,False,False,False,True,Two Specific Aims,Identify and validate genes and intracellular signaling pathways associated with NME1 expression.,Evaluate the functional role of NME1 and NME1-mediated signaling in neuroblastoma cell and tumor growth and spread.,,,,,"Children with aggressive neuroblastoma tumors have poor rates of survival and cure despite intensive treatment, and new therapies are needed. Treatments that block the actions of important proteins and pathways in neuroblastoma tumors are likely to be more effective with fewer side effects. We have identified an association between the levels of the NME1 gene and the rates of survival of children with neuroblastoma, and we have also identified an association between the levels of the NME1 gene and signaling pathways that potentially control neuroblastoma cell growth and spread, suggesting that NME1 may be a good candidate target for new neuroblastoma treatments. We propose to determine the genes and pathways in neuroblastoma cells that are controlled by NME1 and to explore how NME1 expression levels and activity affect neuroblastoma tumor cell growth, survival, and spread. The results of these studies will likely identify new proteins that could serve as targets for new types of treatment, leading to improved success of neuroblastoma therapy and improved chances of survival for children with neuroblastoma.",100000.0,2020-07-01,2021-06-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
142,20.0,Initial,20.1,Characterization of a GOLPH3 Pathway Inhibitor to Enable a Hit-to-Lead Grant to Develop a Novel Cancer Therapeutic,Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,Determine the critical kinase target of MLS1377,"Develop more potent, specific, and drug-like structural analogs of MLS1377",Determine ADME/PK for improved analogs of MLS1377,,,,"To more effectively combat cancer we need new therapies directed at new targets. We discovered a signaling pathway involving a protein called GOLPH3 that drives a high fraction of cancers that together cause a high proportion of cancer deaths, including lung, breast, prostate, and colorectal cancers. The GOLPH3 pathway is  unlike other pathways that drive cancer, and so inhibitors of the pathway provide a unique approach to cancer treatment. Existing data indicate that inhibition of the GOLPH3 pathway preferentially kills cancer. We have identified a potent inhibitor of the pathway, and propose experiments to better define its mechanism of action to enable further development to produce a compound that would be suitable as a novel therapeutic agent, completely unlike all current therapeutic strategies for cancer. ",125000.0,2019-07-01,2020-06-30,Complete,False,False,False,True,False,False,False,False,True,False,False,False,False,False,True,False,False,No,,,0.0,,,,,None,No,,Three
143,83.0,Initial,20.2,Characterization of a GOLPH3 Pathway Inhibitor to Enable a Hit-to-Lead Grant to Develop a Novel Cancer Therapeutic,Sanford Burnum,,False,True,False,False,False,Three Specific Aims,Determine the critical kinase target of MLS1377,"Develop more potent, specific, and drug-like structural analogs of MLS1377",Determine ADME/PK for improved analogs of MLS1377,,,,"To more effectively combat cancer we need new therapies directed at new targets. We discovered a signaling pathway involving a protein called GOLPH3 that drives a high fraction of cancers that together cause a high proportion of cancer deaths, including lung, breast, prostate, and colorectal cancers. The GOLPH3 pathway is unlike other pathways that drive cancer, and so inhibitors of the pathway provide a unique approach to cancer treatment. Existing data indicate that inhibition of the GOLPH3 pathway preferentially kills cancer. We have identified a potent inhibitor of the pathway, and propose experiments to better define its mechanism of action to enable further development to produce a compound that would be suitable as a novel therapeutic agent, completely unlike all current therapeutic strategies for cancer.",125000.0,2019-07-01,2020-06-30,Complete,False,False,False,True,False,False,False,False,True,False,False,False,False,False,True,False,False,No,,,0.0,,,,,None,No,,Zero
144,21.0,Initial,21.1,Microbe-Associated Colorectal Cancer (M.A.C.S),Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Model infection-inflammation-driven polyp-to-CRC progression using human organoids.,Determine the prognostic impact of the MACS via the development of a 'polyp-print'.,,,,,"This proposal revolves around the discovery, characterization, disease modeling and harnessing the diagnostic and therapeutic potential of a novel tumor suppressive pathway in the gut that normally protects the gut barrier  from the luminal microbes but is lost during the initiation of colon cancers. The combined synergy of several transdisciplinary approaches is used to reveal when and how the microbes may alter host cell properties to ultimately fuel cancer initiation. The proposal also promises to deliver a therapeutic target/therapy for protecting the gut from these cancer-causing microbes and halt the formation and progression of colon polyps and to validate a novel set of markers for predicting which polyps in the colons are at highest risk for progressing to colon cancers.",125000.0,2019-07-15,2020-07-14,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,,,0.0,,,,,,No,,Two
145,108.0,Initial,21.2,Microbe-Associated Colorectal Cancer (M.A.C.S),Sanford Burnum,,False,True,False,False,False,Two Specific Aims,Model infection-inflammation-driven polyp-to-CRC progression using human organoids.,Determine the prognostic impact of the MACS via the development of a 'polyp-print'.,,,,,"This proposal revolves around the discovery, characterization, disease modeling and harnessing the diagnostic and therapeutic potential of a novel tumor suppressive pathway in the gut that normally protects the gut barrier from the luminal microbes but is lost during the initiation of colon cancers. The combined synergy of several transdisciplinary approaches is used to reveal when and how the microbes may alter host cell properties to ultimately fuel cancer initiation. The proposal also promises to deliver a therapeutic target/therapy for protecting the gut from these cancer-causing microbes and halt the formation and progression of colon polyps and to validate a novel set of markers for predicting which polyps in the colons are at highest risk for progressing to colon cancers.",125000.0,2019-07-15,2020-07-14,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,The opportunity to set up collaborations with other researchers in San Diego is a huge advantage.,,0.0,,,,,None,No,,Zero
146,23.0,Initial,23.1,Evaluation of carcinogen exposure via genome-wide DNA-adduct signatures,Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,Develop a model to predict exposure from Ad-Seq profiles.,Associate specimen Ad-Seq profiles to risk factors and somatic mutations.,,,,,"Multiple organs of the body are constantly exposed to a plethora of carcinogens from exogenous origin (e.g., alcohol, tobacco, pollution), or due to endogenous processes (inflammation, infection), many of which reacts  with the DNA. These damages, called DNA adducts, in absence of repair, can lead to somatic mutations and become the primary cause of cancer. Importantly, and similar to what has been observed for tumor mutations,  every tissue in every patient likely has a unique set of damages representing a signature of their life-long exposures and subsequent modeling by cellular processes and inherited genetics. In this project, we will validate and apply a novel genome-wide assay (Ad-Seq) to globally examine the landscape of DNA adducts, ignoring  their exact chemistry but rather relying on their genomic location and DNA sequence preference. We will utilize the resulting molecular profiles to predict exposure and compare damages in the DNA of normal tissues to mutations found in the adjacent tumor. This work will establish Ad-Seq profiling as a novel tool to assess personal  cancer risk, integrating both environment and genetics, reporting on the global molecular consequences of carcinogens on the DNA. The approach will therefore provide a more direct and richer context to investigate the link between mutagenic exposure and subsequent mutations, leading to more personal prevention and screening strategies.",125000.0,2019-01-01,2019-12-31,Complete,False,False,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,Any grant award helps with Advancement and academic file. ,,0.0,,,,,none,No,,Zero
147,86.0,Initial,23.2,Evaluation of carcinogen exposure via genome-wide DNA-adduct signatures,Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,Develop a model to predict exposure from Ad-Seq profiles.,Associate specimen Ad-Seq profiles to risk factors and somatic mutations.,,,,,"Multiple organs of the body are constantly exposed to a plethora of carcinogens from exogenous origin (e.g., alcohol, tobacco, pollution), or due to endogenous processes (inflammation, infection), many of which reacts with the DNA. These damages, called DNA adducts, in absence of repair, can lead to somatic mutations and become the primary cause of cancer. Importantly, and similar to what has been observed for tumor mutations, every tissue in every patient likely has a unique set of damages representing a signature of their life-long exposures and subsequent modeling by cellular processes and inherited genetics. In this project, we will validate and apply a novel genome-wide assay (Ad-Seq) to globally examine the landscape of DNA adducts, ignoring their exact chemistry but rather relying on their genomic location and DNA sequence preference. We will utilize the resulting molecular profiles to predict exposure and compare damages in the DNA of normal tissues to mutations found in the adjacent tumor. This work will establish Ad-Seq profiling as a novel tool to assess personal cancer risk, integrating both environment and genetics, reporting on the global molecular consequences of carcinogens on the DNA. The approach will therefore provide a more direct and richer context to investigate the link between mutagenic exposure and subsequent mutations, leading to more personal prevention and screening strategies.",125000.0,2019-01-01,2019-12-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,,0.0,,,,,,No,,Zero
148,24.0,Initial,24.1,Impact of Metformin on Clonal Hematopoiesis and Clinical Outcomes in Breast Cancer,Moores Cancer Center,,True,False,False,False,False,Three Specific Aims,Characterize the burden and genetic profile of CH after adjuvant chemotherapy for breast  cancer.,Examine the effect of metformin on the clonal burden of therapy-related CH.,Describe the clinical significance of therapy-related CH and its impact on clinical outcomes.,,,,"Clonal hematopoiesis describes a common pre-cancerous condition where blood stem cells gain one or more mutations in cancer-associated genes that allow them to grow and expand abnormally at the expense of their normal counterparts. Chemotherapy triggers DNA damage and inflammation within the bone marrow microenvironment prompting certain blood stem cells with adverse mutations to expand even further, significantly increasing the risk for developing very aggressive blood cancers for which current treatments are ineffective and survival is measured in months. There is a critical need for improved predictive and preventative measures for secondary blood cancers in patients who are otherwise cured from their primary cancer. Metformin is a widely-used diabetes drug that blocks several inflammatory pathways and could have profound effects on the bone marrow microenvironment to reduce the risk of secondary blood cancers in  individuals treated with particularly causative chemotherapeutic agents. We will study how treatment with metformin affects clonal hematopoiesis and disease outcomes in women who received chemotherapy after surgery for breast cancer. Exploring how inflammation after chemotherapy exposure affects mutant blood stem cells leading to predisposition for secondary blood cancers will impact how we screen and follow clonal hematopoiesis in the foreseeable future and integrate preventative efforts long term for breast cancer and other solid tumors.",125000.0,2019-03-02,2020-03-01,Complete,False,False,False,True,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,It provided the sole support for this project which had been scored but not funded as an R01 submission in part due to insufficient preliminary data. We were able to proceed with this project because of this funding as it would have otherwise been abandoned. ,,0.0,,,,,None,No,,One
149,88.0,Initial,24.2,Impact of Metformin on Clonal Hematopoiesis and Clinical Outcomes in Breast Cancer,Moores Cancer Center,,True,False,False,False,False,Three Specific Aims,Characterize the burden and genetic profile of CH after adjuvant chemotherapy for breast cancer.,Examine the effect of metformin on the clonal burden of therapy-related CH.,Describe the clinical significance of therapy-related CH and its impact on clinical outcomes.,,,,"Clonal hematopoiesis describes a common pre-cancerous condition where blood stem cells gain one or more mutations in cancer-associated genes that allow them to grow and expand abnormally at the expense of their normal counterparts. Chemotherapy triggers DNA damage and inflammation within the bone marrow microenvironment prompting certain blood stem cells with adverse mutations to expand even further, significantly increasing the risk for developing very aggressive blood cancers for which current treatments are ineffective and survival is measured in months. There is a critical need for improved predictive and preventative measures for secondary blood cancers in patients who are otherwise cured from their primary cancer. Metformin is a widely-used diabetes drug that blocks several inflammatory pathways and could have profound effects on the bone marrow microenvironment to reduce the risk of secondary blood cancers in individuals treated with particularly causative chemotherapeutic agents. We will study how treatment with metformin affects clonal hematopoiesis and disease outcomes in women who received chemotherapy after surgery for breast cancer. Exploring how inflammation after chemotherapy exposure affects mutant blood stem cells leading to predisposition for secondary blood cancers will impact how we screen and follow clonal hematopoiesis in the foreseeable future and integrate preventative efforts long term for breast cancer and other solid tumors.",125000.0,2019-03-02,2020-03-01,Complete,False,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,,0.0,,,,,none,No,,One
150,29.0,Initial,29.1,Natural Killer Cells for Treatment of Medulloblastoma,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,Determine whether MB cells are susceptible to NK-mediated killing in vitro,Test whether NK cells can be used for immunotherapy against p53-mutant MB tumors in vivo,,,,,"Immunotherapy is emerging as a powerful approach to treating cancer. Most immunotherapies work by increasing the activity of immune cells called T cells, but T cells can only attack tumor cells if the tumor cells display a protein on their surface called MHC-I. In our recent studies of the childhood brain tumor  medulloblastoma, we discovered that tumor cells frequently shut off expression of MHC-1, and thereby become invisible to T cells. This raises the possibility that these patients may be insensitive to T cell-based immunotherapy. In contrast, a different type of immune cell called a natural killer cell is not dependent on (and  is actually inhibited by) MHC-I, and thus may be better able to kill tumors that do not express MHC-I. In the proposed studies, we will test whether natural killer cells can be used to attack and kill medulloblastoma cells that lack MHC-I. If successful, these studies could markedly increase the numbers of patients who benefit from this type of cell-based immunotherapy.",125000.0,2018-06-01,2019-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
151,98.0,Initial,29.2,Natural Killer Cells for Treatment of Medulloblastoma,Sanford Burnum,,False,False,True,False,False,Two Specific Aims,Determine whether MB cells are susceptible to NK-mediated killing in vitro,Test whether NK cells can be used for immunotherapy against p53-mutant MB tumors in vivo,,,,,"Immunotherapy is emerging as a powerful approach to treating cancer. Most immunotherapies work by increasing the activity of immune cells called T cells, but T cells can only attack tumor cells if the tumor cells display a protein on their surface called MHC-I. In our recent studies of the childhood brain tumor medulloblastoma, we discovered that tumor cells frequently shut off expression of MHC-1, and thereby become invisible to T cells. This raises the possibility that these patients may be insensitive to T cell-based immunotherapy. In contrast, a different type of immune cell called a natural killer cell is not dependent on (and is actually inhibited by) MHC-I, and thus may be better able to kill tumors that do not express MHC-I. In the proposed studies, we will test whether natural killer cells can be used to attack and kill medulloblastoma cells that lack MHC-I. If successful, these studies could markedly increase the numbers of patients who benefit from this type of cell-based immunotherapy.",125000.0,2018-06-01,2019-05-31,Complete,False,False,False,False,False,True,False,True,False,False,False,False,False,False,False,False,False,No,,,0.0,,,,,,No,,Zero
152,30.0,Initial,30.1,Targeting FZD7 in human cancers,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,Characterizing the anti-FZD7 antibody and FZD7 expression in cancer cells.,Using the anti-FZD7 antibody to block growth of cancer cells.,,,,,"A major shortcoming of current cancer therapies is lack of specificity. Chemotherapeutic drugs act on fast dividing cells, such as cancer cells. However, cells in normal tissues, such as skin, blood and the gastrointestinal tract, also divide and hence are highly sensitive to chemotherapeutic drugs, resulting in many  undesired toxic side-effects and the all-too-common misconception that cancer treatments do more harm than good. Recent advances in immunotherapies overcome many of the issues associated with chemotherapy. With the rapid advances in molecular profiling of human cancers and precision medicine, it is now possible to identify patient-specific mutations in cancers and design specific immunotherapies to block the aggressive growth of these cancers.  We have identified the gene FRIZZLED7 (FZD7) as a molecular marker of many cancer types. With its highly restricted expression pattern-absent in children and adults and present in the embryo and various cancers- FZD7 is an ideal target for immunotherapies. We have developed an antibody that only reacts with FZD7, thus  providing us with a molecular handle to identify, target and potentially kill cancer cells. In this application, we propose to leverage our uniquely specific FZD7 antibody to develop highly selective strategies to combat cancers in which FZD7 is highly expressed.  The short-term goals of the proposed research are foundational and basic in nature. Successful completion of  this 1-year study will immediately feed into our long-term goals, including clinical development, filing of a new investigational drug (IND) application with the FDA, and initiating a Phase 1 clinical trial.",125000.0,2019-01-01,2019-12-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,"The initial studies supported by Pedal the Cause helped me establish a viable cancer-related line of research in my lab, which has attracted the interests of graduate students and post-docs.",,0.0,,,,,none,Yes,"Patent No.: US 10,766,962",Two
153,99.0,Initial,30.2,Targeting FZD7 in human cancers,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,Characterizing the anti-FZD7 antibody and FZD7 expression in cancer cells.,Using the anti-FZD7 antibody to block growth of cancer cells.,,,,,"A major shortcoming of current cancer therapies is lack of specificity. Chemotherapeutic drugs act on fast dividing cells, such as cancer cells. However, cells in normal tissues, such as skin, blood and the gastrointestinal tract, also divide and hence are highly sensitive to chemotherapeutic drugs, resulting in many undesired toxic side-effects and the all-too-common misconception that cancer treatments do more harm than good. Recent advances in immunotherapies overcome many of the issues associated with chemotherapy. With the rapid advances in molecular profiling of human cancers and precision medicine, it is now possible to identify patient-specific mutations in cancers and design specific immunotherapies to block the aggressive growth of these cancers.  We have identified the gene FRIZZLED7 (FZD7) as a molecular marker of many cancer types. With its highly restricted expression pattern-absent in children and adults and present in the embryo and various cancers- FZD7 is an ideal target for immunotherapies. We have developed an antibody that only reacts with FZD7, thus providing us with a molecular handle to identify, target and potentially kill cancer cells. In this application, we propose to leverage our uniquely specific FZD7 antibody to develop highly selective strategies to combat cancers in which FZD7 is highly expressed.  The short-term goals of the proposed research are foundational and basic in nature. Successful completion of this 1-year study will immediately feed into our long-term goals, including clinical development, filing of a new investigational drug (IND) application with the FDA, and initiating a Phase 1 clinical trial.",125000.0,2019-01-01,2019-12-31,Complete,False,False,False,False,False,False,False,False,False,False,True,False,False,False,False,False,False,Yes,"Myan Do, a PhD candidate at UCSD, was the first author on the Molecular Cancer Therapeutics paper",,0.0,,,,,"No, because product is licensed to Pfizer",Yes,"The epitope and the sequence of the antibody were patented by UCSD, patent number 10,766.  The inventors are Karl Willert and Dennis Carson",Two
154,43.0,Initial,43.1,Low Dose Chemotherapy for Immuno-activation in Lung Cancer,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,To investigate the effects of low dose immunogenic chemotherapy with oxaliplatin in a  clinical trial of NSCLC patients after progression on anti-PD1 antibodies. We will characterize the efficacy of response and safety of the combination of oxaliplatin and checkpoint inhibition.,"To investigate the patient-derived samples for antitumor and immune biomarkers that  correlate with oxaliplatin-enhanced antitumor immunity. We will conduct RNA-seq studies, flow cytometry and immunohistochemistry to determine the effect of oxaliplatin on MHC-I surface expression and antigen processing and presentation machinery.",,,,,"Immune checkpoint inhibitors are a new class of drugs that have revolutionized lung cancer treatment across various lines of therapy. The most versatile of this group are antibodies that target molecule on immune cells called checkpoints, namely PD-1 or its ligand PD-L1. Although effective in many cancer types, response rates to these drugs rarely exceed 30-40% in later lines of therapy, necessitating the search for agents that may combine to work in synergy with checkpoint blockers to increase effectiveness. Using mouse models of cancer,  we found that the conventional chemotherapeutic drug oxaliplatin has the unique ability to greatly enhance the  response to immunotherapy. Traditional doses of chemotherapy may not be needed when combined with immunotherapy. We will investigate how low doses of chemotherapy may increase an immune response and minimize side effects in a clinical trial. Furthermore, we will investigate lung tumor specimens to find markers that will help us to better understand how we can pair appropriate therapies for patients in the future.",150000.0,2019-01-01,2020-12-31,Complete,False,False,False,False,True,False,False,False,False,False,False,False,False,False,False,False,False,Yes,Provided an opportunity to continue research goals.,,1.0,Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC)    NCT04043195 ,19.0,NIVOLUMAB (ANTI-PD1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA4 ANTIBODY) IN COMBINATION WITH IMMUNOGENIC CHEMOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER,,none,No,,One
155,120.0,Initial,43.2,Low Dose Chemotherapy for Immuno-activation in Lung Cancer,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,To investigate the effects of low dose immunogenic chemotherapy with oxaliplatin in a clinical trial of NSCLC patients after progression on anti-PD1 antibodies. We will characterize the efficacy of response and safety of the combination of oxaliplatin and checkpoint inhibition.,"To investigate the patient-derived samples for antitumor and immune biomarkers that correlate with oxaliplatin-enhanced antitumor immunity. We will conduct RNA-seq studies, flow cytometry and immunohistochemistry to determine the effect of oxaliplatin on MHC-I surface expression and antigen processing and presentation machinery.",,,,,"Immune checkpoint inhibitors are a new class of drugs that have revolutionized lung cancer treatment across various lines of therapy. The most versatile of this group are antibodies that target molecule on immune cells called checkpoints, namely PD-1 or its ligand PD-L1. Although effective in many cancer types, response rates to these drugs rarely exceed 30-40% in later lines of therapy, necessitating the search for agents that may combine to work in synergy with checkpoint blockers to increase effectiveness. Using mouse models of cancer, we found that the conventional chemotherapeutic drug oxaliplatin has the unique ability to greatly enhance the response to immunotherapy. Traditional doses of chemotherapy may not be needed when combined with immunotherapy. We will investigate how low doses of chemotherapy may increase an immune response and minimize side effects in a clinical trial. Furthermore, we will investigate lung tumor specimens to find markers that will help us to better understand how we can pair appropriate therapies for patients in the future.",150000.0,2019-01-01,2020-12-31,Complete,False,False,False,False,False,False,True,False,False,False,False,False,False,False,False,False,False,No,,,1.0,,19.0,,,None.,No,,One
156,32.0,Initial,32.1,Responses of Melanoma Patients to Checkpoint Immunotherapy,Sanford Burnum,,False,False,True,False,False,Two Specific Aims,To assess the anti-tumor responses of melanoma patient T cells to immunotherapy.,To determine if PSGL-1 can be targeted in human melanoma patient CD8 T cells to support greater  T cell responses.,,,,,"Advances in immunotherapy for cancer have yielded tremendous optimism that even aggressive cancers, including metastatic melanoma, can one day be cured in the majority of patients. However, many patients fail to  respond to current treatments, or their tumors become resistant to treatment. It has been proposed that the T cells that are necessary for tumor eradication become refractory to treatment, by the development of progressive  loss of function. Thus, there is a critical need to better understand the loss of T cell function in patients and to develop new targets for immune modulation by distinct immune mechanisms. This pilot project is a collaboration between Dr. Linda Bradley in the Tumor Microenvironment and Cancer Immunology program at  the Sanford Burnham Prebys Medical Discovery Institute (SBP) and Dr. Gregory Daniels in the Solid Therapeutics program at Moore's Cancer Center (MCC). We seek to evaluate the responses of melanoma patient T cells to anti-PD-1 blockade, the frequencies of responsive vs non-responsive subsets of T cells, and the potential for blocking a new T cell inhibitory receptor that we discovered, designated PSGL-1, as a new  immunotherapy for metastatic melanoma and other cancers.",119768.0,2018-06-01,2019-05-31,Complete,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,True,False,Yes,This funding allowed a senior postdoctoral fellow in the Bradley lab to extend her work on the regulation of T cell exhaustion form mouse models of melanoma to human melanoma patient samples.,,0.0,,,,,No companies have been established.,No,,One
157,101.0,Initial,32.2,Responses of Melanoma Patients to Checkpoint Immunotherapy,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,To assess the anti-tumor responses of melanoma patient T cells to immunotherapy.,To determine if PSGL-1 can be targeted in human melanoma patient CD8 T cells to support greater T cell responses.,,,,,"Advances in immunotherapy for cancer have yielded tremendous optimism that even aggressive cancers, including metastatic melanoma, can one day be cured in the majority of patients. However, many patients fail to respond to current treatments, or their tumors become resistant to treatment. It has been proposed that the T cells that are necessary for tumor eradication become refractory to treatment, by the development of progressive loss of function. Thus, there is a critical need to better understand the loss of T cell function in patients and to develop new targets for immune modulation by distinct immune mechanisms. This pilot project is a collaboration between Dr. Linda Bradley in the Tumor Microenvironment and Cancer Immunology program at the Sanford Burnham Prebys Medical Discovery Institute (SBP) and Dr. Gregory Daniels in the Solid Therapeutics program at Moore's Cancer Center (MCC). We seek to evaluate the responses of melanoma patient T cells to anti-PD-1 blockade, the frequencies of responsive vs non-responsive subsets of T cells, and the potential for blocking a new T cell inhibitory receptor that we discovered, designated PSGL-1, as a new immunotherapy for metastatic melanoma and other cancers.",119768.0,2018-06-01,2019-05-31,Complete,False,False,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,Supports my academic advancement,,0.0,,,,,,Yes,"Patent was filed prior to study. ""L. Bradley and R. Tinoco hold the patent for targeting PSGL-1 on T cells in the treatment of infectious diseases, cancers, and immune and inflammatory diseases.""",One
158,35.0,Initial,35.1,Targeting A Therapeutic Vulnerability in PTEN-Deficient Brain Tumors,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Develop intracellular DAXX-H3.3 Protein-Protein Interaction (PPI) reporter using ReBiL platform.,Interrogate DAXX-H3.3 PPI through peptide-mediated complex disruption.,,,,,"Glioblastoma (GBM), the most common primary brain tumor in adults, is a highly invasive neurologically destructive tumor with a survival range of 12-15 months, despite aggressive treatment efforts. Like most cancers, gain of function of oncogenes and/or loss of function of tumor suppressor genes are common in GBM,  and in addition to bestowing enhanced growth to the tumor, these genetic alterations create collateral dependencies on cellular processes, otherwise known as synthetic vulnerabilities, that can be targeted for cancer therapy. A gene associated with the aggressive nature of GBM is the PTEN tumor suppressor gene, which is affected in ~40% of patients. This proposal aims to leverage this information by establishing a new molecular-based platform designed to rapidly identify molecules able to inhibit the growth of PTEN-deficient GBMs. By focusing on this genetically distinct class of GBMs, this proposal represents a unique personalized  therapeutic approach to target an Achilles heel that arises as a consequence of a specific gene mutation.",125000.0,2018-06-01,2019-05-31,Complete,False,False,False,False,False,False,True,False,False,False,False,False,False,False,False,False,False,Yes,This grant was part of my portfolio for a 2 step academic advancement in 1/1/2020.,,0.0,,,,,none,No,,One
159,110.0,Initial,35.2,Targeting A Therapeutic Vulnerability in PTEN-Deficient Brain Tumors,Salk Institute,,False,True,False,False,False,Two Specific Aims,Develop intracellular DAXX-H3.3 Protein-Protein Interaction (PPI) reporter using ReBiL platform.,Interrogate DAXX-H3.3 PPI through peptide-mediated complex disruption.,,,,,"Glioblastoma (GBM), the most common primary brain tumor in adults, is a highly invasive neurologically destructive tumor with a survival range of 12-15 months, despite aggressive treatment efforts. Like most cancers, gain of function of oncogenes and/or loss of function of tumor suppressor genes are common in GBM, and in addition to bestowing enhanced growth to the tumor, these genetic alterations create collateral dependencies on cellular processes, otherwise known as synthetic vulnerabilities, that can be targeted for cancer therapy. A gene associated with the aggressive nature of GBM is the PTEN tumor suppressor gene, which is affected in ~40% of patients. This proposal aims to leverage this information by establishing a new molecular-based platform designed to rapidly identify molecules able to inhibit the growth of PTEN-deficient GBMs. By focusing on this genetically distinct class of GBMs, this proposal represents a unique personalized therapeutic approach to target an Achilles heel that arises as a consequence of a specific gene mutation.",125000.0,2018-06-01,2019-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
160,15.0,Initial,15.1,Elucidating the role of Syk kinase and Syk inhibitors combined with Radiation therapy in Neuroblastoma,Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,We will dissect the role of macrophage Syk Kinase in neuroblastoma tumor progression and identify downstream factors of Syk kinase that are important in mediating immunosuppression.,We will determine if inhibition of Syk kinase is a feasible strategy to enhance radiotherapy in combination with immune- checkpoint inhibitor therapy in neuroblastoma.,,,,,"Neuroblastoma is a cancer that develops in certain types of nerve tissues and is responsible for more than 15% of all childhood cancer deaths. Despite aggressive treatments including  chemotherapy, radiation, and immunotherapy the 5 year survival of children with high risk  neuroblastoma is only 40-50%. We are proposing a targeted strategy to make immunotherapy and  radiotherapy more powerful in this cancer. In a study performed in mice, we found that Syk kinase controls the response of immune cells called macrophages. When cancer cells start growing in body, macrophages get recruited into the tumor and try to kill and destroy cancer cells, but very soon these macrophages get educated by cancer cells to promote tumor growth and to suppress the activity of other immune cells, especially T cells. This change in phenotype of macrophages does not allow the T cells to enter in to the tumor and it also interferes with the success of immunotherapy. Similarly, after radiotherapy, macrophages hinder the activity of T cells which leads to tumor relapse. Our  studies have shown that inhibiting the action of Syk kinase caused macrophages and T cells to mount a continued response against pediatric tumors grafted onto mice. Moreover, we found that combination of Syk inhibitors with checkpoint inhibitors improved survival of mice grafted with pediatric tumors. Since macrophage response is suppressed in pediatric cancer patients, these results might be translated into therapy against neuroblastoma and can be combined with conventional radiotherapy and checkpoint inhibitors to improve survival of these children.",125000.0,2020-07-01,2021-06-30,Complete,False,False,True,False,False,False,False,False,False,True,False,False,False,False,False,False,False,Yes,Mehreen Ishfaq was a visiting graduate student in my lab and she pursued her research in my lab ,,0.0,,,,,,No,,Three
161,76.0,Initial,15.2,Elucidating the role of Syk kinase and Syk inhibitors combined with Radiation therapy in Neuroblastoma,Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,We will dissect the role of macrophage Syk Kinase in neuroblastoma tumor progression and identify downstream factors of Syk kinase that are important in mediating immunosuppression.,We will determine if inhibition of Syk kinase is a feasible strategy to enhance radiotherapy in combination with immune- checkpoint inhibitor therapy in neuroblastoma.,,,,,"Neuroblastoma is a cancer that develops in certain types of nerve tissues and is responsible for more than 15% of all childhood cancer deaths. Despite aggressive treatments including chemotherapy, radiation, and immunotherapy the 5 year survival of children with high risk neuroblastoma is only 40-50%. We are proposing a targeted strategy to make immunotherapy and radiotherapy more powerful in this cancer. In a study performed in mice, we found that Syk kinase controls the response of immune cells called macrophages. When cancer cells start growing in body, macrophages get recruited into the tumor and try to kill and destroy cancer cells, but very soon these macrophages get educated by cancer cells to promote tumor growth and to suppress the activity of other immune cells, especially T cells. This change in phenotype of macrophages does not allow the T cells to enter in to the tumor and it also interferes with the success of immunotherapy. Similarly, after radiotherapy, macrophages hinder the activity of T cells which leads to tumor relapse. Our studies have shown that inhibiting the action of Syk kinase caused macrophages and T cells to mount a continued response against pediatric tumors grafted onto mice. Moreover, we found that combination of Syk inhibitors with checkpoint inhibitors improved survival of mice grafted with pediatric tumors. Since macrophage response is suppressed in pediatric cancer patients, these results might be translated into therapy against neuroblastoma and can be combined with conventional radiotherapy and checkpoint inhibitors to improve survival of these children.",125000.0,2020-07-01,2021-06-30,Complete,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,,,0.0,,,,,,No,,Two
162,36.0,Initial,36.1,Epigenetic profiling of endometrial cancer,Salk Institute,,True,False,False,False,False,Two Specific Aims,Discover and define molecular subtypes in EC through SE profiling,Discover transcriptional networks in ECs through Assay for Transposase-Accessible Chromatin  (ATAC-seq) profiling  ,,,,,"Endometrial Cancer is the fourth most common cancer in women and the most commonly diagnosed gynecologic cancer, and is rising in both incidence and mortality. While the prognosis for patient with early stage EC is quite good, those presenting with advanced stage or recurrent disease have a more guarded  prognosis. Treatment often involves surgery to remove the uterus and other affected organs. Radiation and/or chemotherapy are sometimes required to help improve outcomes. Despite advances in surgical management and therapeutics, the 5-year survival for patients with advanced stage or recurrent disease approaches 50% and represents a significant unmet clinical need. In an effort to improve outcomes, researchers are looking to leverage knowledge of genetic events caused by mutations in the DNA sequence that promote or ""drive"" EC.  This approach is limited, however, by the effectiveness of targeted therapies for each ""driver"" event. Indeed, many genetic drivers are non-targetable. Alternatively, we hypothesize that the epigenetic signature of EC will  reveal many more genes with potential ""driver"" activity based not on genetic mutation, but modifications at regulatory sequences affecting gene expression. Our approach is to profile 20 EC samples from patients treated at the Moores Cancer Center, UC San Diego using next-generation sequencing methods. These data  will be used to classify ECs into subtypes and to identify genes on which each subtype depends. Our goal is to develop a classification system based on epigenetic features that will improve diagnosis and help identify novel treatment strategies for EC.",125000.0,2018-06-01,2019-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,Not applicable,0.0,,,,,none,No,,Two
163,111.0,Initial,36.2,Epigenetic profiling of endometrial cancer,Moores Cancer Center,,True,False,False,False,False,Two Specific Aims,Discover and define molecular subtypes in EC through SE profiling,Discover transcriptional networks in ECs through Assay for Transposase-Accessible Chromatin  (ATAC-seq) profiling  ,,,,,"Endometrial Cancer is the fourth most common cancer in women and the most commonly diagnosed gynecologic cancer, and is rising in both incidence and mortality. While the prognosis for patient with early stage EC is quite good, those presenting with advanced stage or recurrent disease have a more guarded prognosis. Treatment often involves surgery to remove the uterus and other affected organs. Radiation and/or chemotherapy are sometimes required to help improve outcomes. Despite advances in surgical management and therapeutics, the 5-year survival for patients with advanced stage or recurrent disease approaches 50% and represents a significant unmet clinical need. In an effort to improve outcomes, researchers are looking to leverage knowledge of genetic events caused by mutations in the DNA sequence that promote or ""drive"" EC.  This approach is limited, however, by the effectiveness of targeted therapies for each ""driver"" event. Indeed, many genetic drivers are non-targetable. Alternatively, we hypothesize that the epigenetic signature of EC will reveal many more genes with potential ""driver"" activity based not on genetic mutation, but modifications at regulatory sequences affecting gene expression. Our approach is to profile 20 EC samples from patients treated at the Moores Cancer Center, UC San Diego using next-generation sequencing methods. These data  will be used to classify ECs into subtypes and to identify genes on which each subtype depends. Our goal is to develop a classification system based on epigenetic features that will improve diagnosis and help identify novel treatment strategies for EC.  ",125000.0,2018-06-01,2019-05-31,Complete,False,False,True,False,True,False,False,False,False,False,False,False,False,False,False,False,False,Yes,"This grant funding helped catalyze my collaborative research efforts within the cancer center, and also set the framework for efforts working with the tissue bio repository. Importantly, this work has also been pivotal in my ongoing phase 2, actively accruing clinical trial examining an EZH2 inhibitor in ARID1A mutated endometrial and clear cell ovarian cancer patients. We are using the data that emerges from these samples to help inform translational efforts on that trial.",,0.0,,,,,Not applicable,No,,One
164,37.0,Initial,37.1,Development and Implementation of a Peer-Navigation Intervention to Improve Research Literacy in Pediatric Cancer Trials,Rady Children's,,False,False,False,True,False,Two Specific Aims,"Develop and pilot test COMPRENDO, a tailored PNI, to improve parental research literacy in  pediatric cancer clinical trials.",Compare the preliminary effectiveness of COMPRENDO vs. usual practice in improving  research literacy outcomes among parents of children with newly diagnosed cancer.,,,,,"Whereas Hispanic children will comprise 33% of the U.S. population by 2060 and have higher incidence of certain cancers, their participation in biomedical research is critically low and they have poorer survival rates than non-Hispanic Whites. Interventions to improve research literacy (capacity to understand and act on information to make decisions about research) and clinical trial participation, particularly for Hispanics, are lacking. The objective of this proposal is to improve research literacy in parents of children with cancer and increase clinical trial participation, particularly for Hispanics by developing and implementing a culturally and linguistically tailored peer-navigation intervention. By increasing minority participation in clinical trials, we can effectively translate discoveries and treatments equally, and, ultimately, improve equity of survival among diverse populations.",100000.0,2018-06-01,2019-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,"Yes, funding has been instrumental to advance my career, obtain additional funding, obtain preliminary data for funding, yield data for publication and change my  faculty series to Clinical X at UCSD.",,0.0,,,,,na,No,,Six - Ten
165,112.0,Initial,37.2,Development and Implementation of a Peer-Navigation Intervention to Improve Research Literacy in Pediatric Cancer Trials,Moores Cancer Center,,False,False,False,True,False,Two Specific Aims,"Develop and pilot test COMPRENDO, a tailored PNI, to improve parental research literacy in pediatric cancer clinical trials.",Compare the preliminary effectiveness of COMPRENDO vs. usual practice in improving research literacy outcomes among parents of children with newly diagnosed cancer.,,,,,"Whereas Hispanic children will comprise 33% of the U.S. population by 2060 and have higher incidence of certain cancers, their participation in biomedical research is critically low and they have poorer survival rates than non-Hispanic Whites. Interventions to improve research literacy (capacity to understand and act on information to make decisions about research) and clinical trial participation, particularly for Hispanics, are lacking. The objective of this proposal is to improve research literacy in parents of children with cancer and increase clinical trial participation, particularly for Hispanics by developing and implementing a culturally and linguistically tailored peer-navigation intervention. By increasing minority participation in clinical trials, we can effectively translate discoveries and treatments equally, and, ultimately, improve equity of survival among diverse populations.",100000.0,2018-06-01,2019-05-31,Complete,False,False,False,False,True,False,False,False,False,False,False,False,False,False,False,False,False,Yes,Serving as mentor to Dr. Aristizabal.,,0.0,,,,,,No,,Six - Ten
166,10.0,Initial,10.1,Peptide Targeted Delivery of Epigenetic Therapies in Pancreatic Cancer,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,Tumor-targeted delivery of bromodomain inhibitors to synergize with immune checkpoint  inhibition.,Overcome immunosuppression through peptide targeting of tumor-associated fibroblasts.,,,,,"Pancreatic cancer is a devastating disease with few effective treatments. Moreover, recent immunotherapy approaches that have been remarkably successful in certain cancers have failed in pancreatic cancer. This poor performance of current therapies is in large part due to the presence of a complex cellular support network or stroma that surrounds the tumor. Importantly, the presence of the stroma compromises the immune response as well as drug delivery to the tumor. Cancer associated fibroblasts (CAFs) are major contributors to this stromal response, and as such, approaches that reduce the activities of CAFs may improve the effectiveness of existing therapies. Towards this end, we have promising findings that the epigenetic drug OTX can reduce the tumor  supporting and immune suppressive actions of CAFs, however the adverse side effects of OTX are prohibitive.  Here we will explore whether targeting technologies that focus drug delivery to the pancreas are able to reduce the adverse effects of OTX, and whether the therapeutic effects of this combination therapy are sufficient to enable immunotherapies. In addition, we will explore whether the existing targeting approach can be modified to selectively target the critical CAF population. These studies will be undertaken in mouse models that accurately  mimic human disease, where the effects of therapy combinations on disease burden and ultimately survival will be measured. The potential of these studies to improve the effectiveness while simultaneously reducing the adverse effects of existing therapies, as well as to sensitize pancreatic cancer to immunotherapies, could profoundly increase patient survival.",125000.0,2020-09-01,2021-08-30,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,,0.0,,,,,,No,,Two
167,67.0,Initial,10.2,Peptide Targeted Delivery of Epigenetic Therapies in Pancreatic Cancer,Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,Tumor-targeted delivery of bromodomain inhibitors to synergize with immune checkpoint inhibition.,Overcome immunosuppression through peptide targeting of tumor-associated fibroblasts.,,,,,"Pancreatic cancer is a devastating disease with few effective treatments. Moreover, recent immunotherapy approaches that have been remarkably successful in certain cancers have failed in pancreatic cancer. This poor performance of current therapies is in large part due to the presence of a complex cellular support network or stroma that surrounds the tumor. Importantly, the presence of the stroma compromises the immune response as well as drug delivery to the tumor. Cancer associated fibroblasts (CAFs) are major contributors to this stromal response, and as such, approaches that reduce the activities of CAFs may improve the effectiveness of existing therapies. Towards this end, we have promising findings that the epigenetic drug OTX can reduce the tumor  supporting and immune suppressive actions of CAFs, however the adverse side effects of OTX are prohibitive.  Here we will explore whether targeting technologies that focus drug delivery to the pancreas are able to reduce the adverse effects of OTX, and whether the therapeutic effects of this combination therapy are sufficient to enable immunotherapies. In addition, we will explore whether the existing targeting approach can be modified to selectively target the critical CAF population. These studies will be undertaken in mouse models that accurately  mimic human disease, where the effects of therapy combinations on disease burden and ultimately survival will be measured. The potential of these studies to improve the effectiveness while simultaneously reducing the adverse effects of existing therapies, as well as to sensitize pancreatic cancer to immunotherapies, could profoundly increase patient survival.  ",125000.0,2020-09-01,2021-08-30,Complete,False,False,True,False,False,False,False,False,True,False,False,False,False,False,False,False,True,Yes,,,0.0,,,,,None at this time,Yes,N/A  ,Two
168,40.0,Initial,40.1,"A Phase 1b pilot clinical trial of cirmtuzumab, an anti-ROR1 monoclonal antibody, in combination with paclitaxel for the treatment of patients with metastatic, or locally advanced, unresectable breast cancer",Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,"To determine the safety and tolerability during the first 4 weeks of fixed dose cirmtuzumab when administered in combination with weekly standard of care paclitaxel to patients with metastatic, or locally advanced, unrespectable breast cancer.",To determine the safety and tolerability of cirmtuzumab in combination with paclitaxel by ongoing evaluation of adverse events (AE's) during treatment and follow up.  To assess clinical activity by evaluating objective tumor response and time to progression as defined by RECIST v1.1.  To measure ROR1 receptor density on primary tumor and on putative cancer stem cell population and to correlate this with anti-tumor activity.,,,,,"Despite recent advances as of 2018, breast cancer remains the second highest cause of cancer-related death in women.  While some women are living longer than ever with breast cancer, both triple negative and aggressive types of estrogen positive breast cancer remain life threatening and ultimately resistant to currently approved breast cancer therapies.  One theory why many breast cancers become resistant to treatment is that current cancer therapies are not targeting cancer stem cells.  Cancer stem cells (or cells with stem cell characteristics) can remain in the bod after treatment completes and allow cancer cells to resist chemotherapy, regenerate tumors and spread as metastases.  At UC San Diego Moores Cancer Center, we have developed a highly specific immunotherapy called cirmtuzumab that may address this unmet need by targeting cancer stem cells.  Laboratory studies by Dr. Thomas Kipps have shown that this immunotherapy combined with chemotherapy decreases growth of patient-derived breast tumors in animals.  Out research suggests this therapy may be beneficial to women with advanced, aggressive breast cancer.  Therefore, we have developed a clinical trial to study cirmtuzumab in combination with paclitaxel, a chemotherapy that is safe, well studied, and known to be effective in breast cancer.  The goal of this study is to evaluate safety of the combination, to understand benefit to patients, to investigate how the combination inhibits cancer growth, and to determine how to study this combination in the future.",300000.0,2019-01-01,2021-12-31,Complete,False,False,True,True,True,True,False,False,False,False,True,False,False,False,False,False,False,No,,This collaboration emerged from development of ROR1 antibody program in CLL in Dr. Kipps lab with the intent to determine if ROR1 blockade with cirmtuzumab would have application in other cancers - specifically breast cancer.,0.0,,,,,None,No,,Two
169,117.0,Initial,40.2,"A Phase 1b pilot clinical trial of cirmtuzumab, an anti-ROR1 monoclonal antibody, in combination with paclitaxel for the treatment of patients with metastatic, or locally advanced, unresectable breast cancer",Moores Cancer Center,,False,False,True,False,False,Two Specific Aims,"To determine the safety and tolerability during the first 4 weeks of fixed dose cirmtuzumab when administered in combination with weekly standard of care paclitaxel to patients with metastatic, or locally advanced, unrespectable breast cancer.",To determine the safety and tolerability of cirmtuzumab in combination with paclitaxel by ongoing evaluation of adverse events (AE's) during treatment and follow up.  To assess clinical activity by evaluating objective tumor response and time to progression as defined by RECIST v1.1.  To measure ROR1 receptor density on primary tumor and on putative cancer stem cell population and to correlate this with anti-tumor activity.,,,,,"Despite recent advances as of 2018, breast cancer remains the second highest cause of cancer-related death in women.  While some women are living longer than ever with breast cancer, both triple negative and aggressive types of estrogen positive breast cancer remain life threatening and ultimately resistant to currently approved breast cancer therapies.  One theory why many breast cancers become resistant to treatment is that current cancer therapies are not targeting cancer stem cells.  Cancer stem cells (or cells with stem cell characteristics) can remain in the bod after treatment completes and allow cancer cells to resist chemotherapy, regenerate tumors and spread as metastases.  At UC San Diego Moores Cancer Center, we have developed a highly specific immunotherapy called cirmtuzumab that may address this unmet need by targeting cancer stem cells.  Laboratory studies by Dr. Thomas Kipps have shown that this immunotherapy combined with chemotherapy decreases growth of patient-derived breast tumors in animals.  Out research suggests this therapy may be beneficial to women with advanced, aggressive breast cancer.  Therefore, we have developed a clinical trial to study cirmtuzumab in combination with paclitaxel, a chemotherapy that is safe, well studied, and known to be effective in breast cancer.  The goal of this study is to evaluate safety of the combination, to understand benefit to patients, to investigate how the combination inhibits cancer growth, and to determine how to study this combination in the future.",300000.0,2019-01-01,2022-12-31,Complete,False,False,True,True,True,True,False,True,True,False,True,False,False,False,False,False,False,Yes,I applied for accelerated advancement from Assistant to Associate Professor during this time period and my funding and investigator initiated trial were like a big factor in helping me achieve this advancement,,1.0,"A Phase 1b Trial of Cirmtuzumab and Paclitaxel in Metastatic or Locally Advanced, Unresectable Breast Cancer",15.0,,,No companies were founded as a result of my trial. The pre-existing company Oncternal helped partially fund this trial in addition to funds from Pedal the Cause.,No,,One
170,41.0,Initial,41.1,"An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)",Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,Primary objective: To determine overall response rate at 6 months.,"Secondary objective: To determine progression-free survival, overall survival, and TMZ safety/tolerability.",Exploratory objective: To investigate serum metabolites as biomarkers of TMZ response.,,,,"Gastrointestinal stromal tumor (GIST) caused by mutations in succinate dehydrogenase (SDH) genes that control sugar metabolism is a rare form of cancer that affects 150-200 patients annually. Making the situation worse, these tumors are inherited, and mostly affect teenagers and young adults. There no effective therapies for treating this cancer, nor are there available research models for studying drugs. However, our group has grown the first human GIST cells that have defects in these sugar genes in order to study this deadly cancer.  We have identified temozolomide, a chemotherapy drug taken in pill form, as effective for killing these cells in the laboratory. Furthermore, we successfully treated a small group of UC San Diego GIST patients with temozolomide after they failed traditional GIST treatments. We now aim to perform a clinical trial to scientifically  test the effectiveness of this drug in patients with GIST caused by these sugar metabolism defects. We will also check blood levels of sugar breakdown products to determine if these are useful for following treatment responses. Overall, this represents a novel, homegrown, translation from bench-to-bedside using the  FDA-approved drug temozolomide to treat a lethal form of cancer that has no effective treatment. We anticipate these studies will: 1) identify the first successful therapy for these GIST patients; and 2) yield new insights into monitoring their drug treatment responses. These studies have the potential for immediately  changing clinical care of GIST patients in the prime of life.",300000.0,2019-01-01,2020-12-31,Complete,False,False,True,True,True,False,False,False,False,False,False,False,False,False,False,False,False,Yes,"The PTC funding lead to preliminary data for an FDA R01 grant ($1.5M for DC and IDC) to continue the trial, as well as a Phase One Foundation ($0.5M). Thus, the PTC funding has lead to $2.0M in additional funding.",,1.0,Trial Name:    Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor  NCT#: NCT03556384,13.0,"An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)",,None,No,,Three
171,118.0,Initial,41.2,"An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)",Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,Primary objective: To determine overall response rate at 6 months.,"Secondary objective: To determine progression-free survival, overall survival, and TMZ safety/tolerability.",Exploratory objective: To investigate serum metabolites as biomarkers of TMZ response.,,,,"Gastrointestinal stromal tumor (GIST) caused by mutations in succinate dehydrogenase (SDH) genes that control sugar metabolism is a rare form of cancer that affects 150-200 patients annually. Making the situation worse, these tumors are inherited, and mostly affect teenagers and young adults. There no effective therapies for treating this cancer, nor are there available research models for studying drugs. However, our group has grown the first human GIST cells that have defects in these sugar genes in order to study this deadly cancer.  We have identified temozolomide, a chemotherapy drug taken in pill form, as effective for killing these cells in the laboratory. Furthermore, we successfully treated a small group of UC San Diego GIST patients with temozolomide after they failed traditional GIST treatments. We now aim to perform a clinical trial to scientifically test the effectiveness of this drug in patients with GIST caused by these sugar metabolism defects. We will also check blood levels of sugar breakdown products to determine if these are useful for following treatment responses. Overall, this represents a novel, homegrown, translation from bench-to-bedside using the FDA-approved drug temozolomide to treat a lethal form of cancer that has no effective treatment. We anticipate these studies will: 1) identify the first successful therapy for these GIST patients; and 2) yield new insights into monitoring their drug treatment responses. These studies have the potential for immediately changing clinical care of GIST patients in the prime of life.",300000.0,2019-01-01,2020-12-31,Complete,False,False,True,True,True,False,False,False,False,False,False,False,False,False,False,False,False,No,,,1.0,,18.0,,,,No,,One
172,5.0,Initial,5.1,A National Phase I Study of Cabozantinib in Combination with 13-cis-Retinoic Acid in Children with Relapsed or Refractory Solid Tumors,Rady Children's,,False,False,False,False,True,Two Specific Aims,"Determine the safety, dose-limiting toxicities, maximum tolerated dose, and  pharmacodynamic efficacy of cabozantinib in combination with 13-cis-retinoic acid (CRA) in children with relapsed or refractory solid tumors. ",Identify biomarkers predictive of patient responses to cabozantinib therapy. ,,,,,"Children with high-risk and recurrent solid tumors have extremely poor outcomes despite aggressive therapy, and new treatments are desperately needed. Growth factor receptors are proteins on the surfaces of cancer cells that generate signals leading to cancer cell growth and spread, and these receptors therefore  represent potential targets for new treatments for many pediatric solid tumors. Cabozantinib is an inhibitor of several key growth factor receptors and kills pediatric solid tumor cells, and the effectiveness of cabozantinib is  increased when combined with 13-cis-retinoic acid. However, the safety and efficacy of the combination of cabozantinib with 13-cis-retinoic acid in children with solid tumors are unknown. We believe that cabozantinib and 13-cis-retinoic acid will be safe and effective in children with relapsed and refractory solid tumors and that  children will have altered levels of specific proteins in their blood and tumor cells after cabozantinib treatment.  We will test the combination of cabozantinib and 13-cis-retinoic acid in a national multi-institutional phase I clinical trial for children with relapsed and refractory solid tumors, including brain tumors, and we will also evaluate the levels of proteins in patient blood and tumor samples to determine their association with responses to treatment.  The results from this proposed research will provide important information to evaluate a unique treatment combination that could improve the chances of survival in children with all forms of cancer.",200000.0,2021-07-01,2023-06-30,Complete,False,False,False,True,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,The availability of funding from Padres Pedal the Cause was critical in maintaining stable funding to support ongoing research and productivity required for my retention and advancement at UCSD.,,1.0,A National Phase I Study of Cabozantinib in Combination with 13-cis-Retinoic Acid in Children with Relapsed or Refractory Solid Tumors,6.0,,,None,No,,One
173,60.0,Initial,5.2,A National Phase I Study of Cabozantinib in Combination with 13-cis-Retinoic Acid in Children with Relapsed or Refractory Solid Tumors,Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,"Determine the safety, dose-limiting toxicities, maximum tolerated dose, and pharmacodynamic efficacy of cabozantinib in combination with 13-cis-retinoic acid (CRA) in children with relapsed solid tumors.",Identify biomarkers predictive of patient responses to cabozantinib therapy.,,,,,"Children with high-risk and recurrent solid tumors have extremely poor outcomes despite aggressive therapy, and new treatments are desperately needed. Growth factor receptors are proteins on the surfaces of cancer cells that generate signals leading to cancer cell growth and spread, and these receptors therefore  represent potential targets for new treatments for many pediatric solid tumors. Cabozantinib is an inhibitor of several key growth factor receptors and kills pediatric solid tumor cells, and the effectiveness of cabozantinib is  increased when combined with 13-cis-retinoic acid. However, the safety and efficacy of the combination of cabozantinib with 13-cis-retinoic acid in children with solid tumors are unknown. We believe that cabozantinib and 13-cis-retinoic acid will be safe and effective in children with relapsed and refractory solid tumors and that  children will have altered levels of specific proteins in their blood and tumor cells after cabozantinib treatment.  We will test the combination of cabozantinib and 13-cis-retinoic acid in a national multi-institutional phase I clinical trial for children with relapsed and refractory solid tumors, including brain tumors, and we will also evaluate the levels of proteins in patient blood and tumor samples to determine their association with responses to treatment.  The results from this proposed research will provide important information to evaluate a unique treatment combination that could improve the chances of survival in children with all forms of cancer.  ",200000.0,2020-12-01,2022-11-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
174,4.0,Initial,4.1,Functional Roles for Histidine Kinase Signaling in Neuroblastoma,Rady Children's,,False,False,False,False,True,Two Specific Aims,Evaluate the functional role of NME1 expression and of histidine kinase activity  in neuroblastoma cell differentiation,Evaluate the functional role of NME1 histidine kinase activity in neuroblastoma  tumor growth and metastasis.,,,,,"Children with aggressive neuroblastoma have poor cure rates despite intensive treatment, and new therapies are needed. Treatments that inhibit important proteins and pathways in neuroblastoma tumors are likely to be more effective with fewer side effects. We have identified an association between expression of the NME1 gene and the survival rates of children with neuroblastoma, suggesting that NME1 may be a good candidate target for new neuroblastoma treatments. NME1 can act as a histidine kinase by adding phosphate to  the amino acid histidine in other proteins in neuroblastoma cells, representing a previously undiscovered way for cells to control the function of proteins required for neuroblastoma growth and survival. We propose to explore  how the NME1 histidine kinase affects neuroblastoma tumor cell maturation, growth, survival, and spread. The results of these studies will likely identify new proteins that could serve as targets for new types of treatment,  leading to improved success of neuroblastoma therapy and improved chances of survival for children with neuroblastoma.",100000.0,2019-07-15,2020-07-14,Complete,False,False,False,True,False,False,False,False,False,False,False,False,False,False,True,False,False,Yes,The availability of funding from Padres Pedal the Cause has been critical in maintaining stable funding to support ongoing research and productivity required for my retention and advancement at UCSD.,,0.0,,,,,none,No,,Two
175,58.0,Initial,4.2,Functional Roles for Histidine Kinase Signaling in Neuroblastoma,Salk Institute,,False,False,False,False,True,Two Specific Aims,Evaluate the functional role of NME1 expression and of histidine kinase activity in neuroblastoma cell differentiation,Evaluate the functional role of NME1 histidine kinase activity in neuroblastoma tumor growth and metastasis.,,,,,"Children with aggressive neuroblastoma have poor cure rates despite intensive treatment, and new therapies are needed. Treatments that inhibit important proteins and pathways in neuroblastoma tumors are likely to be more effective with fewer side effects. We have identified an association between expression of the NME1 gene and the survival rates of children with neuroblastoma, suggesting that NME1 may be a good candidate target for new neuroblastoma treatments. NME1 can act as a histidine kinase by adding phosphate to the amino acid histidine in other proteins in neuroblastoma cells, representing a previously undiscovered way for cells to control the function of proteins required for neuroblastoma growth and survival. We propose to explore  how the NME1 histidine kinase affects neuroblastoma tumor cell maturation, growth, survival, and spread. The results of these studies will likely identify new proteins that could serve as targets for new types of treatment, leading to improved success of neuroblastoma therapy and improved chances of survival for children with neuroblastoma.  ",100000.0,2019-06-01,2020-05-31,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
176,16.0,Initial,16.1,A pilot trial to test the benefit of real time drug screening to determine individualized treatment plans for children and young adults with relapsed or refractory medulloblastoma,Rady Children's,,False,False,False,False,True,Two Specific Aims,"Determine the feasibility, safety and efficacy of using drug screening and DNA sequencing as a basis for treatment recommendations for children with recurrent MB.",Test whether patient-derived xenografts can be used to understand and optimize responses to  recommended therapies,,,,,"Medulloblastoma is the most common malignant brain tumor in children. Although significant advances have been made in treating medulloblastoma, many patients still die from the disease, and those who survive suffer  severe long-term side effects from therapy. Patients who relapse have extremely poor outcomes, and new approaches to treating them are particularly important. We propose to carry out a unique clinical trial in which we take tissue from a patient's tumors at the time of surgery, sequence it to identify mutations that may be  causing the tumor, and also test the sensitivity of tumor cells to drugs that have been used against other cancers.  Using this approach, we hope to identify more effective therapies for each patient. Our previous studies have  demonstrated the feasibility of performing sequencing and drug testing on patient samples, and have shown that these analyses can provide insight into possible therapies. Our proposed trial will test whether this type of analyses can be done in a clinical setting, whether results can be used by a panel of experts to make  recommendations for therapy, and whether these recommendations are beneficial for patients. If our approach is successful it will improve outcomes for relapsed MB patients and provide a new paradigm for personalized  therapy of other pediatric cancers.",100000.0,2020-07-01,2021-06-30,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,The grant was critical in my initial retention during my period as interim division chief of neurology.,,1.0,Individualized therapy for refractory medulloblastoma,0.0,,,,No,,One
177,77.0,Initial,16.2,A pilot trial to test the benefit of real time drug screening to determine individualized treatment plans for children and young adults with relapsed or refractory medulloblastoma,Sanford Burnum,,False,False,False,False,True,Two Specific Aims,"Determine the feasibility, safety and efficacy of using drug screening and DNA sequencing as a basis for treatment recommendations for children with recurrent MB.",Test whether patient-derived xenografts can be used to understand and optimize responses to recommended therapies,,,,,"Medulloblastoma is the most common malignant brain tumor in children. Although significant advances have been made in treating medulloblastoma, many patients still die from the disease, and those who survive suffer severe long-term side effects from therapy. Patients who relapse have extremely poor outcomes, and new approaches to treating them are particularly important. We propose to carry out a unique clinical trial in which we take tissue from a patient's tumors at the time of surgery, sequence it to identify mutations that may be causing the tumor, and also test the sensitivity of tumor cells to drugs that have been used against other cancers.  Using this approach, we hope to identify more effective therapies for each patient. Our previous studies have demonstrated the feasibility of performing sequencing and drug testing on patient samples, and have shown that these analyses can provide insight into possible therapies. Our proposed trial will test whether this type of analyses can be done in a clinical setting, whether results can be used by a panel of experts to make recommendations for therapy, and whether these recommendations are beneficial for patients. If our approach is successful, it will improve outcomes for relapsed MB patients and provide a new paradigm for personalized therapy of other pediatric cancers.",100000.0,2020-07-01,2021-06-30,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,No,,,0.0,,,,,,No,,Zero
178,8.0,Initial,8.1,"A Phase 1B, Nonrandomized Trial Investigating Docetaxel Combined with Cirmtuzumab in Patients with Metastatic Castration Resistant Prostate Cancer",Moores Cancer Center,,False,True,False,False,False,Three Specific Aims,To investigate the safety and tolerability of cirmtuzumab combined with docetaxel in  men with metastatic castration resistant prostate cancer (CRPC).,To evaluate the anti-tumor activity of cirmtuzumab combined with docetaxel in men  with metastatic CRPC.,To prospectively interrogate the Wnt signaling pathway and characterize the impact of  cirmtuzumab and docetaxel on Wnt pathway activity.,,,,"Metastatic castration resistant prostate cancer (CRPC) is a lethal disease that claims 30,000 lives annually in the U.S. Although current approved drugs will slow the growth of metastatic CRPC, development of drug resistance-and cancer progression-is inevitable. It is therefore imperative to develop new treatments to  improve survival. As we learn more about the factors driving progression of metastatic prostate cancer, we have discovered that the Wnt signaling pathway is activated in these patients. The Wnt pathway possibly confers resistance to standard drug treatments, including hormone therapy and chemotherapy. Prior attempts to target this pathway have been unsuccessful. Cirmtuzumab, a ROR1-binding monoclonal antibody which inhibits the Wnt pathway, is a compelling new drug with the potential to treat CRPC by blocking Wnt activity.  Cirmtuzumab was developed at UCSD by Drs. Kipps, Jamieson, and Carson. Studies are underway in chronic lymphocytic leukemia and breast cancer. We hypothesize that the addition of cirmtuzumab to docetaxel, a chemotherapy drug, will be safe and effective for patients with metastatic CRPC. To test this hypothesis for  the first time, we propose a clinical trial of cirmtuzumab combined with docetaxel in men with prostate cancer. To better understand mechanisms of drug resistance, and which patients might benefit most from  cirmtuzumab, we will perform molecular analyses of cancer tissue and blood samples throughout the study.  This multidisciplinary, collaborative effort harnesses the expertise of clinical and laboratory scientists at UCSD;  and if successful, may reveal a new and unique drug to improve survival for patients with CRPC.",150000.0,2020-01-01,2021-12-31,Complete,False,False,True,True,True,False,True,False,False,False,False,False,False,False,False,False,False,Yes,Yes this grant was supporting the infrastructure to coordinate the clinical trial.,,1.0,"Phase 1B, Nonrandomized Trial Investigating Docetaxel Combined with Cirmtuzumab in Patients with Metastatic Castration Resistant Prostate Cancer",0.0,,,Oncternal,No,,Zero
179,187.0,Initial,187.1,An over-expressed GPCR in pacreatic cancer associated fibroblasts as a novel therapeutic target,Moores Cancer Center,,False,True,False,False,False,Two Specific Aims,Define PCAF activities in response to GPCR activation by low pH.,Develop and validate an assay to find inhibitors of GPR68 and use this assay in a pilot screen of the SBP library of compounds.,,,,,"Pancreatic ductal adenocarcinoma (PDAC) is the most common and deadly form of pancreatic cancer with <93% of PDAC patients dying less than 5 years after their diagnosis.  Part of the difficulty in treating PDAC is its characteristic dense scarring (""fibrosis"").  This scarring is generated by pancreatic cancer associated fibroblasts (PCAFs).  This project seeks to build on our recent discovery that PCAFs have high expression of novel protein on their cell surface.  This protein, known as a GPCR, is activated by the acidic (low pH) environment that exists in pancreatic cancers.  When activated by this low pH, the PCAFs communicate with the PDAC cells to enhance their growth.  In this project, UCSD investigators will conduct studies to define additional responses produced by exposure of CAFs to low pH and with Sanford-Burnham-Prebys Cancer Center/Medical Discovery Institute (SBP), will assess ""libraries"" (collections) of chemical compounds, certain of which are predicted to antagonize the GPCR we identified and which, as a result, should block the production of scarring and stimulation of PDAC growth by the PCAFs.  These studies that combine efforts at UCSD with those at SBP thus focus on the ""tumor microenvironment"" in which PDAC cells and PCAFs interact and will test the idea that a drug that blocks a special type of GPCR present in PCAF cells can provide a novel way to assist in the treatment PDAC tumors and thus may be a new way to improve the outcome of this very deadly type of cancer.",75000.0,2017-05-01,2018-04-30,Complete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
180,50.0,Initial,50.1,Tissue-specific role of SMARCB1 in pediatric rhabdoid tumors,Moores Cancer Center,,False,False,False,False,True,Two Specific Aims,Determine cellular constraints on the ability of SMARCB1 inactivation to initiate tumorigenesis.  ,Investigate mechanisms underlying tissue-specific effects of SMARCB1 deletion.   ,,,,,"This project aims to identify the mechanisms underlying initiation of pediatric rhabdoid tumors of the kidney and atypical teratoid rhabdoid tumors (ATRT) of the brain, which result from deletion of the SMARCB1 gene. To  determine why SMARCB1 deletion initiates tumors only in certain tissues and developmental stages the project will investigate differences in the effect of eliminating SMARCB1 expression on cells of different tissue types and attempt to identify potential therapeutic targets which could aid in the treatment of patients with  these lethal childhood tumors, which currently have very limited therapeutic options.",75000.0,2017-06-01,2018-05-31,Complete,False,False,False,False,False,False,True,False,True,False,False,False,False,False,False,False,False,Yes,This grant and the publication that resulted (PMID: 32912900) were part of my portfolio for a 2 step academic advancement in 1/1/2020.,,0.0,,,,,none,No,,One
181,38.0,Initial,38.1,Transcriptomic and epigenomic profiling to reveal TIL and microglia functional phenotype and clonality in pediatric brain tumors,Rady Children's,,False,False,True,False,False,Two Specific Aims,"Tumor-infiltrating CD4+ T cell, CD8+ T cell and CD19+ B cell to reveal their functional phenotype, TCR/BCR sequence and clonality in pediatric brain tumors.",Tumor-associated microglia and other key immune cell subsets to unravel their co-regulatory relationship and tumor regulatory mechanisms. ,,,,,"Brain tumors are a leading cause of death among childhood cancers. Significant proportion of these cancers remains incurable despite surgery, chemotherapy and radiation, which are the current standard of care treatments. Besides, there is significant long-term morbidity, impaired functioning and reduced quality of life in survivors following such treatment. Therefore, newer and less toxic treatments are urgently needed for these tumors. Immunotherapy, a treatment that involves harnessing the body's own immune system to eliminate the tumor, has not only been successful in some adult cancers but also has the advantage of being less toxic and having potential for long-term tumor control. Previous studies have shown that children have better survival outcome when their brain tumors harbor immune cells indicating an anti-tumor immune response. However, a complete picture of the type of infiltrating immune cell, its function, what it is directed against and the other factors/cells within the tumor that influence them, are all unknown. It is important to understand this in order to identify new targets for immunotherapy to boost the anti-tumor immune response. We will undertake an unbiased and comprehensive analysis of the immune cells infiltrating pediatric brain tumors using cutting-edge technology including single cell sequencing that helps us to look into each of these cells individually in great detail. This will enable to select out the specific type of immune cell that is best geared to fight the tumor and utilize this information for personalized cancer therapy. ",100000.0,2018-06-01,2019-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,"During my hematology oncology fellowship, I undertook research which led to a publication in Nature Immunology (2017). This PTC award was instrumental in supporting my research following my fellowship and led up to a successful application to the NIH for an NCI K08 career development award.",,0.0,,,,,None,No,,Two
182,39.0,Initial,39.1,A Phase 1b Safety and Feasibility Study of Personalized  Immunotherapy in Adults with Advanced Cancers,Moores Cancer Center,,False,False,True,False,False,Three Specific Aims,Conduct a phase 1b clinical trial to assess dose-limiting toxicities and adverse events from a personalized pSLP vaccine administered with an anti-PD1 antibody.,Characterize the vaccine contribution to T cell responses. We will enroll patients in two cohorts administering the vaccine either concurrently or sequentially with an anti-PD1 antibody.,Determine the extent of epitope spreading secondary to vaccine and anti-PD1 therapy.,,,,"Immunotherapy has produced a paradigm shift in the way we approach and manager cancer.  In the last few years we have seen unprecedented improvements in cancer survival stemming from immunotherapy with corresponding expedited drug approvals by the FDA.  These agents are generally well tolerated and can have deep and enduring responses once immune recognition of the tumor has occurred.  Unfortunately, over 80% of cancer patients do not benefit from current immunotherapies because the available drugs are ineffective at inducing immune rejection of the tumor.  Accordingly, we hypothesized that if a patient's immune system is stimulated to recognize their cancer then a vigorous anti-tumor response can be achieved.  Over the last four years, we have developed a method of identifying targets in a patient's cancer that can be seen by their immune system, so called ""neoantigens"".  We are now taking this discovery to the clinic by conducting a clinical trial using a personalized neoantigen vaccine in combination with standard immunotherapy.  The clinical trial will test the feasibility of creating truly individualized cancer vaccines and demonstrating the efficacy of this approach at inducing immune responses against a patient's cancer.  This study will lay the groundwork for larger trials for patients with metastatic cancer.  This study will lay the groundwork for larger trials for patents with metastatic cancer, irrespective of the primary tumor site, and for studies testing the effectiveness of personalized cancer vaccines at preventing cancer reoccurrence after definitive therapy.  This work will usher in a new era of transformational immunotherapy that is precise, tailored to the patient, and with little to no side effects.",150000.0,2019-01-01,2019-12-31,Complete,False,False,True,True,True,False,False,False,False,False,False,False,False,False,False,False,False,Yes,The funds were critical in advancing the career of Aaron Miller in the Division of Hematology/Oncology,,1.0,NCT05153304  Protocol PCV-001  A Phase I/II Safety and Feasibility Study of Personalized Immunotherapy in Adults with Upper Gastrointestinal Tract Cancers.,2.0,,,"Yes, Lykeion",Yes,Patent filed for the neoantigen discovery and identification platform,Six - Ten
183,113.0,Initial,38.2,"Transcriptomic, epigenomic profiling to reveal TIL, microglia functional phenotype, and clonality in pediatric brain tumors",LJI,,False,False,True,False,False,Two Specific Aims,"Tumor-infiltrating CD4+ T cell, CD8+ T cell and CD19+ B cell to reveal their functional phenotype, TCR/BCR sequence and clonality in pediatric brain tumors.",Tumor-associated microglia and other key immune cell subsets to unravel their co-regulatory relationship and tumor regulatory mechanisms.,,,,,"Brain tumors are a leading cause of death among childhood cancers. Significant proportion of these cancers remains incurable despite surgery, chemotherapy and radiation, which are the current standard of care treatments. Besides, there is significant long-term morbidity, impaired functioning and reduced quality of life in survivors following such treatment. Therefore, newer and less toxic treatments are urgently needed for these tumors. Immunotherapy, a treatment that involves harnessing the body's own immune system to eliminate the tumor, has not only been successful in some adult cancers but also has the advantage of being less toxic and having potential for long-term tumor control. Previous studies have shown that children have better survival outcome when their brain tumors harbor immune cells indicating an anti-tumor immune response. However, a complete picture of the type of infiltrating immune cell, its function, what it is directed against and the other factors/cells within the tumor that influence them, are all unknown. It is important to understand this in order to identify new targets for immunotherapy to boost the anti-tumor immune response. We will undertake an unbiased and comprehensive analysis of the immune cells infiltrating pediatric brain tumors using cutting-edge technology including single cell sequencing that helps us to look into each of these cells individually in great detail. This will enable to select out the specific type of immune cell that is best geared to fight the tumor and utilize this information for personalized cancer therapy.",100000.0,2018-06-01,2019-05-31,Complete,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,Yes,The Pedal The Cause funding was an important funding support for the lead PI of this project (Dr Ganesan). ,,0.0,,,,,None,No,,Two
184,55.0,Initial,55.1,Novel kinase inhibitors in combination with retinoic acide for neuroblastoma,Rady Children's,,False,False,False,False,True,Two Specific Aims,Determine the efficacy of CRA treatment combined with inhibitors of the RASMAPK pathway in neuroblastoma preclinical models.,Evaluate the functional role of the RAS-MAPK pathway in neuroblastoma tumor  cell resistance to CRA.,,,,,"Children with aggressive neuroblastoma have poor cure rates despite intensive treatment that  includes chemotherapy, surgery, radiation therapy, and maintenance therapy with 13-cis-retinoic acid (CRA). Aggressive neuroblastoma tumors frequently relapse after the completion of treatment, likely due to residual tumor cells that are resistant to the effects of CRA. Kinases are proteins that can stimulate tumor cell growth and survival, and a large number of new drugs are available that block or inhibit kinase function, resulting in tumor cell death. Identification of individual kinases needed for neuroblastoma cell survival after CRA treatment will lead to new treatment combinations for children with relapsed neuroblastoma using these new kinase inhibitors combined with CRA. In our initial  experiments, we have identified a kinase named ""MEK,"" a member of a key signaling pathway in cancer cells, as a kinase needed for neuroblastoma tumor cell survival after CRA treatment. We propose to evaluate the role of MEK in neuroblastoma tumor cell resistance to CRA and the effectiveness of treatment with CRA combined with new drugs that block MEK activity. The results of these studies will  identify treatment combinations using readily available drugs that can be rapidly tested in clinical trials, leading to improved success of neuroblastoma therapy and improved chances of survival for children with neuroblastoma.",75000.0,2017-06-01,2018-05-31,Complete,False,False,True,True,False,False,False,True,False,False,False,False,False,False,False,False,False,Yes,The availability of funding from Padres Pedal the Cause was critical in maintaining stable funding to support ongoing research and productivity required for my retention and advancement at UCSD.,,1.0,A National Phase I Study of Cabozantinib in Combination with 13-cis-Retinoic Acid in Children with Relapsed or Refractory Solid Tumors,6.0,,,none,No,,Three
185,207.0,Initial,,Science,UCSD - not a member of Moores Cancer Center,,False,False,False,True,False,Three Specific Aims,science project,Health Project,Both,,,,diana,75000.0,2022-08-01,2022-08-31,Incomplete,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,
